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  Abstract 
 




Non-communicable diseases (NCDs) are a major and increasing global health issue. They 
represent 71% (41million) of all global deaths including 3.9 million due to chronic 
respiratory diseases (CRDs) and chronic obstructive pulmonary disease (COPD) in 
particular. COPD is now the third most common cause of death globally; 90% of COPD 
deaths occur in Low and Middle-Income Countries (LMICs). Sub-Saharan Africa (SSA) and 
Middle East and North Africa (MENA) countries report similar mortality rates from COPD 
of 18 per 100,000 population. However, the burden of COPD SSA is disputed and reports 
offer variable prevalence estimates, ranging from 4.1% to 22.2%. The work in this thesis set 
out to contribute new knowledge to this area by conducting a review of the literature about 
non-communicable lung disease in SSA and MENA and through population-based cross-
sectional studies (one urban and one rural) of the burden of non-communicable lung disease 
in adults in Sudan.  
 
For the literature review, a broad review was undertaken to capture the breadth of work on 
non-communicable lung disease in SSA and MENA. The two cross-sectional studies were 
done to the same core Burden of Obstructive Lung Diseases (BOLD) protocol. The urban 
study was done in Khartoum state and sampled from the non-institutionalised population 
aged 40 years and above; the rural study was done in Gezira state and used the same sampling 
approach but with an extended age range – 18 and above. Alongside the rural study the 
potential role for digital data was explored for future studies of this nature.  
 
Review of the literature found that whilst research has been done in this area, it is limited in 
breadth and depth. The prevalence of chronic respiratory symptoms (mainly shortness of 
breath was 10.9% and 18.7% in the urban and rural study participants, respectively). The 
prevalence of post bronchodilator airflow obstruction was 10.3% and 14.8% in urban Sudan 
and 5.5% and 7.7% in rural Sudan using Lower Limit of Normal (LLN) and Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) definitions respectively. Older age was the 
main factor associated with airflow obstruction in both populations and helps to explain the 
difference in prevalence between the urban and rural studies as the latter included younger 
participants. Low Forced Vital Capacity (FVC) prevalence estimates were similar in the 
urban and rural studies - 58.1% vs 58% (Third National Health and Nutrition Examination 
Survey (NHANES) reference values), respectively. Pilot testing of digital compared to 
paper-based data capture found high levels of agreement between the two approaches 
suggesting that the former could be adopted in future work of this nature.  
 
Taken together, the work presented in this thesis highlights the limited breadth and depth of 
research on non-communicable lung disease in SSA and MENA to date and identifies a high 
burden of chronic respiratory symptoms and spirometric abnormalities (mainly low FVC) in 
adults in urban and rural Sudan. These findings suggest there is a substantial but under-
recognised burden of non-communicable lung disease in Sudan and elsewhere in SSA and 
MENA that calls for greater attention from the research community alongside public health 
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  General introduction 
 
 Global burden of NCDs 
Non-communicable diseases (NCDs), including cardiovascular diseases, diabetes, 
cancer and chronic respiratory diseases (primarily asthma and chronic obstructive 
pulmonary disease (COPD)), caused about 41 million deaths worldwide, 
representing 71% of all deaths (1). According to the latest WHO estimates, 15 million 
people aged between 30 and 69 die from NCDs annually (1). Eighty five percent of 
these deaths occurred in low and middle-income countries (1,2). The WHO NCDs 
status report of 2014 highlights that the number of deaths due to NCDs increased 
from 35 to 38 million in 2012 (3). NCDs are considered a major cause of deaths in 
LMICs, excluding those in sub-Saharan Africa(SSA)(4) as HIV/AIDS, pregnancy-
related conditions, hypertension and injuries are the leading causes of death among 
adults in SSA(5). However, the projected data suggest a rapid increase in NCDs in 
SSA over the coming years which will have a significant economic impact, with the 
disease burden disproportionately affecting working-age-adults (4). NCDs have been 
identified by the WHO as a barrier to personal, community and national 
development, and as such addressing these diseases is an urgent development issue 
(4).  
 
The WHO world health report in 2000 stated that lower respiratory tract infections, 
COPD, tuberculosis (TB) and lung cancer are amongst the top 10 causes of death 
worldwide. Respiratory diseases represent 17.4% of all deaths and 13.3% of all 
Disability-Adjusted Life Years (DALYs) (6). According to the report, the burden of 
chronic respiratory diseases (CRDs) including asthma, COPD, and lung cancer will 
increase as a result of tobacco usage and population ageing (6). However, CRDs are 
given limited attention, given their public health importance (7). The WHO strategy 
for prevention and management of CRDs was developed in 2001(6) but as stated by 
D Enarson  and Aït-khaled et al,  this strategy was only followed lately in 2005 and 
highlighted the need to integrate CRD prevention and control programs into health 
systems worldwide (7). COPD, asthma, occupational lung diseases, post-TB and 
post-pneumonia CRDs have been declared as emerging public health problem in 





 Africa/MENA Region 
The Middle East and North African (MENA) region is located between Asia, Africa, 
and Europe, extending from Morocco to Pakistan, and is known as the Greater 
Middle East. Based on the United Nations agencies categorisation (9), the region 
includes 23 countries (Figure 1.1). Countries are sometimes omitted from MENA 
depending on organizational definitions, such as that of the World Bank (10), and are 
instead considered part of North Africa or Asia. These countries include Sudan, 
Somalia, Afghanistan, and Pakistan. In Sudan, as in the region, Islam is the 








SSA is the region on the continent located south of the Sahara. The area is divided 
into sub-regions: West, East, Middle and South Africa. All African countries 
included in this region are either fully or partially located south of the Sahara. Sudan 
is often geographically located in SSA but is also considered part of North Africa 
and Arab world (11) (Figure 1.2). 
                                               
 
1 Figure Source: HIV and other sexually transmitted infections research in the Middle East and 




 Figure 1.2 Sub-Saharan Africa as defined by the United Nations agencies (in 
colour) 2  
 
The Eastern Mediterranean Region Office (EMRO) is a regional office established 
by the WHO to support health and provide health statistics from most MENA 
countries, including Sudan. The EMRO reported that tackling NCDs in MENA is 
crucial as there is a growing burden of NCDs in the region where the reported number 
of deaths was 2.2 million in 2012, representing 53% of all deaths and an alarming 
rise of NCD prevalence is expected to result in 2.4 million deaths per year in the 
region by 2025 (12). Regional data on CRDs mostly concern asthma and COPD and 
suggests that about 8% of the population in the EMRO have asthma and the number 
of deaths due to asthma expected in the region for 2030 is 27,000. There is substantial 
variation in premature mortalities resulting from NCDs in the region, varying from 
                                               
 




24% in Tunisia to 63% in Afghanistan (13). Available data for mortality due to CRD 
in the region ranges from 2% to 4% (13). 
 
In Africa as a whole, the WHO predicts an increase of 27% in NCD deaths by 2030. 
While the burden of communicable diseases has been the primary concern, this is 
changing rapidly; by 2030 the number of deaths due to NCDs is expected to outstrip 
the number of deaths due to communicable, maternal perinatal and nutritional 
diseases combined (14). In addition, there is a projected increase of 50% in number 
of deaths due to NCDs  in LMIC by 2030 (15). The expectation that NCDs will 
become the leading cause of ill health, premature death and disability in Africa means 
their burden will increasingly negatively affect socio-economic development on the 
continent (14,15). Premature deaths due to NCDs was 43% in 2011 as reported by 
WHO, higher than in EMRO (13). However, SSA is expected to have a considerable 
change in NCDs mortality and deaths due to NCDs is projected to account for 46% 
of all deaths by 2030 (15).  
 
Despite the epidemiological transition from communicable to non-communicable 
diseases, research has focused on the former to date (16). Organisations like the 
WHO have identified the need for research including basic burden of disease data 
about NCDs as a priority and have created a global action plan for the prevention and 
control of NCDs as well as region-specific plans of action, as in EMRO (12,17). In 
addition, the East African NCD Alliance (NCDA) recently  led the creation of a 
continent-wide NCD Research Group to aid NCD research in a comprehensive, 
multi-sectoral and harmonised methodology by including a region-wide group of 
multi-disciplinary teams (18). 
 
  Sudan 
Sudan is in North East Africa, bordered by 7 countries (Fig. 1.3). Sudan, now known 
as North Sudan, is the third largest country in Africa and the sixteenth largest in the 
world with a population of  41,511,526 (19,20). Sudan is a rich country in terms of 
natural resources and population but has been affected by war for most of its 
independent history since 1955 with most conflict occurring in the South, in Southern 
Kordufan and Blue Nile states. In 2011, its southern states seceded, forming the 
Republic of South Sudan causing considerable economic instability. Loss of oil 
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income was the most significant issue as this represented over half of the 
government’s income and 95% of its exports. This has resulted in much decreased 
economic growth (21) as well as the unequal distribution of economic resources and 
reduced access to natural resources. The government’s failure to overcome these 
challenges were cited by the World Bank as a major determinant of poverty in Sudan 
(21).  
Civil conflicts have also recently spread to other parts of northern Sudan in the Darfur 
states. Health, population, and nutrition have been significantly affected by these 
conflicts. WHO reported that more than 2 million people have died, and more than 4 
million are currently internally displaced or have become refugees because of these 
conflicts and their related impacts. Health services have been extremely negatively 







Figure 1.3 Sudan, country map and neighbouring countries.3 
                                               
 
3 Map source: https://www.thinglink.com/scene/885206811320254465 
 
 22 
As reported by WHO, the total deaths from NCDs in Sudan were estimated to be 
297,000 in 2012 which accounts for 34% of the total deaths in the country that year. 
Lower respiratory infections were the leading cause of death, killing 37.8 thousand 
people in 2012 (23). WHO reported that CRDs accounted for 2% of the total deaths 
from NCDs, though they highlighted that these estimates have a high degree of 
uncertainty because they are not based on national NCD mortality data (24).  
Nevertheless, in 2016 reports by the Federal Ministry of health in Sudan showed that 
NCDs represented 87% of the patients attending outpatient clinics in hospitals, while 
respiratory diseases were the fourth highest cause of death in Sudan, accounting for 
3.9% of the total number of the deaths in hospitals and 10.3% of the total number of 
child deaths. The prevalence of respiratory disease is 36 people per 1000, ranking 
second highest after Malaria.  Additionally, deaths due to respiratory disease 
represent 5.5% and 3.2% of the total number of deaths in Khartoum and Gezira state 
respectively (25). On the other hand, according to El Sony et al, asthma ranked the 
third most common cause of hospitalization following pneumonia and malaria in 
2004 (26).  
 
COPD, amongst other CRDs, has been inadequately investigated in Sudan and 
studies regarding disease prevalence and their main determinants are scarce, being 
conducted only in specific populations such miners and coronary artery disease 
patients (27,28).   
 
  Khartoum and Gezira state 
Khartoum State is located in the heart of Sudan and is bordered by 7 other states 
(River Nile, Northern State, Kassala, Gadaref, Gezira, White Nile and North 
Kordofan). It is the most populated and urbanized state in Sudan consisting of urban, 
semi-urban, rural, and internally displaced populations from different conflict areas 
with a total population of 5,274,321. Respiratory diseases were listed as one of the 
most common causes of death in hospitals in Khartoum state in 2016; contributing 
5.5% of the total deaths in Sudan due to respiratory diseases.  
Gezira state is in the eastern central region of Sudan, lies south of Khartoum state 
and is bordered by 4 localities (Khartoum, Gadaref, White Nile and Sinnar). It has a 
population of 3,780,915. The population of the state is rural, with 80% of its people 
living in rural areas and 19.1% urban according to the 2008 national census(20). 
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Respiratory diseases were again listed as one of the most common causes of death in 
hospitals in Gezira state in 2016; contributing 3.2% of the total deaths in Sudan due 
to respiratory disease.  
 
 The health system in Sudan 
The Sudanese health policy aims at assuring an equitable access to preventive, 
promotive and curative health services to the population. The country follows a three-
tier health-care delivery system: (A) Federal level, which is mainly responsible for 
the formulation of national policies, plans and strategies: resource mobilization, 
overall monitoring and evaluation, coordination, supervision, training and external 
relations; (B) State level, which is responsible for the formulation of State policies, 
plans and strategies, according to federal guidelines, funding and implementation of 
plans; and (C) Local/district level, which is mainly responsible for the 
implementation of national/state policies and service delivery based on the primary 
health care approach. Hospitals in Khartoum and Gezira States vary from state to 
local level, and are categorized into general, specialized, and rural hospitals. In 
addition, there are sector hospitals which belong to specific sectors such as the 
military, the police, or the Ministry of education. Since 1976, primary health care has 
been adopted as a key strategy for healthcare provision in Sudan and this has been 
further emphasized in the national comprehensive strategy for health (1992-2002) 
and in the 25-year strategic health plan (2003-2027) - see Figure 1.4 (22). Private 
for-profit and non-government organization sectors are supplementing the health 





 Figure 1.4  The health-care system organization of Sudan4 
 
 Asthma and COPD services in Sudan 
Sudan’s Asthma Guidelines were developed in 2002 (29) and built on the 
International Union Against Tuberculosis and Lung disease (The Union) model 
while adapted for the Sudanese context. These guidelines made the use of essential 
medicines mandatory due to limited resources (30). Nevertheless, these guidelines 
have not yet been widely adopted in the country. Peak flow meters are not used 
effectively for diagnosis and staff remain unable to carry out the long-term 
management of asthma patients (26). Asthma services are normally provided in 
emergency rooms in Sudan as a first referral point. Hospitalised patients are asked to 
attend follow-up appointments in specialised outpatient clinics.  Unlike asthma, there 
are no management guidelines for COPD in Sudan and the use of spirometry devices 
for diagnosis is confined to particular specialised hospitals.  Additionally, COPD is 
poorly understood by both the general public and some physicians in Sudan. 
 
 Smartphone data collection  
Smartphones have been described as the combination of the traditional Personal 
Digital Assistant (PDA) and mobile phone, with an improved focus on the mobile 
phone part. These handheld devices incorporate mobile phone capabilities with the 
                                               
 
4 Sudan Federal Ministry of Health (www.fmoh.gov.sd) 
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more common features of a handheld computer or PDA.  As information 
communication technologies grow, with software supporting ‘Android’ platforms 
and the development of many open-source applications, researchers in the health 
sector have begun using smartphones as a tool in patient data collection, disease 
surveillance, clinical research and national surveys (31,32). However, paper-based 
questionnaires continue to be the main data collection tool in many countries, 
especially in SSA (32).  
 
 The Epidemiological laboratory  
The Epidemiological Laboratory (Epi-Lab) is a public health services research 
centre, situated in a non-governmental, non-profit organization based in Khartoum, 
Sudan (33). It has been designated as a collaborative Centre of the WHO and the 
International Union against Tuberculosis and Lung Disease (The Union) and WHO. 
The University of Oslo and the International Cooperation, International Tuberculosis 
Foundation (LHLI) are co-founders.  
 
In order to assess the burden of chronic NCDs in Sudan (especially COPD) Epi-Lab 
has been involved in implementing two Burden of Obstructive Pulmonary Lung 
Disease (BOLD) studies in Sudan in collaboration with Imperial college, London. 
Fieldwork for the first study was done between 2012 and 2014 in Khartoum State 
and for the second study between 2015 and 2016 in Gezira State. Epi-lab has hosted 
all studies presented in this thesis.  
 
  Objectives 
 
Overall:  
• To improve our understanding of chronic non-communicable lung disease in 
Sudan. 
Specific: 
• To measure the prevalence and investigate the main risk factors of airflow 
obstruction and chronic obstructive pulmonary disease in Khartoum State. 
• To measure the prevalence and investigate the main risk factors of non-
communicable chronic lung diseases in adults in Gezira State. 
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• To study the variation in the prevalence of airflow obstruction and other chronic 
lung disease between rural and urban populations in Sudan. 
• To compare prevalence findings from Sudan with global findings in BOLD 
studies. 
• To study the applicability of using smartphones in the data collection of BOLD 
studies. 
• To compare smartphone data collection methods with paper-based methods in 
BOLD studies with respect to accuracy, completeness, and the quality of data in 
Gezira State, Sudan. 
 
 This thesis 
The thesis consists of six chapters. Chapter 1 (this chapter) has presented is a general 
introduction to the topics and objectives of the study. Chapter 2 is an overview of the 
literature on the epidemiology of non-communicable lung disease in SSA and MENA 
with a focus on asthma and COPD. Chapter three describes a study of the burden, 
prevalence, and main determinants of CRD in urban Sudan. Chapter four describes a 
study of the burden, prevalence, and main determinants of CRD in rural Sudan. 
Chapter 5 describes a study of the use of automated data collection in comparison to 
traditional paper-based collection done as part of the rural survey conducted in Gezira 
state. Chapter 6 concludes the thesis with a summary and discussion of the findings 
of these studies and identifies areas for further research. A schematic presentation of 






Figure 1.5  Study conceptual framework of the burden of non-communicable lung diseases 
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 The epidemiology of Chronic Obstructive Pulmonary 
Disease and asthma in SSA and MENA regions 
 
 Search strategy  
A detailed search strategy was developed and revised appropriately for the following 
electronic databases: PubMed, Science direct, Global health, Medline, Google 
Scholar, and BOLD website, using English only text from established peer- reviewed 
journals with no time limits, however most recent publications were included. Due 
to the lack of academic articles in the area of the epidemiology of chronic non 
communicable lung diseases in SSA and MENA regions wider search strategy was 
undertaken using more general terms to identify studies for inclusion in this review. 
The search strategy combinations of key terms and inclusion criteria are stated in 
Appendix (1). The researcher also reviewed relevant academic books, organisational 
publications and grey literature.  
 
 Introduction 
Non-communicable diseases (NCDs) are a major and increasing global health issue. 
Annually, death from the main four categories of NCDs represents 71% of the global 
death (2). Of these, 3.9 million were due to CRDs. WHO estimated that over the 
following decade respiratory diseases would be responsible for the largest increase 
in global mortality (17,34). LMICs are responsible for 80% of the NCD deaths, of 
which an estimated 12% are due to respiratory problems, particularly asthma and 
COPD (2,34). Respiratory diseases also have significant economic impacts, causing 
4.7% of global DALYs, two-thirds of which are due to COPD and one-fifth due to 
asthma (2). Much of the details has already been given in the preceding chapter.   
 
The impact of CRDs in the developing world is a growing problem. COPD rose from 
the fourth to the third most common cause of death between 1990 and 2010 (35–37). 
Ninety per cent of COPD deaths now occur in LMICs (38–41). However, in many of 
these countries, governments and medical professionals have historically not given 
CRDs commensurate attention. This study set out to review the literature on the 
epidemiology of CRDs in sub-Saharan Africa (SSA) and the Middle East and North 
Africa (MENA) with a focus on asthma and COPD.  
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 Airflow Obstruction  
Airflow obstruction indicates predominant spirometric  findings of a reduced 
expiratory airflow compared to the total amount of air exhaled. Its defined as a 
reduction in the ratio of forced expiratory volume in 1 second (FEV1) to forced vital 
capacity(FVC). Its considered as the central feature of chronic obstructive pulmonary 
disease (COPD) and primarily associated with smoking(42–44).  
 
 COPD 
In the previous decade, airflow obstruction has frequently been defined as a 
functional disorder, which is the result of different diseases such as chronic bronchitis 
or emphysema, bronchiectasis, bronchiolitis obliterans, chronic post-tuberculosis 
lung disease and smoking-related airway disease (45–47).  
Four professional boards defined COPD and adopted the same key points in the 
definition for COPD as the European Respiratory Society (ERS) in 1995, the 
American Thoracic Society (ATS) in 1995, the British Thoracic Society (BTS) in 
1997 and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in 
1998 (47). 
The ATS and ERS define COPD as a “preventable and treatable disease state 
characterised by airflow limitation that is not fully reversible” (48,49). GOLD 
standardised the definition of COPD to a “preventable and treatable disease 
categorised by persistent airflow limitations which is mostly increasingly related and 
enhanced by chronic inflammatory responses of the airways and lung to harmful 
elements or smokes” (49). Despite this, varying definitions of COPD are used 
globally (50). COPD is mainly caused by cigarette smoking and leads to symptoms 
of cough, excessive sputum production, and breathlessness, causing considerable 
disability as the illness progresses (51).  
 
 Asthma 
The Global Initiative for Asthma (GINA) defines asthma as a “heterogeneous 
disease, usually characterised by chronic airway inflammation. It is characterised by 
a history of respiratory symptoms such as wheeze, shortness of breath, chest tightness 
and cough that vary in intensity and over time, together with expiratory airflow 
limitation” (52). However, asthma lacks a gold standard definition with other 
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definitions also in use. Nevertheless, bronchial hyper-responsiveness, airway 
inflammation, and obstruction which may be reduced spontaneously or with 
medication are widely accepted features (53). There can be a chronic reduction in 
FEV1 and peak expiratory flow (PEF), with the degree of reduction being one marker 
of disease severity (54).  
In epidemiological settings, methods of identifying asthma mainly depend on airway 
reversibility, however a study by Albert et al reported a limitation of using 
bronchodilator reversibility as an indication for asthma as the study concluded that 
reversibility status on one occasion is an unreliable basis for concluding clinical 
decisions(55).  
 
 Disease management and global initiatives 
Several guidelines, such as GOLD, GINA, and the ‘Allergic Rhinitis and its Impact 
on Asthma’ (ARIA) guidelines were developed to improve the management of 
CRDs. 
 
 CRDs initiatives  
In 2002, the WHO developed ‘The Global Strategy for the Prevention and Control 
of NCDs’. Clear objectives were drawn to provide better surveillance and monitor 
NCLD trends and lower the level of exposure to recognised risk factors. Moreover, 
it aimed to strengthen the available health care systems (6). In addition to general 
guidelines for NCLDs, asthma and COPD action plans for 2013 up to 2020 were 
developed to follow the WHO treatment guidelines and provide influenza 
vaccination for patients with COPD (17,56). In 2002 and 2003, the WHO conducted 
the World Health Survey as a standardised survey tool to allow comparisons between 
diseases findings, including asthma within and between countries to inform policy in 
a wide range of countries (57,58). 
 
 COPD initiatives 
Consistent across different guidelines, such as GOLD, the ERS and ATS, is the need 
for spirometry to diagnose COPD (48,59–62). GOLD requires the diagnosis of 
COPD to be based on spirometric testing, specifically the documentation of a post-
bronchodilator ‘forced expiratory volume in one second’ (FEV1) to ‘forced vital 
capacity’ (FVC) ratio (FEV1/FVC) of <0.7 (61,63). In addition to spirometry, COPD 
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is also diagnosed based on the level of patient symptoms and potential risk of 
exacerbations (59,61,64) . In contrast, the American Thoracic Society (ATS) and 
European Respiratory Society (ERS) defines COPD as FEV1/FVC ratio below the 
lower limit of normal (LLN) (46,65).  
 
In 2015, the ERS/ATS published an official statement evaluating recognised COPD 
diagnostic standards and recommending further study to evaluate the long-term 
prognosis of diagnosed patients based on different COPD definitions (48). The 
guidelines highlighted that the confirmation of diagnosis can be ascertained by 
observing airflow limitation, defined by a low post-bronchodilator FEV1/FVC ratio. 
However, exposure to potential causative factors, such as smoking, and present 
symptoms should be taken into consideration. Additionally, the statement 
highlighted that using a fixed cut-off point can potentially overestimate COPD in 
elderly populations while underestimating the disease among populations younger 
than 45, when compared to the use of LLN (48). This was also discussed in GOLD 
2014 and 2016 annual reports, where it was asserted that more frequent diagnoses of 
mild COPD in adults above 45 might be due to the use of fixed ratio FEV1/FVC 
(59,64). In addition GOLD reported that the use of staging based on FEV1 only was 
insufficient and there is a lack of proof for different staging classifications and 
therefore the GOLD staging system has been modified (59,64). 
 
 BOLD Initiative  
The BOLD initiative was established to further develop international standardised 
methods for estimating COPD prevalence and associated risk factors in populations 
who are 40 and older (66,67). It has been designed to provide consistent methods 
with which to compare COPD burden within and between countries, as well as to 
study the variations, where they exist (68,69). Additionally, it aims to measure the 
influence of COPD on quality of life, activity limitation, respiratory symptoms and 
usage of healthcare services (67,70). BOLD studies have provided a framework for 
assessing the economic burden of COPD by developing the ‘BOLD Health Economic 
Model’ (66,70) and the distribution of the disease in relation to age, sex, and smoking 
status across a range of countries and settings (67,69). BOLD studies have also 
helped to describe the clinical symptoms reported by subjects diagnosed with COPD 
(67), provided a comparison of the effect of using different definitions such as 
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ATS/ERS and GOLD on COPD prevalence and explored the variation of risk factors 
and their impact on the variation of COPD prevalence (67,68).     
 
In all BOLD studies implemented worldwide, the BOLD Operations Centre provides 
training for local study staff, materials to be used for questionnaires and data 
collection forms, in addition to quality control tools for collected spirometry data as 
well as for questionnaire data at each stage of the collection process (68). This 
includes a revision of the pre- and post-bronchodilator spirometry test, as well as the 
questionnaire data.  A web platform for electronic data entry in all BOLD studies has 
also been developed by the BOLD Operation Centre with all paper questionnaires 
collected in the field being entered electronically (68). 
 
 Asthma initiatives 
In the 1990s, GINA proposed strategies and guidelines for asthma management, and 
standardised the definition so it could be clearly distinguished from other respiratory 
diseases (71). In 1996, the International Union Against Tuberculosis and Lung 
Disease adopted these guidelines to control asthma in developing countries (72). 
However, as demonstrated by Aït-Khaled et al, there is a need to effectively utilise 
these guidelines, especially in rural areas in Africa (73).  
 
  Global COPD and asthma disease burden  
The Global Burden of Disease study estimated that COPD affected almost 251 
million people globally in 2016 and resulted in 3.17 million deaths (5% of all global 
deaths in 2016) (74). However, it is poorly recognised and undertreated in most 
populations (74,75). Asthma is estimated to affect 235 million people, and the WHO 
reported that 383,000 deaths in 2015 were due to asthma (76). Furthermore, 635 
million people are reported to be living with some level of asthma-like symptoms 
(57). 
 
Worldwide, males and females are affected by COPD to a similar extent (4.9% and 
4.7%, respectively) (77). The gender distribution of asthma varies with age: in 
childhood males are more frequently affected, but after adolescence prevalence is 
higher among females (78). Overall, asthma is estimated to affect slightly more 




WHO estimates that 65 million people have moderate to severe COPD and three 
million people die as a direct cause of it annually. This corresponds to 5% of all 
global deaths, the majority of which occur in LMICs. Deaths from COPD show an 
upward trajectory (79,80). The number of individuals affected by asthma is predicted 
to increase to 400 million by 2025 (57,81).  
 
In Africa, mortality from COPD was estimated to be 18.1 per 100,000 in 2001 with 
a similar rate, 18.3 per 100,000, seen in Eastern Mediterranean countries (47). While 
deaths less frequently result from asthma than COPD, WHO estimates that there are 
250,000 deaths per year from asthma, mainly in LMICs (82). Asthma is in the top 
twenty causes of disability in children globally (73).  
 
  Burden of COPD in United States, Europe and Asia and Pacific  
Different studies are currently being conducted across the world to estimate the 
prevalence of COPD. NHANES III (Third National Health and Nutrition Survey) 
was the most important study in COPD prevalence in US from 1988 to 1994. It 
highlighted many challenges and limitations in previous studies regarding COPD and 
unexpectedly estimated high levels of COPD prevalence in adult populations (83). 
The study reported a prevalence of 13.9% with approximately 10% of these classified 
as a disease stage of severe or very severe (83). 
 
According to the most recent published data from NHANES III the prevalence of 
respiratory symptoms, COPD and asthma that was medically diagnosed in US 
populations aged 25 and older was 15.1% based on spirometric lung function testing 
and 5.2% based on medical diagnosis of COPD (chronic bronchitis, emphysema, or 
both) (84). In contrast, a recent study from Canada illustrated that estimations of 
worldwide COPD prevalence range from 5% to 10% (85).  
 
One popular COPD study was the PLATINO study (Chronic Obstructive Pulmonary 
Disease in five Latin American cities study). It was designed to follow a two-stage 
sampling approach to obtain probability samples of adults aged 40 or older. The study 
prevalence ranged from 7.8% (78/1000) in Mexico City to almost 20% (174/885) in 
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Montevideo. Prevalence was higher in men and older people, and those with a lower 
education level, lower BMI and greater exposure to smoking (86). 
 
Estimates regarding COPD prevalence have shown notable variation around the 
world where different methodologies have been used.  A systematic review that 
included thirty two prevalence estimates from 17 countries and eight WHO classified 
regions, and aimed to understand the true burden of COPD and interpret worldwide 
prevalence findings, argued that several factors complicated the estimation of the true 
burden of COPD (46). Their findings addressed the variability in methods used in 
conducting COPD studies, whether based on spirometry, assessment of respiratory 
symptoms, patient-reported disease or expert opinion. The findings included 
inconsistencies in COPD definitions and reported figures that included asthmatic 
patients (46). As shown in the same systematic review, prevalence estimates varied 
from 0.23% to 18.3% while most well designed studies reported a prevalence 
between 4% and 10% in adult populations (46).   
 
The first quantitative worldwide summary of COPD prevalence literature was 
reported in a systematic review and meta-analysis conducted in 2006 aiming to 
quantify the global burden and prevalence of COPD from population-based studies 
published from 1990 to 2004 (87). This study illustrated the notable variation in 
estimates and heterogeneity of methodologies and definitions used (87). This was 
consistent with the previous stated review (46). It demonstrates that for key regions 
outside Europe and North America high quality estimates for COPD prevalence are 
lacking, and while there are some spirometry studies in American, South-East Asian 
and Western Pacific regions, there were none in Africa or the Eastern Mediterranean 
during the review period (87).  
 
Other studies confirmed these previous study findings and reiterated that many 
factors can influence the prevalence estimations and therefore it is crucial to note the 
country, methods used and base population for reported prevalence (46,69,87). A 
systematic review aimed at understanding the variability of chronic obstructive 
pulmonary disease data in Europe repeated these assertions (45). This review 
included 21 countries and prevalence ranged from 2.1% to 26.1%, while COPD 
mortality rates ranged from 7.2 to 36.1 per 105 population, differing based on 
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country, age group and methods used. In six of the nine papers that used the GOLD 
definition of COPD included in this review, the prevalence findings varied from 
10.2% in Spain to 26.1% in Austria (45).  
 
The International BOLD study of 12 BOLD sites found higher prevalence variation, 
from 13.3% in Germany to 26.1% in Austria (45,69). In addition, prevalence of 
COPD Stage II or higher was 10% in the overall population. This was higher in men 
than in women (11.8% and 8.5% respectively) (69).  
 
In the Asia and Pacific region, COPD was considered a high-burden disease at all 
levels. It was highly associated with mortality and morbidity as shown by most of 
the studies in the region. Different studies from Singapore, Japan, Taiwan and Hong 
Kong reported that 7% to 10% of middle-aged and elderly populations had an airflow 
obstruction and nearly half of them had moderate to severe COPD (88). Recent 
findings from northern Thailand were consistent with the Asia and Pacific region as 
the reported prevalence was estimated to be about 1% across all ages and increasing 
sharply to 8–10% or higher in individuals aged 40 or older (87,89). 
 
 COPD burden in SSA 
The burden of COPD in SSA is disputed and reports offer variable prevalence 
estimates (90,91). Finney et al conducted a systematic review of nine cross-sectional 
studies (five from South Africa, two from Nigeria, one from Malawi and one from 
Cape Verde) reporting a prevalence ranging from 4.1% to 24.8% based on the 
diagnostic method used (92). Chan-Yeung et al estimate a prevalence of 179 per 
100,000 in Africa and 301 per 100,000 in Eastern Mediterranean countries, less than 
that of America and Europe (38,93). However, a recent systematic analysis by 
Adeolaye et al reported the estimated median prevalence of COPD in people aged 40 
or older as 13.4% (range 9.4% to 22.1%), translating to 26.3 million (18.5 to 43.4 
million) cases of COPD in SSA (94). In SSA, Cape Town in South Africa had the 
highest prevalence estimates published in the international BOLD study, where 
GOLD stage II prevalence was 22.2% in men older than 40 (38,79,95). 
 
There are several possible explanations for the variation in COPD prevalence 
estimates. Firstly, relevant epidemiological data is lacking because of a paucity of 
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data from representative samples (27). Secondly, the studies that do exist are limited 
by the lack of a standardised definition of COPD with marked variation in the 
diagnostic methods used (33). In particular, there is a widespread shortage of good 
quality post-bronchodilator spirometry (90,96). Diagnosis frequently depends on 
clinical judgment, and knowledge about COPD is often limited. Many people, 
including health workers, are not well informed about the effects of cigarette 
smoking and exposure to smoke from the burning of biomass fuels on their 
respiratory health (97). 
 
  Asthma burden in SSA 
There is similarly large variation in reported asthma prevalence in Africa. Available 
published data gives estimates of asthma prevalence in SSA between 6% and 20% 
(98). The International Study of Asthma and Allergies in Childhood (ISAAC) has 
been the most widely used prevalence research methodology in Africa (82), as its 
diagnostic criteria have been shown to be reproducible and able to differentiate 
between children with allergic diseases in different areas of the world (99). Another 
review reported that prevalence rates in Africa varied according to the ISSAC study 
results (Ethiopia 9.1%, Kenya 15.8%, Nigeria 13.0% and South Africa 20.3%) while 
rural areas reported lower prevalence than urban areas (38,100). In 2011, Musafiri et 
al reported an increase in asthma prevalence in Africa over the past two decades, 
with 50 million people currently living with asthma (101). In 2013, a systematic 
review by Adeloye et al reported a similar prevalence to that of high-income 
countries. In 1997, the aggregated prevalence was highest in South Africa (53% of 
5-12 year olds) and lowest in The Gambia (1.9% of >15 years) (73). Adeloye et al 
estimated that asthma increased in prevalence from 11.7% in 1990 to 12.8% in 2010 
in the general population. Evidence of this rise is also provided by the Global Burden 
of Asthma Report, which asserts that the highest levels of asthma are in South Africa 
(54). ISAAC phase three reported that Africa, the Indian sub-continent and the 
Eastern Mediterranean had the highest proportion of severe asthmatics (102). 
 
  COPD burden in MENA countries 
As in SSA, the burden of COPD is increasing in MENA countries. Although there is 
a paucity of good epidemiological data, there appear to be substantial differences in 
prevalence estimates between countries in the region (93,96). Tunisia reportedly has 
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a prevalence of 4.2% - 4.7% compared to 125 per 100,000 people in Algeria and 
5.6% in Lebanon (93,103,104). A recent study from Saudi Arabia estimated COPD 
prevalence to be 2.4% in the general population and 14.2% among smokers (105). 
Prevalence of 3.7% in 40 to 80 year olds was reported in Abu Dhabi, United Arab 
Emirates (106). The BREATHE study, a large observational population-based 
survey, completed in ten countries in MENA and Pakistan, reports that the available 
data from the region does not represent national COPD prevalence accurately as 
community-based prevalence surveys in the region are infrequent and available 
epidemiological data are either incomplete or restricted to a small area (93,96,107). 
The estimated overall COPD adjusted prevalence according to symptoms or 
diagnosis and 10-pack/year smoking was 3.6%, and is higher in men than in women 
(5.2% and 1.8%, respectively) (108). 
 
  Asthma burden in MENA countries 
There is substantial variability in the reported prevalence of asthma in the MENA 
region.  In 1998 the ISAAC study reported an overall prevalence of 16.5% in North 
Africa and 10.7% in the Eastern Mediterranean (93). The study showed prevalence 
in children at 5% and 12% in rural and urban Sudan respectively (109), and ranging 
from 8.8% to 9.5% in rural and urban Jordan respectively (93). The World Health 
Survey published the global asthma prevalence from 70 countries in 2012. The 
overall prevalence in the Eastern Mediterranean region was 2.9%, 3.0% and 7.9% 
for ‘doctor diagnosed’, ‘clinical’, and ‘wheezing symptoms asthma’ respectively 
(57). In contrast, the ‘Asthma Insights and Reality in the Maghreb’ (AIRMAG) study 
reported an overall prevalence of 3.6% in the general population of Maghreb, with 
no significant disparity between the three countries (Algeria, Morocco, and Tunisia) 
(73,93,110). Egypt reported a prevalence of 14.7% for wheezing in that year and 
9.4% of medically diagnosed asthma (111). There was varying prevalence in Saudi 
Arabia, ranging from 8% to 25% in children, with 19.6% of adolescents having 
medically diagnosed asthma (112) and 4.1% of adults self-reporting asthma (113). 
Results from Iran showed a similarly varying prevalence ranging from 1.4% to 5.9% 






  COPD studies focused on rural and urban populations  
Studies around the world have studied differences in COPD prevalence between rural 
and urban populations. Others have studied only rural or urban populations.  
A study from two areas in Sweden reported COPD prevalence among never-smokers 
was 2.0% for GOLD1, 1.4% GOLD2 and 1.3% for GOLD3. Occupational exposure 
to gas, dust or fumes in never-smokers was significantly associated with both COPD 
and GOLD grades. There was no significant difference in prevalence between the 
two studied areas or sex and prevalence increased significantly with age (35). 
 
In two areas in China, a study was conducted in populations aged 40 and older in 
urban (Liwang) and rural (Yunyan) areas in Guangdong. The study reported overall 
COPD prevalence of 9.4% and a significant association between COPD and living 
in rural areas. The overall prevalence was significantly higher in non-smoking 
women living in the rural study area (7.2% vs. 2.5% for non-smoking women and 
12.0% vs. 7.4% for overall prevalence). Use of biomass fuels and indoor pollution 
was significantly associated with COPD as use of biomass fuel was found to be 
higher in rural areas (88.1% vs. 0.7% in urban areas) (115). Systematic review 
findings were consistent with the above study and confirmed that prevalence of 
COPD was significantly higher in rural Chinese populations (80). In the same study, 
the overall prevalence of COPD in seven provinces in China was found to be 8.4% 
(men 12.4%, women 5.1%), which was significantly higher for rural residents 
(79,80,116). 
 
A population based cross-sectional study targeting people aged 40 and older in one 
province in in Northern Thailand assessed the differences in COPD prevalence in 
rural and urban communities.  The study assessment, based on the GOLD criteria, 
found that both rural and urban communities were equally under-diagnosed and 
undertreated. COPD prevalence was higher in rural populations (6.8% compared to 
3.7% in urban group). Females had the highest prevalence in the general population 
with more severe disease in rural communities (4.4% in rural vs. 0.9% in urban 
group). These findings were explained as the result of the higher levels of smoking 
among females in rural communities. Other than smoking status and aging, especially 
in urban men, no risk factors were associated with a significant difference in 




In Turkey (83), a BOLD study on COPD prevalence was conducted in different rural 
and urban areas. The study recruited adults aged >18. In the group aged 40 and older, 
COPD prevalence was 9.1%, while in younger adults it was 2.9%. The overall 
prevalence was 6.9%, and 18.1% in both current smokers and those aged 40 and 
older. In the younger age group of smokers, the prevalence was 4.5%. Cigarette 
smoke was the greatest cause of COPD in all subgroups except for in females in rural 
areas. Similar to findings from other studies in developing countries and Africa 
(89,97,117), this study found 54.5% of females with COPD living in rural areas were 
exposed to smoke from biomass fuels.  Smoking was responsible for COPD in 40% 
of females and 91% in males in the urban region and 26% in the rural region. Eighty 
per cent of COPD patients in rural regions had COPD due to exposure at work (83). 
This finding was replicated in a study from India which asserted that the COPD 
burden among rural women in developing countries was largely a consequence of 
chronic exposure to biomass fuels smoke (118). 
 
In Tunisia, a survey was conducted on the general population living in the urban area 
of Sousse. Two areas were surveyed and participants were aged 40 and older. The 
prevalence, according to GOLD, of stage 1 COPD was 7.8% and of stage 2 COPD 
was 4.2%. COPD was more prevalent in participants with BMI<20kg/m (low) and 
in participants aged 70 and older. In smokers who smoked <10 packs per year, the 
COPD prevalence was 2.3%, while it was 16.1% in smokers of ≥20 packs per year 
(104). 
 
FRESH AIR Uganda is one of the first studies in SSA to use a strong sampling 
approach and world-renowned diagnostic methods. This was one of the first 
population-based, randomised, cross-sectional surveys done in a rural area of a Sub-
Saharan country focusing on the prevalence and burden of COPD (90,97). The study 
identified COPD in younger age groups where the prevalence was highest in people 
aged 30–39 years (17 [38%] of 45 men, 20 [40%] of 50 women). The overall COPD 
prevalence in the study was 16.2% (15.4% in men and 16.8% in women). As in many 
other studies, key risk factors were biomass smoke for both sexes (93% were exposed 
to biomass smoke), and tobacco smoke for men (97). In addition, COPD was 




In Rwanda, another study aimed to estimate the prevalence of Atopy, asthma and 
COPD (101), using a study group aged 15-80 in Kigali town or Huye District. The 
study estimated prevalence of airflow obstruction was 14%. The overall prevalence 
of COPD was 4.5% while asthma prevalence was 8.9%. COPD prevalence was found 
to be associated with smoking, being male and aging. In older participants (45 and 
older), COPD prevalence was 9.6%. This was fairly consistent with findings of 
studies from Europe, Asia and America. In current and ex-smokers prevalence rates 
were 11.2% and 8.6% respectively and this was also consistent with previous 
findings (101). Asthma prevalence was higher in urban than rural areas, while no 
differences were found between rural and urban areas regarding COPD. As reported 
in the same study, having two thirds of the participants aged below 45 resulted in a 
lower prevalence of COPD when compared with data in the few existing studies 
where prevalence ranges from 5.3% to 47.4% (101). 
 
  Risk factors for COPD in SSA and MENA 
There are several common environmental risk factors for CRD including tobacco 
smoking, household and outdoor air pollution and exposure to dust, gases or fumes 
in occupational settings (36). Genetic factors are also implicated, though this is 
beyond the scope of this review. It has, however, been recently acknowledged that 
for both the asthma and COPD burden in LMICs, other causes are also contributing, 
particularly tuberculosis (TB), HIV and rapid urbanisation. 
 
 Tobacco 
Tobacco smoking, alongside population aging, are causes widely regarded as the 
most important risk factors for COPD globally (66,69,94). The WHO reports that 
smoking alone causes about 42% of CRD (120). Maternal smoking during pregnancy 
is a risk factor for asthma in paediatric patients (121,122). The sharp increase in 
smoking rates in LMICs reflecting the ‘success’ of intensive efforts by the Tobacco 
Industry to expand into African markets will see the global prevalence of COPD 
increase over coming decades (69,89,101,123).  
 
The burden of tobacco use in African countries is estimated to be between 8% and 
43% for men and between 5% and 30% for women (101). COPD prevalence in 
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current smokers in men ranges from 9.4% to 56.9%, with comparable broad ranges 
seen for other risk factors such as history of tuberculosis, exposure to biomass fuels 
smoke or occupational fumes (91,92). Smoking is also increasing in the MENA 
region. An epidemiological study in Turkey reported that COPD prevalence in 
current male smokers older than 40 was 18.1%, and was 4.5% amongst younger 
smokers. Furthermore, 25.5% of the women and 57.2% of the men were current 
smokers. The rate of smoking varies greatly within the region, from 20% of men in 
Iran to 63% in Turkey (93). The Burden of Obstructive Lung Disease (BOLD) study 
analysed COPD prevalence and mortality in association with smoking and poverty, 
and reports that tobacco and exposure to environmental tobacco smoke remain the 
greatest risk factors for airflow obstruction (36). However, many areas with high 
COPD mortality rates have a low consumption of tobacco (36,75). Tobacco alone, 
therefore, does not fully explain the varying prevalence globally, and other factors 
need to be investigated in LMICs (36,69,91,97,117). 
 
 Household air pollution 
Exposure to household air pollution from biomass fuels smoke is a recognised risk 
factor for CRD, particularly for COPD, and mostly among women (88,124). Biomass 
fuels contain material from plants or animals burnt by humans such as wood, animal 
dung, crop residue and grass (38). It is estimated that over 80% of homes in SSA and 
90% of rural houses use biomass fuels (38,117). A Malawian study found that women 
and people of lower socioeconomic status in SSA are particularly affected by 
biomass fuels smoke exposure (125). In MENA countries, household air pollution 
from biomass fuels smoke is also considered a risk factor for CRD, but to a lesser 
extent (47,96). The link between asthma and biomass fuels exposure is less clear 
(126,127), though a recent systematic review reported a relationship between these 
fuels and asthma symptoms (128). In MENA, 25% to 45% of patients with COPD 
were known to have been exposed to biomass fuels smoke and were reported non-
smokers (93). Ben Abdallah et al estimates that 54.5% of the Turkish, rural, female 
participants with COPD that were studied were exposed to biomass fuels smoke. 
However, the same study reports that the relative risk from smoking was 3.4 times 





 Outdoor air pollution  
Outdoor air pollution is variable, differing greatly between urban and rural 
environments and with the degree and nature of local industry. Outdoor air pollution 
tends to be a combination of wood smoke and vehicle exhaust (129), with higher 
levels of nitrogen dioxide, ozone, particulate matter and sulphur dioxide in urban 
areas (130). There has been a rise in the prevalence of asthma that corresponds with 
increasing urbanisation over the last three decades (131) although, in some high 
income countries there has been  a decline in asthma prevalence, hospitalisation and 
death from asthma(52). There is evidence that high levels of vehicle emissions and 
living in an urban environment are correlated with the rising trend in allergic 
respiratory diseases (130). Air pollution has a quantifiable impact on COPD 
mortality and morbidity and is also recognised to have a negative influence on lung 
development in children (80,132). Research on outdoor air pollution and CRD in 
SSA and MENA is limited, and the majority of the data in these regions is 
extrapolated from studies observing other risk factors.  
 
The global population living in urban areas is predicted to increase from 45% to 59% 
by 2025. Africa’s urban population in particular is growing rapidly and predicted to 
increase from 40% to 56% by 2050. The impact of air pollution on CRD can therefore 
also be expected to increase (133). Studies looking at wheezing, asthma and COPD 
in Africa illustrate rural-urban gradients, with generally low levels in the villages and 
increasing prevalence with urbanization (38,134).  
 
 Occupational exposures 
There is little evidence regarding the burden of asthma due to occupational exposure 
in LMICS, particularly African countries outside South Africa (135). Hoy et al 
estimates 15% to 20% of  population burden of asthma are attributable to 
occupational exposure. However, this is only valid in developed countries which 
have strong occupational health data (135). Similarly, the American Thoracic Society 
(ATS) reported occupational exposure as the main cause of 15% prevalence of COPD 
and asthma and was associated with an increased mortality rate in the COPD 
population (136). GINA also reported that occupational exposure can trigger asthma 
in 5% to 20% of adults (71). These findings have been replicated by a study on a 
‘never-smoked population’ in two industrialised areas of Sweden, where 24% of the 
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study population was found to have occupational exposure (35). A Nigerian study 
reported a high prevalence of occupational asthma (6.5%) and rhinitis (78%) in 
woodworkers, which increased with duration of employment (137). As reported by 
Finney et al, COPD was prevalent in 13.4% of South African gold miners and 33.1% 
of Nigerian shoe factory workers (92).  
 
In MENA, there are variable reports regarding occupational exposure. A study from 
Sudan reported that 26% of miners had symptoms of chronic bronchitis where mine 
dust was the leading cause (27,138). The non-smoker BOLD study in Tunisia 
reported 92% of those exposed to occupational pollutants from dust, gas and fumes 
suffered from chronic bronchitis and a significant association (OR 1.87, 95% CI 1.14 
- 12.86) was found between occupational exposure and COPD as well as having more 
respiratory symptoms (103). This is further evidenced by a recent study in Dubai 
which showed a significant association between occupational exposure to dust and 
airflow limitation (OR  2.07, 95% CI 1.20 - 3.59) (139). 
 
 Pulmonary tuberculosis (TB) 
According to the WHO stop TB partnership, there are more than 2.4 billion people 
infected with TB globally and 9.6 million new cases are diagnosed every year, with 
the majority occurring in LMICs. TB patients often have airflow obstruction; studies 
have found prevalence varies from 28% to 68% (140,141). A large study based in 
South Africa in 2004 reported that the strongest predictor of COPD was history of 
TB (OR 4.9, 95% CI 2.6 - 9.2 in men) and (OR 6.6,  95% CI 3.7 - 11.9 in women), 
an association stronger than both smoking and biomass fuels exposure (142). A 
recent study in previously-treated TB patients in Sudan concluded that clinical 
features of CRDs are strongly associated with a history of Previously Treated TB 
(PTB) (143). Additionally, previous studies have found that TB was strongly 
associated with CRDs in areas highly endemic of TB (144). The recent BOLD 
multicentre study stated that self-reported TB was associated with airflow 
obstruction (Adjusted odds ratio 2.51, 95% CI 1.83–3.42) (43). 
 
The ISAAC study found an inverse relationship between asthma symptom 
prevalence and estimated TB incidence (145). It has been hypothesised that exposure 
to mycobacterium tuberculosis may reduce the risk of developing asthma through the 
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induction of a Th1-like immune response (99). However, further studies are required 
as research is lacking.  
 
 HIV 
The link between HIV and chronic respiratory disease is unclear, however in both 
children and adults, HIV patients are reported to have a higher risk of respiratory 
disease (146,147). Countries with a high reported prevalence of HIV also have high 
reported prevalence of asthma (38) and children with HIV on anti-retroviral therapy 
have higher rates of recurrent wheeze (146). Similarly, a study in Cameroon reported 
a positive association between COPD and HIV infection (OR 2.85, CI 1.20-6.74, 
p=0.017). This study found a COPD prevalence of 2.2% in HIV positive patients 
compared to 0.7% in HIV negative participants. It did, however, note the main 
determinants of COPD to be TB, weight and chronic respiratory symptoms (119). 
Similar studies in South Africa and Nigeria have also found an association between 
HIV and airflow obstruction (146). The pathophysiology of the link between 
obstructive lung disease and HIV is not understood but thought to involve the 
development of lung inflammation and a low lung diffusing capacity (147). A rapid 
decline in lung function, obliterative bronchiolitis and severe airflow limitation in 
children with HIV has also been reported (146).  
 
 Socioeconomic status 
Low socioeconomic status is an independent risk factor for COPD and there is a 
significant correlation with lung function, even after adjustment for smoking, 
occupational exposure and ethnicity (90,148). The interplay of several risk factors is 
complex but is thought to include low birth weight, recurrent respiratory infections, 
poor nutrition, poor housing conditions and air pollution (149). A similar pattern of 
exposure to risk factors that impact health care access may also influence the 
development of asthma. Pallasaho et al interviewed 44,483 participants in Finland, 
Sweden and Estonia and reported a significant link between low socioeconomic 
status and asthma-like symptoms (150).  In addition, a recent BOLD study from 12 
sites found that airflow obstruction is always associated with poverty and low 
socioeconomic status at both individual and community level (151). These issues 




 Chronic Asthma 
Chronic airway inflammation and obstruction from uncontrolled asthma has been 
hypothesised as a cause of lung remodelling, leading to fibrosis and the irreversible 
airflow obstruction of COPD (53). Globally the increasing prevalence and ongoing 
lack of access to effective treatment (such as inhaled corticosteroids) will likely be 
contributing to the development of COPD in asthma patients. In addition asthma can 
co-exist with COPD and be a risk factor for COPD development (79). 
 
  Other risk factors that have been implicated globally for asthma 
A recent study in Aberdeen, Scotland targeting school children aged 8–13 reported 
that the associations between asthma and known risk factors had changed over a 50 
year period (152). However, the risk factors known and implicated globally for 
asthma are the following: 
 
 Atopic sensitisation 
Indoor allergens such as house dust, cockroaches and furry pets can sensitize 
asthmatic patients and are considered important risk factors in the emergence of the 
disease in SSA (138,153). The risk of developing asthma is higher in children than 
in adults (153). In polluted urban areas, the prevalence of allergic respiratory diseases 
can be increased by exposure to inhaled allergens, which foster airway sensitization 
and result in a more severe immunoglobulin arbitrated reaction to further 
aeroallergens and airway inflammation (132). A rapid asthmatic reaction can be 
triggered by allergen inhalation. These create immunoglobulin mediated mast cell 
degranulation, downstream inflammation and a late asthmatic reaction, including 
activation of T-helper 2 lymphocytes (154). In many African countries, asthma and 
allergic sensitization are becoming more widespread, a trend supported by studies in 
Ghana, Kenya, Ethiopia and Rwanda. This rising tendency is mostly associated with 
sensitisation to house dust mites, tobacco smoking and living in urbanised areas 
(155). Other specific allergic sensitizers in Africa are span trees, grasses and weeds 
as well as airborne mould spores. In MENA countries, increased asthma prevalence 
has been shown to be associated with increased rates of sandstorms (155). 
Cow milk, eggs, nuts, fish and shellfish are the most allergenic foods, causing an 
IgE-mediated reaction (153,154). About 40% of allergic children have asthma and 
30% will have allergic rhinitis (153). Food induced asthma appears to be less frequent 
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in SSA than in the developed world, though data are limited (154). In a Zimbabwean 
study, tropical dietary lifestyles were considered a probable cause of allergen 
sensitization in Africa as these diets include grains, plants, fruits and even insects 
(155).  
 
 Infections  
In SSA, the incidence of acute respiratory infections is one of the highest in the 
world. Household air pollution is considered to be a risk factor for acute respiratory 
tract infections in children, which in turn may increase the risk of asthma (47). 
Several viral infections can result in asthma in children by causing wheezy bronchitis 
(154). Children who experience severe respiratory infections in early childhood have 
up to a 50% risk of developing asthma in subsequent years of childhood and COPD 
in later life (153,156).  
 
Other important factors implicated in asthma are drugs, exercise, obesity and diet. 
The intake of fruit and vegetables, vitamins A, D and E, zinc and selenium have been 
reported to have a negative association with risk of asthma whilst junk food, salt and 
trans fatty acid intake reported to have a positive association with the risk of 
asthma(157). Obesity is also known to be risk factor for asthma(158). 
 
  Comorbidities  
Patients with COPD often suffer different comorbidities, including cardio-vascular 
disease, osteoporosis, anxiety and depression, malnutrition, metabolic syndrome, 
diabetes, skeletal muscle dysfunction, cachexia, gastrointestinal diseases, lung 
cancer and other respiratory conditions (159–161). Comorbidities can include a wide 
range of diseases that coincide with COPD (162). These diseases can contribute to 
COPD burden, survival, quality of life, degree of severity and are associated with 
poor clinical outcomes (160). Asthma can exist with COPD in clinical settings and 
is a risk factor in the development of COPD as stated above (159).   
 
 
  Conclusions 
NCLD is a present and growing problem across SSA and MENA. There is, however, 
limited epidemiological evidence resulting in gaps in the evidence base and a need 
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for further research. Across both regions, asthma and COPD are likely to be under-
estimated, under-diagnosed, under-treated as well as inadequately prevented 
(38,98,107). Although there have been many global strategies put forward for 
management and control, the implementation of these guidelines inconsistent and 
logistically challenging, especially in LMICs. In these areas, which are facing threats 
from the tobacco epidemic, household and outdoor air pollution and urbanisation, 
there is often limited adoption of international guidelines within resource-limited 
health systems. There are important challenges regarding the lack of diagnostic 
equipment, treatment and trained and experienced health care professionals which 
need to be addressed through strengthening of health systems (138,163).
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  Prevalence and determinants of chronic obstructive 
pulmonary disease in Khartoum, Sudan 
 
 Introduction 
The previous chapter summarised the existing literature on CRD globally and 
identified that there is a lack of information about the burden of disease in SSA and 
MENA.  This chapter outlines a study which documents the burden of COPD in 
Khartoum State. 
 
The global burden of CRDs and COPD has been discussed in the previous chapter. 
There has been little research on COPD in Africa outside of South Africa. The 
prevalence estimates for COPD in SSA (90,91,164) are based on limited 
epidemiological data which lack a standardized definition of COPD. A systematic 
review by Finney et al. (2013) reported only 9 cross-sectional studies from SSA (two 
from South Africa, two from Nigeria, one from Malawi and one from Cape Verde). 
These studies used various diagnostic methods and found a prevalence of COPD 
ranging from 4.1% to 24.8% (92).  
 
The Burden of Obstructive Lung Disease (BOLD) Initiative was established to 
develop standardized methods in order to estimate the prevalence of COPD and 
associated risk factors in populations aged 40 and older (66,68). It also aims to 
measure the influence of COPD on quality of life, ability to perform activities of 
daily living, respiratory symptoms and use of health care services(68,70). BOLD 
study methods have been used in a PLATINO study to assess COPD prevalence in 
five Latin American countries. This was followed by piloting the BOLD study in 
Turkey and China and lessons learned from both PLATINO and the pilot study 
formed the current BOLD study methodology which was developed by the BOLD 
Executive Committee (68). BOLD study objectives and rationale has been discussed 
in section 2.4.2.1 of Chapter 2.   
 
So far, results have been published in local African BOLD studies from Fez in 
Morocco (165), Sousse in Tunisia  (104), Blantyre in Malawi (166) and Ile-Ife in  
Nigeria (167).  
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To date, there are no published data on the prevalence and determinants of COPD in 
Sudan. To help fill this knowledge gap, a population-based, cross-sectional BOLD 
study of the prevalence of COPD in urban Khartoum and the impact of risk factors 
on disease prevalence was conducted. The study discussed in this chapter aimed to 
measure the prevalence and investigate the main risk factors of AFO in Khartoum 




 Study settings, location, and participants  
Khartoum state is divided into 7 localities, across which there is a mix of urban, semi-
urban, rural, and internally displaced populations. The total population of Khartoum 
state is 5,274,321 (Figure 3.1). Three of the 7 localities, with a total population of 
661,617, were randomly selected for sampling in this study. Clusters were formed 
within each locality, comprising 19 in Jabel Awlya, 17 in Sharg Alneel and 11 in 
Omdurman. Each cluster was comprised of 15 households. A total of 280, 258 and 
158 households were then randomly selected from Jabel Awlya, Sharg Alneel and 
Omdurman respectively.  
 
The study aimed to collect  spirometry and questionnaire data from 600 participants. 
The sample size  was selected to provide an acceptable level of precision for 
estimating prevalence in accordance with BOLD protocol(67) See Appendix (4) for 
sampling plan.   
The target population was defined by meaningful administrative borders for which 
other types of routinely collected information are available. In order to avoid 
sampling populations that may have only limited generalizability, the area should 
have a total population, including all ages, of at least 150,000 people (67). 
 
Pre-selection and randomization of clusters and households were carried out before 
the field visits. The selected houses in each cluster were consecutively numbered and 
all eligible adults aged 40 or older in these households were interviewed. Field 
workers returned up to three times to locate absent households at interview time. 
Each participant package had a unique 6-digit identifier that contained both the 
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country and city code.  
Ethical approval was obtained from the Imperial College London and the Ministry 
of Health in Khartoum state ethics committee prior to the start of the study. All 
participants gave written informed consent prior to any data being collected 
(Appendix (2)). 
 
The study participants were aged 40 or older and were selected using a 3-stage 
stratified cluster sampling plan. The exclusion criteria were; aged younger than 40, 
being institutionalized (e.g., living in a community-based care centre or in prison) or 
being medically unfit to perform spirometry (e.g., pregnant women in their third 
trimester and individuals with a history of myocardial infarction or major surgery in 
the previous 3 months). 
 
Where participants were not willing to participate in the study in its entirety, a 
minimal dataset - also used as a refusal questionnaire - was obtained. All study 
participants completed a structured interview administered by a trained interviewer. 
Anthropometric measurements along with pre-bronchodilator and post-
bronchodilator spirometry data were then collected in accordance with the American 
Thoracic Society guidelines using an Easy One System (ndd Medizintechnik, Zurich, 
Switzerland) by three trained and certified technicians in accordance with BOLD 
protocol (68). The questionnaire was administered in an approved translated local 
language (Arabic) and included questions about respiratory symptoms, medical 
history, medications, smoking history, use of biomass fuel, and occupational 
exposure. The clinical data obtained included height, weight, resting heart rate and 
waist and hip circumference (Appendix (3)).  
 
Quality control was carried out at the central BOLD centre at Imperial college 
London. Local training on study standardised methodology was carried out covering 
both questionnaire administration and spirometry test. Piloting of study and 
assessment of data quality was done prior to the start of the main study with technical 
assistance from the BOLD centre.  
 
All study data were pseudo-anonymised and entered in the BOLD online platform of 




Figure 3.1 Khartoum state locality division. Study areas in grey and black (Sharg 
Elnile, Jabel-Awlya and Omdurman ) 
 
 
  Definitions  
Spirometric definitions are illustrated in Table 3.1. Both GOLD definitions and Lower 
Limit of Normal (LLN) as recommended by the ATS/ERS are used to report disease 
prevalence and associated risk factors in this study. Predicted values based on 
standardized values for age, sex and height were calculated based on the third National 
Health and Nutrition Examination Survey (NHANES) (1988–1994) (168). This 
reference range has been used as standard reference that provides ethnically 
appropriate equations for Caucasian Americans, African Americans, and Mexican 
Americans. The use of NHANES enabled comparability with other published BOLD 
studies. The local values were derived from the spirometry results of healthy Sudanese 
adults who had never smoked; did not report any respiratory symptoms, did not report 
current asthma or chronic bronchitis; did not report emphysema or COPD and did not 








Table 3.1 Spirometric definitions (161,168,169) 
 
Findings Spirometric definition 
Post-bronchodilator 
obstruction (GOLD stage 1 
or higher  COPD)1 
FEV1/FVC ratio <0.7 
Post-bronchodilator 
moderate-severe 
obstruction (GOLD stage 2 
or higher  COPD) 1 
FEV1/FVC ratio <0.7 and FEV1 <80% predicted* 
Modified stage 1 or higher 
COPD (LLN) 2 
Post-BD FEV1/FVC < LLN 
Modified stage 2 or higher 
COPD (LLN) 2 
Post-BD FEV1/FVC < LLN and post-BD FEV1 < 
80% predicted 
Low FVC  FEV1/FVC ratio >0.7 and FVC<80% predicted* 
Airway reversibility FEV1 increase >200ml and >12% following 
bronchodilator 
*predicted values based on ages-sex and height standardized taken from NHANES III 
or local values derived from the spirometry of non-smoking and healthy Sudanese 
adults, 1, definitions based on GOLD global burden of lung disease initiative, 2, a 
definition based on below lower limit of normal (LLN). 
 
 
 Statistical analysis 
Subjects who completed full data and minimal questionnaires with acceptable or 
unacceptable spirometry readings were compared using the chi-square test.  
Prevalence estimates of spirometric abnormalities stratified by subject age and sex 
were reported using the NHANES III reference range (68). In addition, prevalence 
estimates were also reported using locally derived spirometry ranges for non-
smoking Sudanese adults with no history of respiratory disease or symptoms. 
Univariate and logistic regression analyses were used to test the associations between 
spirometry abnormalities and several exposure variables including age, sex, 
educational level, self-reported history of tuberculosis (TB), hypertension, diabetes 
and/or heart disease, body mass index, smoking status, smoking pack years, exposure 




Asset-based measures have been commonly used in LMIC as they offer an easily 
collected variable that is constant over short term economic instabilities(170). A 
Mokken scale analysis, which is based on a count of assets owned by the study 
subjects and ranked for their ability to differentiate between different levels of 
wealth; has been used in this study as a proxy of socioeconomic status(170).  The 
analysis included 14 asset related questions included in the BOLD core 
questionnaire. The questions recorded the assets in current time and in the time when 
the participant was 5 years old with a binary (yes/no) responses. Study participants 
were questioned whether their household has any of the following: electricity, flush 
toilet, fixed phone, cell phone, television, radio, refrigerator, car, 
moped/scooter/motorcycle, washing machine, owns their own home, indoor bath or 
shower, indoor tap, or an outdoor tap of their own.  A score of 1 to 10 was created 
and used to test the association between socioeconomic status and spirometric 
abnormality. Only results related to the current owned assets were reported in this 
study.  
 
In addition, occupations reported by participants were grouped into three categories: 
a) Organic, such as working in flour milling cotton jute and farming; b) Inorganic, 
such as working in hard rock, coal mining sand blasting, asbestos, steel milling and 
construction; c) Fumes such as chemical plastics manufacturing, welding firefighting 
and cleaning. Associations between occupation groups and spirometric abnormality 
were tested. In addition, the association with those who had >5 years of occupational 
exposure has been reported. 
 
 Multivariable logistic regression models that included sex, age, and all variables 
from the univariate analysis with a p-value <0.2 were developed. The prevalence of 
respiratory symptoms was reported and associations with the study variables were 
tested using regression analysis. A description of the associations between abnormal 
spirometry and respiratory symptoms was reported. The data were analysed using 
Stata IC 14 (StataCorp, College Station, TX). Prevalence estimates and regression 
models were developed using survey weighting with the Svy package in Stata (14). 
Both univariate and multivariate analysis were reported for the prevalence estimates 
using below Lower Limit of Normal (LLN) and GOLD standards. 
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The response rate was calculated based on total recruited subjects as enumerator 
while having the denominator limited to responders and non-responders.   
 
 Results  
The flow of subjects through the study is shown in Figure 3.2 and Table 3.2. Of the 
998 participants approached, 300 were not traceable, 698 were interviewed and 516 
provided full questionnaire data and had BOLD centre-approved spirometry results. 
Eleven of the 698 consented subjects declined to participate fully in the study but 
completed the minimal data questionnaire, while 2 were ineligible. Of the eligible 
subjects, 54 (7.74%) provided only spirometry readings. The final response rate was 





















Figure 3.2: Participant flow diagram 
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age and sex (n=998) 
Eligible for inclusion (n=698) 
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minimal data (n=11) 
Partial data (n=35) 
Refused, no data collected 
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Ineligible because of age 
(n=2) 
Total population of Jabal-Awlya, 





  Subject characteristics 
The characteristics of the subjects are presented in Tables 3.3 and 3.4. Their mean 
age was 53.8 ± 10.4 (SD) years and 59.3% were men. Out of the total approached 
subjects, 72% conducted a spirometry test, 15% either refused or provided partial 
spirometry data and 13% provided no data. People who refused to participate tended 
to be older (p=0.003, Pearson’s χ2=14.0048). Overall, 35% completed primary 
school education. Men tended to have a higher level of education compared to 
women, as did the group aged 40–49 when compared to other age groups. In total, 
70.9% of participants owned their own home and 66.2% had their own water source. 
Only 20.8% had access to a flush toilet. The mean number of household members 
was 7.8 ± 3.56. No statistically significant difference were seen between those with 
or without usable spirometry results (Table 3.3). 
 
  Environmental Exposures 
Among the respondents, 24% had smoked cigarettes. Of current smokers, 15% were 
men and 0.8% were women. About 24% of smokers had more than 20 pack-years of 
exposure. The age group of 60-69 had the highest smoking exposure compared to 
other groups and 24.6% of them had smoking history. Exposure to indoor biomass 
fuel for more than 6 months was reported by 82% of subjects. In total, 78% reported 
having used an open, indoor fire fuelled by coal or charcoal for cooking for ≥6 
months, while 35% used firewood and 21% used kerosene. Overall, women tended 
to have a higher mean number of hours of exposure to indoor biomass fuel per year 
than men (70% vs. 54%). Twenty five percent of the responders were working in 
agriculture, textile or food industry and farming was the most commonly reported 
occupation (24%) while 15% of them had more than 5 years of exposure.  50% of 
participants work in mining and construction industry had >5 years of exposure. (See Table 
3.4). 
 
  Other diseases 
In total, 23% of subjects were obese and 7% were underweight. Hypertension was 
self-reported by 20% of all subjects, of whom 55% were women. Diabetes was 
reported by 9% (9.5% of women and 8.8% of men), heart disease by 2% (2.3% of 
women and 1.7% of men), lung cancer by 0.5%, stroke by 0.5% and TB by 0.8% 
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(1.2% of women and 0.6% of men). None of these diseases were associated with any 
type of obstruction or low FVC using either local or NHANES reference ranges, 
except tuberculosis associated with stage 1 COPD or higher using the NHANES 
reference range (OR 0.08, 95% CI 0.01- 0.59). 
 
Table 3.2  Comparison of responders1 and non-responders2 for Khartoum, Sudan 
 
  Responders Non-responders P-value3 
  N=917 N=52  
Age 40-49 226 (38%) 7 (22%) 0.015 
 50-59 200 (34%) 8 (25%)  
 60-69 108 (19%) 9 (28%)  
 70+ 61 (10%) 8(25%)  
     
Gender Male 353 (59%) 18 (55%) 0.587 
 Female 242 (41%) 15 (46%)  
     
Smoking status Current 55 (9%) 0 (0%) 0.362 
 Ex 86 (14%) 1 (8%)  
 Never 454 (76%) 12 (92%)  
     
Doctor diagnosed 
asthma, 
emphysema, CB or 
COPD 
Yes 44 (7%) 0 (0%) 0.309 
 No 551 (93%) 13 (100%)  
     
Other disease Yes 152 (26%) 1 (8%) 0.265 
 No 443 (74%) 12 (92%)  
 
1. Responders are those who completed post-BD spirometry (regardless of QC scores) and the core 
questionnaire. 
2. Non-responders are eligible individuals who are missing the core questionnaire and/or post-BD 
spirometry, but for whom the tabulated variable is known.  








Table 3.3 Comparison of responders1 with and without usable spirometry for 
Khartoum, Sudan 
 





Age 40-49 192(37%) 34(43%) 0.783 
 50-59 176(34%) 24(30%) 
 60-69 94(18%) 14(18%) 
 70+ 54(10%) 7(9%) 
Gender Male 306(59%) 47(59%) 0.974 
 Female 210(41%) 32(41%) 
Smoking status Current 50(10%) 5(6%) 0.217 
 Ex-smoker 70(14%) 16(20%) 
 Never 396(77%) 58(73%) 
Doctor diagnosed 
asthma 
Yes 34(7%) 5(6%) 0.931 
 No 482(93%) 74(94%) 
Doctor diagnosed 
COPD 
Yes 2(0%) 0(0%) 0.579 
 No 514(100%) 79(100%) 
Cough Yes 58(11.2%) 8(10.1%) 0.769 
 No 458(88.8%) 71(89.9%) 
Phlegm Yes 59(11.4%) 8(10.1%) 0.732 
 No 457(88.6%) 71(89.9%) 
Wheeze Yes 17(3.3%) 1(1.3%) 0.327 
 No 499(96.7%) 78(98.7%) 
Shortness of breathe Yes 53(11.1%) 9(12%) 0.816 
 No 425(89%) 66(88%) 
Any Symptoms Yes 122(24.7%) 17(22.4%) 0.667 
 No 373(75.4%)       59(77.6%) 
1. Responders are those who completed post-BD spirometry  (regardless of QC scores) and the core 
questionnaire. 
2. Usable spirometry defined as post-BD quality scores>1 for each of FEV1 and FVC  
3. Two-sided p-value based on Pearson chi-square test. NOTE: In some cases numbers are too small 





Table 3.4 Characteristics of all subjects who completed a full BOLD core 
questionnaire, including those with and without spirometry results. 
 
Variable (n) N(%) 
Age group, years (n=595)  
40–49 226 (38.0) 
50–59 200 (33.6)  
60–69 108 (18.2)  
70+ 61 (10.3) 
Sex (n=595)  
Male 353 (59.3) 
Female 242 (40.7) 
Level of education (n=593)  
None  125 (21.1)       
Primary school 207 (34.9)       
Middle school  69 (11.6)        
High school or above  192 (32.4)       
Mean years of education (n=595) 6.49 (5.5) 
Home ownership (n=595)   
Yes 422 (70.9)        
No 168 (28.2)        
Access to private indoor or outdoor water supply (n=595)   
Yes 394 (66.2)        
No 199 (33.5)       
Access to flush toilet in home (n=595)   
Yes 124 (20.8)      
No 466 (78.3)       
Smoking status (n=595)   
Current smoker 55 (9.2) 
Ex smoker 86 (14.5) 
Never smoked 454 (76.3) 
Pack-years of smoking (n=595)  
Never smoked  454 (76.3) 
>0 and <10 71 (11.9) 
≥10 70 (11.8) 
Biomass exposure (n=532)   
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Yes 422 (82.4) 
No 90 (17.6) 
Farm work for ≥3 months (n=527)   
Yes 126 (23.9) 
No 401 (76.1) 
Body mass index (n=588)  
Underweight (<18.5)  39 (6.6) 
Normal (18.5–24.9)  226 (38.4) 
Overweight (25.0–29.9)  189 (32.1) 
Obese (≥30) 134 (22.8) 
Reported history of tuberculosis (n=595)  
Yes 5 (0.8) 
No 590 (99.2) 
Reported history of hypertension (n=595)  
Yes 118 (19.8) 
No 477 (80.2) 
Reported history of diabetes (n=595)  
Yes 54 (9.1) 
No 541 (90.9) 
Reported history of heart disease (n=595)  
Yes 12 (2.0) 
No 583 (98.0) 
Current Mokken scale (Mean ± SD) 5.18 ±2.67 
0 50 (8.6) 
1 30 ( 5.1) 
2 27 (4.6) 
3 42 (7.2) 
4 53 (9.1) 
5 88 (15.0) 
6 90 (15.4) 
7 91 (15.6) 
8 64 (10.9)   
9 32 (5.5) 
10 18 ( 3.1) 
Occupation group 1 137(25.8) 
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>5 years of exposure in group 1 104 (14.9) 
Occupation group 2 61(11.5) 
>5 years of exposure in group 2 40(50.7) 
Occupation group 3 25(5.7) 
>5 years of exposure in group 3 19(2.7) 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry) 
Occupation group 3: Welders, firefighters, cleaners or exposed to chemicals and 
fumes during work 
 
 
  Respiratory symptoms 
At least one respiratory symptom was reported by 23% (SE 1.9) of subjects and 
respiratory symptoms that interfered with daily activities was reported by 1.9% (SE 
0.5). A cough was reported by 10.4% (SE 1.3), with the highest prevalence recorded 
in subjects aged 70+ years (11.9% [SE 4.9]). The prevalence of cough was higher in 
men than in women (10.6% [SE 1.6] vs. 10.1% [SE 2.0]. Chronic cough (lasting for 
more than 3 months per year) was reported by 4.0% (SE 0.8) of the study population. 
Production of sputum was reported by 11% (SE 1.3) and chronic production of 
sputum (for more than 3 months per year) was reported by 5% (SE 0.9). Shortness 
of breath was reported by 11% (SE 1.3), and 41% (SE 6.5) of this group stopped 
walking after 100 yards because of breathing problems. A wheeze in the past 12 
months in the absence of a cold was the least commonly reported symptom (3.0% 
[SE 0.7], Table 3.5, Figure 3.3). A small positive correlation was found between all 
respiratory symptoms (p<0.05, Pearson’s r correlation <0.4) except a medium 
positive correlation between sputum production and cough (p<0.001, Pearson’s r 
correlation = 0.43). 
 
Medically diagnosed respiratory disease was reported by 7.4% of the participants 
that contributed full data sets.  Medically diagnosed asthma and COPD was reported 
by 6.6% and 2.1% of subjects respectively. Medically diagnosed COPD, chronic 






Table 3.5: Age and gender stratified prevalence of respiratory symptoms among 















Cough (do you 
usually cough 
when you don't 
have a cold?) 
40-49 9% (2.7)  9.1% (2.6) 9.4% (1.9)  
50-59 10% (2.7)  10.6% (3.4)  10.7% (1.9) 
60-69 12% (3.8) 9.9% (5.4)  11.6% (3.2) 
70+ 11% (4.7)  13.1% (8.8) 11.9% (4.9) 
Total 10.6% (1.6) 10.1% (2.0) 10.4% (1.3) 
Sputum (do you 





40-49 16% (3.4) 10.8% (2.8)  13.6% (2.3)     
50-59 10.9% (2.7) 5.8% (2.5) 8.6% (1.9) 
60-69 10.2% (3.2)   13% (6.1)  11.4% (3.2)  
70+ 11.9% (5.1) 0 6.4% (2.9) 
Total 13.2% (1.9)  8.5% (1.7) 11.1% (1.3)    
Wheeze (have you 
had wheezing / 
whistling in your 
chest at any point 
in past 12m, in 
the absence of a 
cold) 
40-49 4.5% (2.0) 3.3% (1.6)  4% (1.3) 
50-59 1.7% (1.1)     1.1%(1.1)  1.4 (0.8)     
60-69  7.6% (3.0)    0 4.3% (1.7) 
70+ 0 0 0 
Total 3.7% (1.1)    1.8%(0.91)  2.9% (0.7) 
Shortness of 
breath (Currently 
do you have 
shortness of 
breath when 
hurrying on the 
level or walking 
up a slight hill?) 
40-49 10.5% (3.0)    17.8%(3.6)   13.8% (2.3)  
50-59 6.1% (2.2)    12.3%(3.7)    9.04% (2.1)    
60-69 7.5% (3.2)    6.7%(4.6)   7.2% (2.7)    
70+ 10.7% (4.6)    5.5%(5.4)    8.3% (3.5)    
Total 8.9% (1.7)    13.2%(2.2)    10.9% (1.3) 
 
    
Any respiratory 




40-49 25.8% (4.2)    25.3%(4.1) 25.6% (2.9)    
50-59 21.1% (3.7)      19.2%(4.4)  20.2% (2.8)     
60-69 26.5% (5.2)    22.7%(7.5)    24.8% (4.4) 
70+ 23.7% (6.7)    18.4%(9.8)    21.8% (5.8)   










your usual daily 
activities?) 
40-49 0.9% (0.9) 5%(2.0)     2.8% (1.1)    
50-59 0 3.7% (2.1) 1.6% (0.9)    
60-69 1.3% (1.3)     0 0.7% (0.7) 
70+ 1.8% (1.7)    0 0.9% (0.9) 
Total 0.8% (0.5)   3.4%(1.1)    1.9%(0.5)   
* Presence of respiratory symptoms were determined using questions, derived from the 
BOLD study core questionnaire: Usual cough: Do you usually cough when you don’t have 
a cold? Usual sputum: Do you usually bring up phlegm from your chest, or do you usually 
have phlegm in your chest that is difficult to bring up, when you don’t have a cold? 
Exertional dyspnea: Are you usually troubled by breathlessness when hurrying on the level 
or walking up a slight hill? Wheeze: Have you had wheeze/whistling in your chest at any 
time in the past 12 months? In the last 12 months have you had this wheeze or whistling only 
when you have had a cold? Functional limitation: did you have an attack of breath shortness 






Figure 3.3:  Prevalence of respiratory symptoms among the study participants. The 
upper bar represents symptom prevalence in women (n=242) and the lower bar 























































Figure 3.4:  Prevalence of respiratory symptoms among the study participants. The 
upper bar represents symptom prevalence in women (n=242) and the lower bar 
represents symptom prevalence in men (n=353).  
 
  Spirometry  
No statistically significant differences were found between age and gender groups 
who did and did not complete the spirometry test, (p=0.783, Pearson’s χ2=1.0774) 
and (p=0.974, Pearson’s χ2=0.001) respectively. 
 
  Spirometry results based on GOLD definitions 
Post-bronchodilator obstruction (GOLD stage 1) was seen in 14.8% (SE 1.6) of the 
total study population (16.6% [SE 2.1] of men and 12.5% [SE 2.5] of women). 
Subjects aged 60–69 had the highest prevalence of GOLD stage 1 or higher COPD 
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the overall population had GOLD stage 2 or higher (13.9% [SE 1.9] of men and 
10.9% [SE 2.3] of women). Male smokers with more than 20 packs per years had the 
highest prevalence of GOLD stage 1 and stage 2 COPD (19.8% [SE 6.6] and 17.3 
[SE 6.2]) compared to other smoking groups. Using the locally derived reference 
range, 5.2% (SE 0.9) of the total study population had GOLD stage 2 COPD (6.1% 
[SE 1.3] of men and 4% [SE 1.4] of women). Similarly, subjects aged 60–69 had the 
highest prevalence of GOLD stage 2 using both the local and NHANES reference 





Figure 3.5 Estimated Population Prevalence of airway obstruction by age and sex using 
(NHANES) reference range for the Sudanese population in subjects completing standard 
ATS spirometry (n=516). The upper graph represents the prevalence of GOLD Stage 1 or 
higher COPD (Post-BD FEV1/FVC <0.7) and the lower graph represents the prevalence of 





 Spirometry results based on LLN definition 
Using below LLN of the NHANES reference range for white Americans, modified 
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11.2 [SE 2.4] of women). On other hand using the locally derived reference range 
the prevalence was 5.7% [SE 1.1] (5.2% [SE 1.3] of men and 6.3 [SE 1.9] of women). 
Subjects aged 60–69 had the highest prevalence of modified stage 1 or higher COPD 
using below LLN (13.4% [SE 3.8]). According to the NHANES III reference range, 
prevalence of modified stage 2 or higher COPD using below LLN was 9.4% [SE 1.4) 
(8.8% [SE 1.7] of men and (10.1% [SE 2.2] of women). Males with 0-10 pack years 
of smoking exposure had the highest prevalence of modified stage 1 and 2 COPD 
using below LLN compared to other smoking groups (15.3% [SE 5.2] and 14% [SE 
5.1]). Using the locally derived reference range, 3.0% [SE 0.8] of the study 
population had modified stage 2 or higher COPD (2.9% [SE 0.9] of men and 3.1% 
[SE 1.3] of women).  Similarly, subjects aged 60–69 had the highest prevalence of 
stage 2 or higher COPD using both the local and NHANES reference ranges (17.6% 




Figure 3.6: Estimated Population Prevalence of airway obstruction by age and sex 
using (NHANES) reference range for the Sudanese population in subjects 
completing standard ATS spirometry (n=516). The upper graph represents the 
prevalence of LLN Modified Stage 1 or higher COPD (Post-BD FEV1/FVC < LLN) 
and the lower graph represents the prevalence of LLN Modified Stage 2 or higher 




















Figure 3.7 Estimated Prevalence of airway obstruction by sex using National Health 
and Nutrition Examination Survey reference ranges (NHANES) for the Sudanese 
population in subjects completing standard ATS spirometry (n=516). The graph 
represents the prevalence of GOLD Stage 1 or higher COPD (Post-BD FEV1/FVC 
<0.7) and the prevalence of LLN Modified Stage 1 or higher COPD (Post-BD 
FEV1/FVC < LLN). 
 
 
 Airway reversibility 
Airway reversibility was found in 6.1% [SE 1.1] of the total study population and 
was more prevalent in women than in men (8% [SE 1.9] vs. 4.4% [SE 1.1]). Airway 
obstruction persisted after use of a bronchodilator in 10.5% (SE 5.1) of subjects with 
reversibility. Prevalence was higher using LLN (18.5% [SE 4.0]) – see Table 3.9. 
 
 Low FVC 
Low FVC was more prevalent than obstruction in both sexes and in all age groups. 
Using the NHANES III reference range, the overall estimated prevalence was 58.8% 
(SE 2.2). Low FVC was more slightly common in men than in women (59.5% [SE 
2.9] vs. 58.1% [SE 3.6]). Respiratory symptoms were more present in those with low 
FVC as 53.3% of those with respiratory symptoms had low FVC (52.5% phlegm and 
56.6% shortness of breath). However, having cough was significantly higher in those 
without spirometric restriction (Table 3.10). However, using the local reference 
range, a far lower prevalence estimate of low FVC (11.3% [SE 1.4]) was found 













Table 3.6 Age and gender stratified prevalence estimates for abnormal spirometry 
among participants with full spirometry data using GOLD definition   
Spirometric 
definition  




















40-49 8.1% (2.9)    3.9% (1.9)     6.1% (1.8)    
50-59 15.5% (3.4)  13.1% (4.3)  14.4% (2.7)  
60-69 35.4 (5.8)    26.5% (8.5)    31.6% (4.9)    
70+ 26.6 (7.3)    26.3% (11.4)    26.5% (6.9)    
Total 16.6% (2.1)   12.5% (2.5)  14.8% (1.6)   
Post bronchodilator 
moderate to severe 
obstruction 
FEV1/FVC ratio<70% 
and FEV1 <80% 
predicted (NHANES 
ref range) (GOLD 
stage 2) 
40-49 8.1% (2.9)    3.9% (1.9)    6.2% (1.8) 
50-59 12.8% (3.1)    13.1% (4.3)     12.9% (2.6) 
60-69 31.1% (5.7)    22.9% (8.2)    27.6% (4.8) 
70+ 15.5% (5.9)     18.4%(9.8)     17.0% (5.8) 
Total 13.9% (1.9)    10.9% (2.3) 12.6% (1.5)  
Post bronchodilator 
moderate to severe 
obstruction 
FEV1/FVC ratio<70% 
and FEV1 <80% 
PREDICTED (locally 
derived ref range) 
(GOLD stage 2) 
40-49 3.4% (1.9)    3.0% (1.6)    3.1% (1.3)    
50-59 6.2% (2.3) 3.1% (2.2)    4.9% (1.6)   
60-69 16.2% (4.5) 7.8% (5.3)     12.6% (3.5) 
70+ 2.2% (2.2) 5.3% (5.2)    3.8% (2.8) 
Total  6.1% (1.3) 4.0% (1.4)    5.2% (0.9) 
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Table 3.7 Age and gender stratified prevalence estimates for abnormal spirometry 




(reference range)  
















(FEV1/FVC < LLN) 
(NHANES ref range) 
40-49 6.8 (2.7) 4.9 (2.1) 5.9 (1.7) 
50-59 10.4 (2.9) 13.1 (4.4) 11.5 (2.5) 
60-69 17.9 (4.7) 19.0 (7.6) 18.4 (4.2) 
70+ 5.6 (3.9) 21.1 (10.8) 13.4 (6.0) 
Total 9.5 (1.7) 11.2 (2.4) 10.3 (1.4) 
Post bronchodilator 
obstruction 
(FEV1/FVC < LLN) 
(locally derived ref 
range) 
40-49 4.7 (2.3) 3.0 (1.7) 3.9 (1.5) 
50-59 4.3 (1.9) 3.1 (2.2) 3.8 (1.4) 
60-69 11.9 (3.9) 15.4 (7.1) 13.4 (3.8) 
70+ - 13.2 (8.8) 6.7 (4.6) 
Total 5.2 (1.3) 6.2 (1.9) 5.7 (1.1) 
Post bronchodilator 
moderate to severe 
obstruction  
(FEV1/FVC < LLN 
and POST-BD FEV1 < 
80% predicted) 
(NHANES  ref range) 
40-49 6.8 (2.6) 4.9 (2.1)  5.9 (1.7) 
50-59 8.6 (2.6) 13.1 (4.3) 10.5 (2.4) 
60-69 16.4 (4.5) 18.9 (7.6) 17.6 (4.2) 
70+ 5.6 (3.9) 13.2 (8.8) 9.4 (4.9) 
Total 8.8 (1.7) 10.1 (2.2) 9.4 (1.4) 
Post bronchodilator 
moderate to severe 
obstruction  
FEV1/FVC < LLN 
and post-BD FEV1 < 
80% predicted 
(locally derived ref 
range) 
40-49 1.1 (1.1) 3.0 (1.7) 2.0 (1.0) 
50-59 3.5 (1.7) 1.8 (1.8) 2.8 (1.3) 
60-69 8.8 (3.4) 3.9 (3.9) 6.7 (2.6) 
70+ - 5.3 (5.2) 2.7 (2.6) 






Table 3.8 Estimated Population Prevalence (SE) of abnormal spirometry by pack 
years and sex  
    Pack-years   
  Sex Never 
smokers 




(SE) of GOLD 
Stage 1 or 
higher COPD 
Male 15.4 (2.6) 19.3 (5.7) 16.9 (7.0) 19.8 (6.6) 16.7 (2.1) 
Female 12.9 (2.6) * * * 12.5 (2.6) 




(SE) of GOLD 
Stage 2 or 
higher COPD 
Male 13.0 (2.4) 14.0 (5.1) 16.9 (7.0) 17.3 (6.2) 14.0 (2.0) 
Female 11.3 (2.4) * * * 11.0 (2.3) 




(SE) of LLN 
Modified Stage 
1 or higher 
COPD 
Male 8.9 (2.1) 15.3 (5.2) 4.5 (3.2) 7.4 (4.2) 9.5 (1.7) 
Female 11.5 (2.5) * * * 11.2 (2.4) 
Total 10.4 (1.7) 13.7 (4.7) 4.4 (3.1) 7.4 (4.2) 10.3 (1.4) 
Prevalence 
(SE) of LLN 
Modified Stage 
2 or higher 
COPD 
Male 8.1 (2.1) 14 (5.1) 4.5 (3.2) 7.4 (4.2) 8.8 (1.7) 
Female 10.4 (2.3) * * * 10.1 (2.2) 
Total 9.4 (1.6) 12.6 (4.6) 4.4 (3.1) 7.4 (4.2) 9.4 (1.4) 
* No observation in this group 
 
 
Table 3.9 Age and gender stratified prevalence estimates for airway reversibility 





















fev1 increase ≥200ml 
and ≥12% following 
bronchodilator 
40-49 1.3% (1.3)    4.9% (2.2)    3% (1.2)  
50-59 7.2% (2.5)    9.1% (3.6)    8.1% (2.1)    
60-69 5.9% (2.9) 18.3% (7.4) 11.2% (3.6) 
70+ 7.5% (4.3) 5.3% (5.2) 6.4% (3.4) 
Total 4.4% (1.1) 8% (1.9) 6.1% (1.1) 
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Table 3.10  Presence of respiratory symptoms in those with/without low FVC 
 
Spirometric restriction Abnormal FVC N(%) Normal FVC N(%) P-value 
Cough 25(43.1) 33(56.9) 0.025 
Phlegm 31( 52.5) 28( 47.5) 0.476 
Wheeze 8(47.1)  9( 52.9) 0.406 
Shortness of breathe 30(56.6)  23(43.4) 0.874 
Functional limitation 6(60) 4(40) 0.84 
Any respiratory 
symptoms 
65(53.3) 57(46.7) 0.332 
 
 
Table 3.11 Age and gender stratified prevalence estimates for low FVC using both 




(reference range)  





















40-49 75.7% (4.6)    65% (4.7) 70.6% (3.3)    
50-59 56% (4.7)    60.6% (6.2) 57.9% (3.7)     
60-69 37.5% (5.9) 44% (9.6)    40.3% (5.3)    
70+ 35.4% (7.8) 44.7% (12.7)  40.1% (7.5)    






(locally derived ref 
range) 
40-49 11.1% (3.3)  11.5% (3.1)    11.3% (2.3)  
50-59 16.5% (3.4)     12.5% (4.2)    14.7% (2.7)    
60-69 5.9% (2.8)    7.2% (4.9)     6.4% (2.7) 
70+ 14.3% (5.6)    5.3% (5.2)  7.7% (3.9) 






 Factors associated with respiratory symptoms  
There was no significant association between a cough and any of the risk factors 
investigated in either bivariate or multivariate analysis. 
In both multivariate and bivariate analyses, regular production of sputum was 
negatively associated with age (Table 3.12). Subjects aged 60–69 were less likely to 
report regular sputum production (OR 0.39, 95% CI 0.16–0.93) than those aged 40–
49. There was a significantly increased likelihood of regular sputum production if 
the patient was an ex-smoker (OR 2.66, 95% CI 1.09–6.50) and had diabetes (OR 
4.04, 95% CI 1.82–8.96). There was no observed trend in Mokken scale points and 
all respiratory symptoms. Participants with lower socioeconomic status; who scored 
2 in Mokken scale tend to have higher odds of sputum production in both bivariate 
and multivariate analysis ( OR 7.18, 95% CI  1.16-44.53). 
In multivariate analysis, the likelihood of having shortness of breath was 
significantly greater in subjects exposed to indoor biomass fuel (OR 4.56, 95% CI 
1.44–14.43). The presence of wheeze was only associated with currently being a 
smoker (OR 3.49, 95% CI 1.02–11.96).  
Cough was less commonly reported in those with low FVC using LLN (odds ratio 
[OR] 0.48, 95% confidence interval [CI 0.27-0.87]) and NHANES (odds ratio [OR] 
0.55, 95% confidence interval [CI 0.30–0.99]). There were no other significant 
associations between spirometric abnormality and respiratory symptoms.
 
 73 
Table 3.12 Multivariate associations between respiratory symptoms and risk factors (all variables significant at level <0.2 in bivariate analysis are 
included) 
 
Variable Usual cough 
 (n=66/ 596) 




Wheeze without cold  
(n= 18/596) 
 Odds ratio 95% CI Odds ratio 95% CI Odds ratio 95% CI Odds ratio 95% CI 
Age group         
40-49 1.0 - 1.0 - 1.0 - 1.0 - 
50-59 1.05 0.54-2.03 0.36*   0.17-0.75 0.49 0.22-1.09 0.34 0.09- 1.33 
60-69 0.99 0.43- 2.29 0.39* 0.16-0.94 0.81 0.31-2.14 1.28 0.45- 3.70 
70+ 0.97 0.36-2.66 0.41  0.15-1.11 0.29 0.05-1.72 - - 
Gender         
Male 1.0 - 1.0 - 1.0 - 1.0 - 
Female 0.79 0.43-1.45 0.93 0.44-1.96 1.37 0.63-2.99 0.61 0.19-1.98 
Year of education 0.96 0.91-1.02   1.03 0.97- 1.09   
Smoking status         
Never   1.0 - 1.0 - 1.0 - 
Current   2.25 0.77- 6.55   3.49* 1.02-11.96 
Ex-smoker   2.67* 1.09-6.50   0.26 0.03-2.07 





  0.19 0.03-1.43 0.53 0.10-2.74 - - 
Normal (BMI 18-25)   1.0 - 1.0 -   
Overweight (BMI 25-30)    0.64 0.30-1.35 2.09 0.91-4.76   
Obese (BMI>30)   0.75 0.34-1.68 2.31 0.94- 5.66   
Reported diabetes          
No   1.0 - 1.0 -   
Yes   4.04* 1.82-8.96 0.26 0.03-1.94   
Have a flush toilet         
No   1.0 - 1.0 - 1.0 - 
Yes   1.24 0.53- 2.87 0.62 0.29-1.33 5.61 0.71-44.36 
Number of people living 
in house 
1.05 0.99-1.12       
Any biomass exposure         
No 1.0 - 1.0 - 1.0 - - - 
Yes 1.69 0.70-4.09 1.93 0.71- 5.23 4.56 * 1.44 -14.43   
Current Mokken scale  OR  P-value  OR  P-value  OR  P-value  OR  P-value 




 Factors associated with post-bronchodilator airway obstruction defined by 
LLN 
Using LLN, subjects aged 60–69 had the highest risk of COPD modified stage 1 or 
higher (OR 3.16, 95% CI 1.20-8.31) and modified stage 2 or higher (OR 3.39, 95% 
CI 1.04- 6.93) compared to those aged 40–49. In contrast, having a higher 
educational level was protective against LLN modified stage 1 or higher COPD in 
bivariate analysis (OR 0.31, 95% CI 0.13–0.76), though no association was identified 
after adjustment. Those who were overweight or obese were less likely to have LLN 
modified stage 1 or higher COPD (OR 0.38, 95% CI 0.17–0.82 and OR 0.34, 95% 
CI 0.13–0.99, respectively). Those with a history of TB were less likely to have LLN 
modified stage 1 or higher COPD (OR 0.08, 95% CI 0.01- 0.59). No other factor was 
significantly associated with airway obstruction (Tables 3.13 and 3.14). 
 
Using the local reference range, subjects aged 60–69 were more likely to have COPD 
stage 1 or higher than their younger counterparts (OR 3.10, 95% CI 1.01-9.57), and 
being obese was negatively associated with obstruction (OR 0.29, 95% CI 0.09- 0.97) 
in multivariable analysis. Having a higher educational level was protective against 
COPD in the bivariate analysis (OR 0.23, 95% CI 0.063 - 0.83), though no 
association was identified after adjustment. Using firewood for cooking for more 
than 6 months was protective against COPD modified stage 2 or higher (OR 0.11, 
95% CI 0.03 - 0.44) in bivariate analysis though no association was identified after 
adjustment. No other association was identified between possible risk factors and 
abnormal spirometry.   
 
 Factors associated with post-bronchodilator airway obstruction defined by 
GOLD 
Older age was significantly associated with airway obstruction. The 70+ age group 
had increased odds of 3.94 (95% CI 1.62-9.56) compared to the younger group (40-
49), though the (60-69) age group had the highest odds of 6.25 (95% CI 2.85-13.72) 
of airway obstruction and 5.21 (95% CI: 2.35-11.55) of moderate-severe obstruction 
compared to those in the 40-49 group.  Being a current smoker had an increased 
chance of 2.56 (95% CI 1.06-6.18)  of having a GOLD stage 2 or higher COPD. 
Being obese and having TB were protective against GOLD stage 2 or higher COPD 
and the odds were (OR: 0.48; 95% CI: 0.23-1.00) and (OR 0.18; 95% CI: 0.04-0.91) 
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respectively. Years of Education was significantly associated with obstruction in the 
bivariate analysis (OR: 0.92; 95% CI: 0.87-0.97) but once the adjustment was made 
no association was identified (Table 3.15 and 3.16). Using the Mokken scale, no 
association observed between socio economic status and both gold stage 1 and stage 
2 COPD.  
 
Using the local reference range in GOLD stage 2 or higher COPD, the age group 60-
69 had increased odds of 3.79 compared to the younger group (95% CI: 1.33-10.81), 
while self-reported TB and being obese were negatively associated with obstruction 
(OR 0.07; 95% CI: 0.01-0.43) and (OR 0.17; 95% CI: 0.03-0.90) in the multivariable 




Table 3.13 Bivariate and multivariable associations of risk factors with Modified Stage 1 or higher COPD defined using NHANES reference range 
(Post-BD FEV1/FVC < LLN; n=64/590) 
 
Variable Bivariate association Multivariable association 
 Odds ratio 95% CI Odds ratio 95% CI 
Age group     
40-49 1.0 - 1.0 - 
50-59 2.08 ± 0.95-4.53 2.13 0.84-5.41 
60-69 3.58 * 1.56-8.22 3.16 * 1.20-8.32 
70+ 2.47 0.76-9.10 1.91 0.60-6.10 
Gender     
Male 1.0 - 1.0 - 
Female 1.20 0.65-2.23 1.31 0.61-2.84 
Level of education     
None    1.0 - 
Primary school 0.46± 0.21-1.02 0.610 0.27-1.34 
Middle school  0.72 0.27-1.91 1.23 0.40-3.81 
High school or above  0.32* 0.134-0.76 0.71 0.28-1.78 
Self-reported TB     
No   1.0 - 
Yes 4.53± 0.72-28.68 0.08 0.01-0.59 
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Body Mass Index (kg/m2)     
Underweight (BMI<18.5)   2.04± 0.72-5.77 1.87 0.66-5.30 
Normal (BMI 18-25) 1.0 - 1.0 - 
Overweight (BMI 25-30) 0.38* 0.18-0.82 0.43 0.18-1.01 
Obese (BMI>30) 0.34* 0.13-0.89 0.35* 0.11-1.17 
Smoking status     
Never 1.0 - 1.0 - 
Current   1.21 0.48-3.05 1.95 0.83-4.59 
Ex smoker 0.76 0.29-1.97 0.72 0.32-1.60 
Smoking pack years     
<10 years 1.0 - - - 
<= 10 years 0.51± 0.19-1.36 - - 
Home ownership     
No 1.0 - - - 
Yes 1.11 0.55-2.23 - - 
Access to private water supply (indoors or 
outdoors) 
    
No 1.0 - - - 




Household has flush toilet     
No 1.0 - - - 
Yes 0.86 0.41-1.82 - - 
Number of people living in house 1.051 0.97-1.14 - - 
Any biomass exposure     
No 1.0 - - - 
Yes 1.80 0.65-4.97 - - 
Use of firewood in cooking >6 month     
No 1.0 - - - 
Yes 0.60± 0.30-0.17 - - 
Occupation group 1 0.87 0.42-1.83 - - 
>5 years of exposure in group1 0.9 0.40-2.05 - - 
Occupation group 2 0.84 0.30-2.41 - - 
>5 years of exposure in group2 0.16± 0.02-1.24 - - 
Occupation group 3 1.63 0.44-6.09 - - 
>5 years of exposure in group3 1.33 0.27-6.66 - - 
Working in farming     
No 1.0 - - - 
Yes 0.95 0.45-1.98 - - 
Current Mokken scale OR P-value OR P-value 
 0.96 0.478 - - 
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± indicates p<0.2; *p<0.05. CI, confidence interval; OR, odds ratio; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity ratio; 
LLN, lower limit of normal; TB, tuberculosis 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry 






Table 3.14 Bivariate and multivariable associations of risk factors with Modified 
Stage 2 or higher COPD defined using NHANES reference range (Post-BD 
FEV1/FVC < LLN and post-BD FEV1 < 80% predicted; n=58/590) 
 
Variable Bivariate association Multivariable association 
 Odds ratio 95% CI Odds ratio 95% CI 
Age group     
40-49 1.0 - 1.0 - 
50-59 1.88± 0.85-4.15 1.85 0.72-4.71 
60-69 3.39* 1.46 -7.84 2.61* 1.01 - 6.77 
70+ 1.65 0.46-6.01 1.08 0.29- 4.00 
Gender     
Male 1.0 - 1.0 - 
Female 1.17 0.62-2.20 1.55 0.71-3.39 
Years of education 0.91* 0.85-0.97 0.95 0.88-1.04 
Self-reported TB     
No 1.0 - 1.0 - 
Yes 5.02± 0.79-31.80 0.05* 0.01-0.34 
Body Mass Index 
(kg/m2) 
    
Underweight 
(BMI<18.5) 
1.42 0.46 - 4.31 1.19 0.34-4.16 
Normal (BMI 18-25) 1.0 - 1.0 - 
Overweight (BMI 25-
30) 
0.36* 0.16-0.81 0.73 * 0.15-0.93 
Obese (BMI>30) 0.31* 0.11- 0.85 0.29 0.08-1.05 
Smoking status     
Never 1.0 - 1.0 - 
Current 1.35 0.53-3.41 2.28 0.96-5.41 
Ex smoker 0.74 0.26-2.05 0.59 0.23-1.49 
Home ownership     
No 1.0 -   




Access to private 
water supply (indoors 
or outdoors) 
    
No 1.0 -   
Yes 1.42 0.74 - 2.74   
Household has flush 
toilet 
    
No 1.0 - - - 
Yes 0.88 0.41-1.89 - - 
Number of people 
living in house 





    
No 1.0 -   
Yes 1.92 0.63-5.82   
Occupation group 1 1.01 0.48- 2.12 - - 




Occupation group 2 0.96 0.33-2.73 - - 




Occupation group 3 1.83 0.49-6.86 - - 




Working in farming     
No 1.0 -   
Yes 0.91± 0.44-1.92 0.61 0.32-1.16 
Current Mokken 
scale 
OR P-value OR P-Value 
 0.94 0.360 - - 
± indicates p<0.2; *p<0.05. CI, confidence interval; or, odds ratio; FEV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity ratio; LLN, lower limit of 





Table 3.15 Bivariate and multivariable associations of risk factors with post 
bronchodilator airway obstruction defined using GOLD and NHANESIII reference 
range (FEV1/FVC ratio <0.7), n= 96 /590) 
 




95% CI Odds 
ratio 
95% CI 
Age group     
40-49 1.0 -   
50-59 2.58* 1.22-   5.47 2.58* 1.18-   5.63 
60-69 7.07* 3.29- 15.21 6.25* 2.85- 13.72 
70+ 5.51* 2.18 -13.92 3.94* 1.62-    9.57 
Gender     
Male 1.0 -   
Female 0.72 0.41-   1.24 0.77 0.40-   1.49 
Years of education 0.92* 0.87-  0.97 0.96 0.91-    1.01 
Self-reported TB     
No 1.0 -   
Yes 2.96  0.47- 18.58   
Body Mass Index (kg/m2)     
Underweight (BMI<18.5) 1.75 0.69- 4.43 2.04 0.77- 5.38 
Normal (BMI 18-25) 1.0 -   
Overweight (BMI 25-30) 0.42 * 0.23 - 0.78 0.51 0.26 - 1.02 
Obese (BMI>30) 0.27* 0.12 - 0.62 0.43 0.16 - 1.11 
Smoking status     
Never 1.0 -   
Current 1.79± 0.85 -3.76 1.95 0.83 - 4.59 
Ex smoker 1.01 0.48 - 2.14 0.72 0.32 -1.60 
Home ownership     
No 1.0 -   
Yes 0.85 0.46 - 1.56   
Access to private water supply      
No 1.0 -   
Yes 1.30  0.76 - 2.24   
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Household has flush toilet     
No 1.0 -   
Yes 0.88 0.47 - 1.63   
Number of people living in house 1.05± 0.98 -1.12 1.04 0.96 -1.12 
Any biomass exposure     
No 1.0 - - - 
Yes 1.62 0.70 - 3.74 - - 
Occupation group 1 1.09 0.60-1.97 - - 
>5 years of exposure in group1 0.79 0.50-1.87 - - 
Occupation group 2 0.92 0.41-2.09 - - 
>5 years of exposure in group2 0.35± 0.10-1.19 - - 
Occupation group 3 1.73 0.58-5.14 - - 
>5 years of exposure in group3 1.37 0.36-5.23 - - 
Working in farming     
No 1.0 - - - 
Yes 1.19 0.65 - 2.15 - - 
Current Mokken scale OR P-value OR P-value 
 0.99 0.784 - - 
±indicates p<0.2; *p<0.05. CI, confidence interval; or, odds ratio; FEV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity ratio; LLN, lower limit of 
normal; TB, tuberculosis 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry 















Table 3.16  Bivariate and multivariable associations of risk factors with moderate-
severe post bronchodilator airway obstruction, defined using GOLD and NHANES III 
reference range (FEV1/FVC ratio <0.7 and FEV1 <80% predicted) n=81/590 
 
Variable Bivariate association Multivariable association 
 Odds ratio 95% CI Odds ratio 95% CI 
Age group     
40-49 1.0 - 1.0 - 




70+ 3.13* 1.13- 8.65 1.57 0.53-4.63 
Gender     
Male 1.0 - 1.0 - 
Female 0.76 0.43-1.34 1.18 0.58-2.38 
Years of education 0.92* 0.88- 0.98 0.96 0.90-1.01 
Self-reported TB     




Body Mass Index 
(kg/m2) 
    
Underweight 
(BMI<18.5) 
1.52 0.57-4.03 1.47 0.47-4.58 
Normal (BMI 18-25) 1.0 - 1.0 - 
Overweight (BMI 25-
30) 
0.43* 0.22-0.83 0.48 * 0.23-0.10 
Obese (BMI>30) 0.29* 0.12-0.71 0.38 0.12-1.17 
Smoking status     
Never 1.0 - 1.0 - 
Current 1.96± 0.91-4.22 2.56* 1.06 - 6.18 
Ex 0.82 0.35-1.90 0.70 0.28 -1.81 
Home ownership     
No 1.0 -   
Yes 0.83 0.43-1.63   
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Access to private 
water supply (indoors 
or outdoors) 
    
Yes 1.09 0.61-1.96   
No 1.0 -   
Household has flush 
toilet 
    
No 1.0 -   
Yes 0.99 0.52-1.87   
Number of people 
living in house 
1.06 ± 0.98-1.13 1.05 0.97-1.14 
Any biomass exposure     
No 1.0 -   
Yes 1.69 0.66-4.31   
Occupation group 1 1.4 0.78-2.57 - - 




Occupation group 2 1 0.42-2.36   




Occupation group 3 2.11± 0.71-6.29 - - 




Working in farming     
No 1.0 -   
Yes 1.53± 0.83-2.80 1.62 0.81- 3.21 
Current Mokken 
scale 
OR P-value OR P-Value 
 0.99 0.850 - - 
± indicates p<0.2; *p<0.05. CI, confidence interval; or, odds ratio; FEV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity ratio; LLN, lower limit 
of normal; TB, tuberculosis 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry 




 Factors associated with low FVC 
Using the NHANES III reference range, low FVC was associated with a 10-20 pack 
year smoking history, having a primary or higher level of education, having more 
people in-house and being obese (OR 2.79; 95% CI: 1.11- 7.00; OR 2.42; 95% CI: 
1.43- 4.09; OR 0.94; 95% CI: 0.89 - 0.99 and OR 1.73; 95% CI: 1.04 - 2.86 
respectively) in bivariate analysis. After adjustments, the younger age group were 
less likely to have low FVC. No other factors were associated with low FVC in 
multivariate analysis (Table 3.17). 
 
 
Table 3.17  Multivariate associations of risk factors with low FVC, defined using 
NHANES III reference range (FEV1/FVC ratio >0.70 and FVC <80% predicted), n= 
328/590 
 
Variable Multivariable association 
  Odds ratio 95% CI 
Age group     
40-49 1 - 
50-59 0.75* 0.50-1.13 
60-69 0.35* 0.21-0.57 
70+ 0.36* 0.19-0.66 
Gender     
Male 1 - 
Female 1.14 0.78-1.65 
Body Mass Index (kg/m2)     
Underweight (BMI<18.5) 1.1 0.54-2.25 
Normal (BMI 18-25) 1 - 
Overweight (BMI 25-30) 1.32 0.88-2.00 
Obese (BMI >30) 1.38 0.85-2.23 
Home ownership     
Yes 1.15 0.79-1.69 
No 1 - 
Number of people living in 
house 0.95* 0.90-0.99 






  Discussion 
In this population-based cross-sectional study, we aimed to investigate the 
prevalence and determinants of COPD in adults in urban Sudan. Our main finding 
was that 14.8% of people in this age group had spirometric findings consistent with 
COPD using GOLD criteria while prevalence was lower using the below LLN 
definition (10%). A high prevalence of low FVC (58.8%) was identified using the 
NHANES III reference range for Caucasian Americans. GOLD stage 2 or higher 
COPD was detected in 12.6% vs 9.4% of the overall population using the same 
reference range, though this decreased to 5.2% vs 3.0% when the local reference 
range was used according to GOLD versus below LLN definitions respectively. 
These findings might be compatible with the ATS/ERS recommendations to use the 
LLN for FEV1/FVC to avoid over-diagnosis of COPD in elderly populations (171). 
However, other studies argued that using LLN might underdiagnose COPD in elderly 
population compared to an expert diagnosis (172). 
 
Using the NHANES III reference range, older age protected against low FVC.  
However, using the local reference range, no association was found between 
spirometric restriction and any of the risk factors.  
 
Our finding of a higher prevalence of obstruction when using the NHANES III 
reference range compared to the local reference range has been reported previously 
(166). The NHANES III reference range is a standardized, validated set of 
spirometric measurements for asymptomatic, Caucasian, non-smoking Americans 
and adjusted for age, sex, and height. However the use of other reference ranges such 
as Global Lung Function Initiative 2012 (GLI 12) might be more suitable in this 
study, NHANES allowed comparability with other published BOLD studies. In the 
present study, the local ranges reported are based on healthy non-smoking Sudanese 
adults participated in this study. In spite of it being the only available data, values of 
the local methodology might be ethnically more suitable compared to NHANES, 
however, different exposures in this settings may constrain it (166). 
 
There is a lack of evidence to explain the finding of low FVC in this population. 
However, low FVC has been reported in other BOLD research in SSA (166,173). 
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Our findings are consistent with other studies in resource-poor settings, but the 
literature in this area is still limited and there is still no valid explanation (36). 
Literature suggested that unidentified environmental factors, low birth weight, early 
exposure to biomass fuel, air pollution and poor diet are common factors associated 
with lung restriction in developing countries (36). In addition, the findings of having 
higher prevalence of respiratory symptoms in those with lung restriction may suggest 
that reduced FVC is associated with burden of lung disease in urban Sudan. 
 
The prevalence of spirometric obstruction in our study is consistent with that in 
similar studies from SSA, where the prevalence of smoking is high (92,94). Previous 
BOLD studies found a prevalence of COPD of 23% in men and 16.9% in women in 
South Africa (36) and an overall prevalence of 7.7% in Nigeria (69,92,167). 
Additionally, the median reported prevalence in Africa in a recent systematic analysis 
of spirometric-based studies was 13.4%, which is in line with our results (94). When 
compared with studies from MENA, our findings for the prevalence of COPD in 
Sudan using both LLN and GOLD definitions are higher than those in Saudi Arabia 
(174), Abu Dhabi (106), Tunisia (103,104), Morocco (165), Algeria (175) and 
Lebanon (93).  
 
Older age was the main risk factor for airflow obstruction in our study, which is 
consistent with both regional and global findings (69,92,94,97,138,166,176). The 
highest prevalence estimates of spirometric obstruction using both LLN and GOLD 
definitions was among 60-69 year olds. This age group also reported a higher 
prevalence of both chronic cough and chronic phlegm and this might be because of 
a higher smoking prevalence when compared to other age groups. In contrast, being 
70+ appeared to be protective against low FVC when compared to the 40–49 age 
group, which contrasts GOLD definitions (161).   
 
A higher educational level was protective against COPD which is consistent with 
other studies, suggesting that airway obstruction is associated with having a lower 
level of education (66,69,79). The significant association between smoking and 
moderate to severe obstruction using the GOLD definition, in the absence of an 
association with spirometric obstruction using LLN, might not be the result of heavy 
smoking given that 50% of the smokers in our study reported a smoking history of 
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less than 10 pack years. Countries with lower smoking rates, such as Malawi and 
Rwanda, have a lower reported prevalence of COPD (138,166). 
 
In our study, participants with high body mass index were less likely to have airflow 
obstruction and low FVC. This contrasts with other studies that have suggested an 
association between high BMI and reduced airflow obstruction(177,178). Moreover, 
the negative association with low FVC is in contrast with previous studies reported 
that obesity is a cause of low FVC as a result of restriction coming from the accretion 
of body fat (173).  
 
Conversely, no significant association between the socioeconomic status, identified 
by using the Mokken scale, and developing post bronchodilator airway obstruction 
using both LLN and GOLD. This is contrasting with other studies suggesting that 
low socioeconomic status may be associated with a progression of airflow limitation 
(94,179). 
 
The lack of a significant association between greater numbers of people per 
household and either obstruction or low FVC is in contrast with other studies 
suggesting that crowded housing and low socioeconomic status may be associated 
with progression of airflow limitation (94,179).  
 
However, participants with low socioeconomic standing and with a greater number 
of people in household were less likely to have low FVC. This contrasts with studies 
that suggest that poverty, low socioeconomic status and crowded housing may be 
associated with a progression of airflow limitation and low FVC in individuals in in 
LMIC (36,94,179). A possible reason for this difference may be due to the low 
intensity of environmental exposure  in this setting. However, using the wealth score 
have been widely used for assessing the socioeconomic status, the Mokken scale has 
been proven to be a valuable tool that provide an indication of individuals’ wealth in 
BOLD studies (170).   
 
We did not observe any association between occupational exposure, whether 
categorised into organic, inorganic or fumes, and developing airway obstruction. 
Twenty-three percent of the subjects in this study were farmers and no association 
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with lung disease was observed. Furthermore, no association between exposure to 
biomass fuel and obstruction was identified except when using firewood for more 
than six months in cooking, which was inversely associated with modified stage 2 
COPD or higher using the local reference range. This is in contrast with published 
reports which assert that exposure to biomass fuel is the biggest risk factor for lung 
disease in Africa (90–92,94). However, a recent study that included 25 BOLD sites 
stated that airflow obstruction measured by post-bronchodilator spirometry was not 
associated with the use of solid fuels for cooking or heating (180). Although causality 
cannot be assumed from this cross-sectional study, it seems reasonable that a positive 
association would be found in this high-use population. It is also plausible that people 
using biomass fuel would experience more symptoms (181), such as shortness of 
breath, which is considered as one of the most common symptoms of COPD. It is 
possible that this group of patients would suffer from chronic bronchitis or non-
obstructive lung diseases. Moreover, the findings of airway reversibility in the whole 
population was  6%. While in participants with post bronchodilator obstruction, 
airway reversibility was 10% and 18% using LLN and GOLD respectively. These 
percentages of airway reversibility (10-18%) might be compatible with asthma 
diagnosis, which is consistent with the prevalence of asthma in Sudanese adults from 
previous studies(182). 
 
Additionally, we found that only 0.2% of reported TB might account for the 
significant negative association between TB and obstruction, which again conflicts 
with the published literature (43,143).  Identification of TB was based on self-
reporting, and many factors might affect the validity of the answers provided, given 
that TB is a highly stigmatized clinical condition the proportion reported here may 
be an underestimate (183). 
 
This study is the first, to our knowledge, to provide prevalence estimates of COPD 
in Sudanese adults using internationally accepted methods and procedures as well as 
an appropriate sampling technique. Following the BOLD project protocol will also 
allow for future comparisons with other COPD studies. 
 
One limitation of our study is that we did not reach the target sample size of 600 
adults above 40 years. This was because 79 participants (12%) had unacceptable 
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spirometry data while 54 participants (8%) had spirometry data only with no linked 
questionnaire data. In addition, missing information for a proportion of the study 
participants limited the cluster-weighted analysis as estimating prevalence based on 
localities and areas was not possible. Furthermore, information on reasons for 
exclusion were not recorded, meaning those who were excluded for medical reasons 
were not separated from those who were excluded for other reasons.  
 
 Conclusions  
In conclusion, the findings of this study suggest that CRD is an important public 
health problem in Sudan and needs to be considered in future public health policies. 
The overall prevalence of COPD in urban Sudan is similar to that found by other 
BOLD centres in countries with similar smoking rates, such as South Africa. 
However, the prevalence of COPD in urban Sudan was relatively high when 
compared with other countries in SSA and MENA. A high prevalence of low FVC 
was also identified, the aetiology and pathophysiology of which is unknown and 



















 The burden of non-communicable lung diseases in adults, 
rural Sudan: A population-based cross-sectional study 
 
  Introduction 
 
The previous chapter summarised the prevalence and main determinant of COPD in 
urban Sudan while reported a high prevalence of the disease in Khartoum State .  This 
chapter outlines a study which documents the burden of chronic non-communicable 
lung diseases  in Gezira State. 
 
Global and regional prevalence estimates of the burden of COPD have been 
discussed in previous chapters and estimates of the burden of asthma have been 
addressed in chapter 2 (section 2.5).  
 
In Sudan, asthma is the third most frequent cause of hospitalisation after pneumonia 
and malaria, and there has been a striking increase in the number of asthma-related 
emergency admissions (26). While COPD has a prevalence rate of 14% and 10% 
using GOLD and LLN definitions as found in previous study of urban Sudan (see 
section 3.3.5, chapter 3), published data on the burden, prevalence, and determinants 
of COPD and asthma in Sudan are scarce (164).   
 
Following the BOLD study conducted in urban Sudan (see chapter 3), this study 
conducted another population-based cross-sectional BOLD study in Gezira state, 
Sudan to provide data regarding the prevalence and determinants of chronic lung 
diseases such as COPD, asthma and other chronic respiratory diseases.  The findings 
of the previous BOLD study suggested a high prevalence of lung obstruction and an 
even higher prevalence of low FVC in urban Sudan. Consequently, this study aimed 
to investigate the burden of chronic lung diseases in different settings in Sudan by 
selecting Gezira state - a more rural area. The study expanded the scope of the 
previous work and included a younger population of ≥18 years to explore the 
prevalence of COPD and other chronic lung diseases such as asthma, as well as 




  Methodology 
  Study settings, location and participants  
Gezira State is one of the 18 states in Sudan. The state is in the eastern central region 
of country and has an area of 27,549 km² and an estimated population of 
approximately 3,780,915. Almost 80.4% live in rural areas, with 19.1% living in 
urban areas according to the 2008 national census of Sudan (20). The Blue Nile River 
dissects the state and Wad Medani is its capital. The state is bordered by Khartoum 
State to the north, Sinnar State to the south, Gadarif State to the east and White Nile 
State to the west. The population of Gezira is distributed across 7 localities, 40 
administrative units and approximately 689 villages, all of which vary in size and 
population. It split by the Blue Nile with further divisions into administrative units, 
capital cities, secondary villages and villages (Figure 4.1). 
 
 
Figure 4.1  Gezira State, Sudan. Locality divisions with study areas in grey and 
black (Alkamleen, Sharg algezira, Wad Medani) 
 
 
Ethical approval was obtained prior to the start of the study from Imperial College 
London, the ethics committee at the ministry of health in Gezira State and the 
Liverpool School of Tropical Medicine (11.03RS). All participants were given 
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written informed consent prior to data collection (See Appendix (2 and 5)). 
 
This study followed a multistage sampling design. Three localities (Sharg Algezira, 
Alkamleen and Wad Medani) were randomly selected from seven localities using a 
simple random sampling approach. The total population of the three selected 
localities is 1,288,947. 
 
Each of the three localities is divided into several administrative units, each of which 
is sub-divided into villages/areas. A simple random sample of 5% of the villages 
(n=35) was selected. 
 
By including 1000 households, we anticipated being able to sample 2000-3000 
adults. All eligible individuals in these households were included. Thirty households 
per village were then sampled. This was followed by a mapping exercise to count 
and locate all households, including nomadic households present at the time of the 
mapping and campo (migrants from other states) residents. In each area/village, 
households were numbered serially and each locality and village was ascribed unique 
numbers. As there were no available data for the number of households at the village 
level, study researchers used simple random sampling to obtain households after 
mapping (Appendix (4) sampling plan). A strategic data management plan was 
developed prior to the start of the data collection which covered all standard 
operating procedures (see Appendix (6)). Pre-selection of areas was carried out prior 
to field visits. Each participant had a unique identification number composed of 9 
digits.  
 
This study included participants aged ≥18 years, living in rural Gezira state. All 
institutionalised people, the medically unfit and pregnant women in their last 
trimester were excluded. 
 
The data were collected through standardised, pre-tested BOLD project 
questionnaires between 25th Aug 2015 and 30th Dec 2016. All consenting participants 
completed structured questionnaires and underwent pre- and post-bronchodilator 
spirometry testing. Data were collected by seven trained data collectors and 
spirometry testing was carried out by a team of five certified technicians. 
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Anthropometric and pre- and post-bronchodilator spirometry testing was performed 
in accordance with the BOLD protocol and the American Thoracic Society (ATS) 
guidelines using the Easy OneTM (NDD Medizintechnic, Zurich, Switzerland) 
spirometer (68).  
 
This study used the same standardised BOLD questionnaires and data collection 
methodology described in the previous study (see section 3.2.1, chapter 3). 
Local training for the data collection team was conducted prior to the start of the 
household survey. Training on performing spirometry testing and associated 
measurements was delivered to the technicians locally by Imperial College London. 
To avoid data loss and the complex data management faced in the previous urban 
study, comprehensive data verification for the whole data set and documentation of 
field challenges was carried out both in the field and before data entry process. Cross-
checking of data was carried out through a field data registry, as well as entry and 
follow-up sheets.   
Data were anonymised and entered into the BOLD international platform at Imperial 
College London. 
 
  Definitions  
COPD disease definitions have been discussed in section 3.2.2, chapter 3 
 
 Statistical analysis 
Statistical analyses were done as discussed in section 3.2.3, chapter 3. 
 
  Results 
3281 participants were approached from 35 villages in rural Gezira, of which 9 were 
Cambo (a rural, mixed-composition, displaced community) (184), 25 were regular 
villages and 1 was Nomadic. There were 2030 subjects with either partial or complete 
pre/post spirometry test data and 1308 subjects with full spirometry test and 
questionnaire data. On the other hand, 542 subjects were having unacceptable 
spirometry results. The participant recruitment diagram is shown below (Figure 4.2). 





































Figure 4.2  Participant recruitment diagram 
 
 
 Participant characteristics 
The mean age (SD) was 39.3 (17) years and 55% were <40 years. Women and men 
were equally distributed (50%). Participants with higher education represented 
44.3%. There was no significant difference between men and women with respect to 
education while the age groups <40 tended to be more educated when compared to 
older groups (66% vs 36% higher education attainment respectively). There were no 
significant differences between sexes, age groups and educational level groups for 
those who did and did not complete spirometry testing.  
 
Total number of people reached 
= 3281                                 
Eligible for inclusion N=2395 
Consented to participate 
N=1850 
Acceptable 
spirometry with full 






Refused to participate with 
minimal data = 299 
Refused no data collected=66 
Partial data= 180 
Total population of Sharg algezira, AlKamleen  and 
Wadmedani localities =1,288,947 
Deceased= 28 
Temporarily left the 
catchment area= 733 
Permanently left the 
catchment area=116 




Responders tended to be <40 years old (P<0.001, Pearson’s χ2= 29.5) when 
compared to non-responders. Women tended to refuse participation more than men 
(p<0.001, Pearson’s χ2= 82.4). Those who had never smoked were more likely to 
fully participate in the study (p<0.001, Pearson's χ2= 40.1) compared to other 
smoking groups (Table 4.1). There were no significant differences between those 
who did and did not complete spirometry test (Table 4.2). Disposition of study 
participant is shown in Table 4.3. 
In total, 17.3% owned more than 6 assets using the Mokken scale, and 92% of 
participants owned their own home and 85% had their own water source. Only 15% 
had access to a flush toilet. The mean number of household members was 7.4 ± 3.3. 
Forty percent of the responders were working in agriculture, textile or food industry and 
farming was the most commonly reported occupation (39%),15% of which had more 
than 5 years of exposure (Table 4.4). 
 
  Environmental Exposures 
 Current smokers represented 10.6% of participants. While 9.9% [SE, 2.9] had ever 
smoked in their life. Among total participants, 13.3% [SE 2.2] had a 10 pack-year 
smoking history or more while 1.9% [SE, 0.2] had a ≥20 pack-year smoking history 
(Table 4.4). 
Forty-eight percent of participants had exposure to biomass fuels for more than 6 
months in their life (36.8% fire coal and 30.5% firewood). On average, those who 
were exposed to biomass fuels had 1.49 ± 1.4 hours of fire coal and 1.13 ± 1.4 hours 
of firewood per day (Table 4.4). 
 
 Other diseases 
In total, 47% of subjects had a normal Body Mass Index (BMI). Hypertension was 
self-reported by 6.4% of all subjects, of whom 70% were women. Diabetes was 
reported by 3.3% (57% were women) and both heart disease and TB were reported 
by 0.3%. None of these diseases were associated with any type of obstruction or 






Table 4.1  Comparison of responders1 and non-responders2 for Gezira, Sudan 





N=1,843 N= 1,278 <0.001  
18-29 626(34%) 565(43.5%)  
30-39 386(20.9%) 270(21.1) 
Age 40-49 328(17.8%) 172(13.5%)  
50-59 240(13%) 134(10.5)  
60-69 173(9.5%) 80(6.3%)  
70+ 90(4.9%) 66(5.2%)      
Gender Male 932(49.9%) 551(43.1%) <0.001 
 
Female 926(50.1%) 728(56.9%)      
Smoking status Current 196(10.7%) 18(5.2%) <0.001 
 
Ex 191(10.4%) 7(2%)  
Never 1445(78.9%) 323(92.8)      
Doctor diagnosed 
asthma, emphysema, 
CB or COPD 
Yes 134(7.4%) 12(3.5%) 0.008 
 
No 1689(92.6%) 336(96.6%) 
 
     
Other disease Yes 165(9.1%) 28(8.1%) 0.533 
 
No 1651(90.9%) 320(92%) 
 
1. Responders are those who completed post-BD spirometry (regardless of QC scores) and the core 
questionnaire. 
2. Non-responders are eligible individuals who are missing the core questionnaire and/or post-BD 
spirometry, but for whom the tabulated variable is known.  












Table 4.2 Comparison of responders1 with and without usable spirometry for Gezira, 
Sudan 
 





Age 18-29 438(33.5%) 188(35.1%) 
0.949 
  30-39 281(21.5%) 105(19.1%) 
  40-49 234(17.9%) 94(17.5%) 
  50-59 170(13%) 70(13.1%) 
  60-69 122 (9.3%) 51(9.5%) 
  70+ 62( 4.7%) 28(5.2%) 
Gender Male 651(49.8%) 272(50.3%) 
0.843 
  Female 657(50.2%) 269(49.7%) 
Smoking status Current 133(10.2%) 63(11.7%) 
0.638   
Ex-
smoker 137(10.6%) 54(10.1%) 
  Never 1,025(79.2%) 420 (78.2%) 
Doctor diagnosed 
asthma Yes 80(6.2%) 37(6.9%) 0.561 
  No 1211(93.8%) 497(93.1%) 
Doctor diagnosed 
COPD Yes 2(0.2%) 0 0.362 
  No 1,292 (99.9%) 55(100%) 
Cough Yes 241(18.7%) 100(18.8%) 
0.94 
  No 1,049 (81.3%) 431 (81.2%) 
Phlegm Yes 181(14%) 80(15%) 
0.591 
  No 1,113(86%) 455 (85.1%) 
Wheeze Yes 60(4.6%) 33(6.2%) 
0.177 
  No 1,235(95.4%) 503(93.8%) 
Shortness of 
breathe Yes 191(18.4%) 82(18.9%) 0.797 
  No 849(81.6%) 351 (81.1%) 
Any Symptoms Yes 460(40.6%) 189 (40.8%) 0.946   No 672(59.4%) 274(59.2%) 
1. Responders are those who completed post-BD spirometry  (regardless of QC scores) and the core 
questionnaire. 
2. Usable spirometry defined as post-BD quality scores>1 for each of FEV1 and FVC  
3. Two-sided p-value based on Pearson chi-square test. NOTE: In some cases numbers are too small 






Table 4.3 Disposition of Study Participants  
 
Outcome  Men Women Total 
Responders:    
Full data collected (Core Ques plus 
acceptable post BD spirometry)  
651 657 1,308 
Full data collected (Core Ques plus 
unacceptable post BD spirometry)  
273 269 542 
Total responders  924 926 1850 
Non-responders:     
Partial data collected  46 134 180 
Refused (minimal data collected)  65 234 299 
Refused (no minimal data 
collected)  
31 35 66 
Only Spirometry data collected  0 0 0 
Unreachable   0 0 0 
Total non-responders  142 403 545 
Ineligible:     
Deceased* 17 11 28 
Temporarily left catchment area 408 325 733 
Permanently left catchment area 72 44 116 
Age ineligible  4 4 8 
Institutionalised  0 0 0 
Untraceable (inaccurate address and 
phone)  
0 1 1 
Total ineligible 501 385 886 
Total selected for recruitment1 1567 1714 3281 
1.  Number of responders + non-responders + ineligibles  








Table 4.4 Characteristics of all participants who completed a full BOLD core 
questionnaire, including those with and without spirometry results 
 
Variable (n) N (%) 
Age group, years (n= 1,844)  
18-29 626 (34) 
30-39 387 (21) 
40–49 328 (17.8) 
50–59 240 (13.0) 
60–69 173 (9.4) 
70+ 90 (4.9) 
Sex (n=1,850)  
Male 924 (50)   
Female 926 (50) 
Level of education (n=1,804)  
None  398 (22.1) 
Primary school 483 (26.8) 
Middle school  124 (6.9) 
High school or above  799 (44.3) 
Home ownership (n=1,831)   
Yes 1,679 (91.7) 
No 151 (8.3) 
Access to private indoor or outdoor water supply (n=1,831)   
Yes 1,551 (84.7) 
No 280 (15.3) 
Access to flush toilet in home (n=1,831)   
Yes 269 (14.7) 
No 1,562 (85.3) 
Number of people in households (1,832)  
<5 people 290 (15.9) 
5-9 people 1,163 (63.5) 
>=10 people 379 (20.7) 
Smoking status (n=1,833)   
Current smoker 197 (10.8) 
Ex-smoker 191 (10.4) 
Never smoked 1,445 (78.8) 
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Pack-years of smoking (n=1809)  
Never smoked  1,445 (79.9) 
>0 and <10 252 (13.9) 
≥10 112 (6.2) 
20 pack-years of smoking (n=1809)  
<20 years 1,764 (97.5) 
>=20 years 45 (2.5) 
Biomass fuel exposure (n= 1,814)   
Yes 876 (48.3) 
No 938 (51.7) 
Farm work for ≥3 months (n= 1,774)   
Yes 697 (39.3) 
No 1,077 (60.7) 
Construction work for ≥3 months (n=1,774)  
Yes 342 (19.2) 
No 1,434 (80.8) 
Body Mass Index (n=1700)  
Underweight (BMI<18.5)  173 (10.2) 
Normal (BMI 18.5–24.9)  800 (47.1) 
Overweight (BMI 25.0–29.9)  415 (24.4) 
Obese (BMI ≥30) 312 (18.4) 
Reported history of tuberculosis (n=1825)  
Yes 6 (0.3) 
No 1,819 (99.7) 
Reported history of hypertension (n=1829)  
Yes 117 (6.4) 
No 1,712 (93.6) 
Reported history of diabetes (n=1828)  
Yes 60 (3.3) 
No 1,768 (96.7) 
Reported history of heart disease (n=595)  
Yes 6 (0.3) 
No 1,821 (99.7) 
Current Mokken scale (Mean ± SD) 5.21±2.36 
0 43 (2.4) 
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1  121 (6.6) 
2  148 (8.1) 
3  150 (8.2) 
4  165 (9.0) 
5  262 (14.3) 
6  318 (17.4 ) 
7  311 (17)  
8  213 (11.6) 
9  88 (4.8) 
10  11 (0.6) 
Occupation group 1  712(40) 
>5 years of exposure in group 1  506(15) 
Occupation group 2  403(22) 
>5 years of exposure in group 2  145(4.4) 
Occupation group 3  95(5.3) 
>5 years of exposure in group 3  27(0.8) 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry) 
Occupation group 3: Welders, firefighters, cleaners or exposed to chemicals and 
fumes during work 
 
 
 Respiratory symptoms 
At least one respiratory symptom, usually present without having a cold, was 
reported by 40.7% [SE 3.1] of subjects, and the 70+ age group had the highest 
prevalence (60.6% [SE 4.3]). Respiratory symptoms that interfered with daily 
activities was reported by 8.4% [SE 1.6] of subjects. Usual cough was the most 
frequently reported symptom (19.5% [SE 1.7]), with the highest prevalence recorded 
in subjects aged 18-29 years (22.5% [SE2.7]. A chronic cough (lasting for more than 
3 months per year) was reported by 2.4% [SE 0.02]. Production of usual sputum was 
reported by 14% [SE 1.9] and chronic production of sputum (for more than 3 months 
per year) was reported by 2.7% [SE 0.001]. Shortness of breath was reported by 
18.7% [SE 0.9], and 38.7% [SE 3.5] of these subjects were unable to walk further 
than 100 yards because of breathing problems. A wheeze in the past 12 months in 
the absence of a cold was the least commonly reported symptom (4.9% [SE 1.2], 
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Table 4.5, Figure 4.3). Overall, females and participants aged 70+ tended to be more 
symptomatic when compared to other groups. However, those aged 60-69 had the 
highest prevalence of sputum production, wheeze and functional limitation due to 
breathing problems. 
 
Participants aged ≥40 years tended to have a higher prevalence of any respiratory 
symptoms 42.2% [SE 2.1], wheeze and sputum production. However, the younger 
group, aged 18-39, had a higher prevalence of a cough, shortness of breath and 
functional limitation due to breathing problems (Table 4.6 and Figure 4.4). A small 
positive correlation was found between all respiratory symptoms (p<0.05, Pearson’s 
r correlation <0.3). 
 
Medically diagnosed respiratory disease was reported by 7.4% of the participants 
that contributed full data sets.  Medically diagnosed asthma and COPD was reported 
by 6.4% and 7.4% of subjects respectively. Medically diagnosed COPD, chronic 
bronchitis or emphysema was reported by 1.7%.  
 
 
Table 4.5 Age and gender stratified prevalence of respiratory symptoms among 


















Cough (do you 
usually cough 
when you don't 
have a cold?) 
 
18-29 20.3 (2.3) 24.3 (3.2) 22.5 (2.7) 
30-39 18.9 (0.6) 18.3 (2.6) 18.5 (1.7) 
40-49 14 (2.7) 17.1 (3.1) 15.7 (1.1) 
50-59 18.6 (2.4) 16.5 (4.7) 17.7 (0.8) 
60-69 9.1 (1.3) 22.8 (0.5) 15.9 (0.6) 
70+ 17 (5.2) 15.2 (3.4) 16.2 (2.6) 
Total 17.9 (0.8) 20.9 (2.6) 19.5 (1.7) 
Sputum (do you 
usually bring up 
18-29 14.2 (2.8) 12.7 (2.4) 13.4 (2.3) 
30-39 18.7 (3) 12.2 (5.3) 14.9 (4.4) 





50-59 15.1 (3.3) 9.8 (4.7) 12.8 (0.7) 
60-69 13.3 (5.3) 20.7 (4.8) 16.9 (4.8) 
70+ 22.4 (8.3) 25.2 (0.1) 23.7 (2.7) 
Total 14.7 (2.1) 13.4 (2.1) 14 (1.9) 
Wheeze (have 
you had wheezing 
/ whistling in your 
chest at any point 
in past 12 
months, in the 
absence of a cold) 
18-29 5.1 (2.2) 3.8 (1.1) 4.4 (1.1) 
30-39 6.5 (0.4) 3.9 (2.3) 5 (1.4) 
40-49 2.2 (2.6) 5.6 (1.5) 4 (2) 
50-59 4.6 (0.1) 7.8 (2.7) 6 (1.2) 
60-69 6.1 (1.4) 10.3 (4.6) 8.1 (2.9) 
70+ 7.4 (4.1) 2.6 (1.7) 5.3 (2.7) 
Total 5 (1.2) 4.7 (1.4) 4.9 (1.2) 
Currently, do you 
have shortness of 
breath when 
hurrying on the 
level or walking 
up a slight hill?) 
18-29 15.2 (1.4) 23.3 (0.7) 19.5 (0.5) 
30-39 18.3 (2.2) 17.7 (6.6) 17.9 (3.7) 
40-49 12.3 (1.2) 22.8 (2.9) 17.1 (1.9) 
50-59 15.5 (1.6) 18.9 (2.5) 16.9 (2) 
60-69 16.6 (1.7) 27 (9.1) 20.8 (3.8) 
70+ 10.2 (4.2) 42.8 (16.5) 22.7 (7.2) 
Total 15.2 (0.9) 22 (2.1) 18.7 (0.9) 
Any respiratory 









18-29 38.4 (4.5) 44.5 (1.8)   41.7 (2.8) 
30-39 40.3 (2.6) 35.1 (7.3) 37.2 (5.5) 
40-49 27.8 (2.8) 45.2 (5.5) 36.2 (3.8) 
50-59 37.6 (1.4) 41.8 (6.4) 39.4 (2.3) 
60-69 34.4 (2.9) 65.1 (2.9) 49 (0.9) 
70+ 52.1 (3.7) 72.4 (16) 60.6 (4.3) 






your usual daily 
activities) 
18-29 5.8 (0.1) 11.9 (3.4) 9.1 (2) 
30-39 8.1 (0.9) 8.8 (3.2) 8.5 (1.9) 
40-49 4.9 (1.6) 8 (3.2) 6.6 (2.6) 
50-59 8.1 (1.9) 6.4 (4.9) 7.4 (3.0) 
60-69 10.5 (1.3) 10.4 (3.6) 10.4 (2.4) 
70+ 7.2 (1.8) 2.6 (1.7) 5.2 (1.5) 






Figure 4.3 Prevalence of respiratory symptoms among the study participants. The upper 
bar represents symptom prevalence in men (n=924) and the lower bar represents symptom 
















































Figure 4.4 Prevalence of respiratory symptoms among the study participants. The upper 
bar represents symptom prevalence in younger groups (18-39) years (n= 1,917) and the lower 
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Table 4.6  Age and gender stratified prevalence of respiratory symptoms among 
















Cough (do you 
usually cough when 
you don't have a 
cold?) 
18-39 19.9 (1.8) 22.4 (2.9) 21.3 (2.4) 
≥40 14.8 (1.5) 17.8 (2) 16.3 (0.2) 
Total 17.9 (0.8) 20.9 (2.6) 19.5 (1.7) 
Sputum (do you 
usually bring up 
phlegm from your 
chest?) 
18-39 15.4 (2.8) 12.6 (3.3) 13.8 (3) 
≥40 13.7 (1.1) 15.5 (1.1) 14.6 (0.8) 
Total 14.7 (2.1) 13.4 (2.1) 14 (1.9) 
Wheeze (have you 
had wheezing / 
whistling in your 
chest at any point in 
past 12m, in the 
absence of a cold?) 
18-39 5.5 (1.6) 3.9 (1.2) 4.6 (1.2) 
≥40 4.4 (1.7) 6.7 (2.3) 5.5 (1.9) 
Total 5 (1.2) 4.7 (1.4) 4.9(1.2) 
Do you have 
shortness of breath 
when hurrying on 
the level or walking 
up a slight hill?) 
18-39 16 (1.6) 21.6 (2) 19 (0.8) 
≥40 13.8 (0.5) 24.1 (2.1) 18.2 (1.3) 
Total 15.2 (0.9) 22 (2.1) 18.7 (0.9) 
Any respiratory 





18-39 38.9 (3.9) 41.6 (3.5) 40.4 (3.6) 
≥40 34.8 (1.3) 50.9 (3.1) 42.2 (2.1) 




interfered with your 
usual daily 
activities?) 
18-39 6.4 (0.9) 11 (3.1) 8.9 (1.9) 
≥40 7.2 (1.1) 7.5 (2.4) 7.4 (1.7) 
Total 6.9 (0.7) 9.8 (2.6)  8.4 (1.6) 
 
 
  Spirometry 
 Spirometry results based on GOLD definitions  
GOLD stage 1 or higher COPD was seen in 3.4% (SE 0.7) of the total study 
population (3.9% [SE 0.4) of men and 3.1% [SE 1.5] of women). Subjects aged 70+ 
years and smokers of 20+ packs per year had the highest prevalence of GOLD stage 
1 COPD (14.1% [SE 5.0] vs. 15% [SE 5.1] respectively) and the highest prevalence 
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of GOLD stage 2 or higher using the locally derived range (7.5% [SE 2] vs. 8% [SE 
3.7] respectively). According to the NHANES reference range, 3% (SE 0.6) of the 
overall population had GOLD stage 2 or higher COPD (3.2% [SE 0.2] of men and 
2.8% [SE 1.4] of women). Using the locally derived reference range, 2% (SE 0.6) of 
the total study population had GOLD stage 2 or higher COPD (1.7% [SE 0.07] of 
men and 2.3% [SE 1.1] of women). Similarly, participants with a smoking history of 
20+ packs per year had the highest prevalence of GOLD stage 2 or higher using 
NHANES (12% [4.1]). However, subjects aged 60–69 years had the highest 
prevalence of GOLD stage 2 or higher COPD using NHANES (11.9% [SE 5.2]) 
(Table 4.7 and Figure 4.5). 
 
 
Table 4.7 Age and gender stratified prevalence estimates for abnormal spirometry, 
among participant with full spirometry data using GOLD definition 
 
Spirometric definition 


















stage 1 or higher) 
18-29 0.5 (0.4) 0.6 (0.7) 0.55 (0.34)    
30-39 1.1 (0.9)  3.5 (2.4)     2.5 (1.0) 
40-49 4.3 (1.7) 4.8 (2.1)  4.6 (0.32) 
50-59 6.5 (2.5) 5.8 (1.4) 6.2 (1.4) 
60-69 14.6 (2.4)  10.6 (7.1) 12.6 (4.7) 
70+ 23.8 (7.8) 3.5 (1.9) 14.1 (5.0) 
Total 3.9 (0.3) 3.1 (1.5) 3.4 (0.8) 
Post bronchodilator 
moderate to severe 
obstruction FEV1/FVC 
ratio<70% and FEV1 
<80% predicted 
(NHANES) GOLD 
stage 2 or higher 
18-29 0.5 (0.5)  0.5 (0.6) 0.6 (0.2) 
30-39 1.1 (0.9) 3.5 (2.4) 2.5 (1.0) 
40-49 3.6 (1.1) 4 (1.6) 3.8 (7.6) 
50-59 6.5 (2.5) 5.8 (1.4) 6.2 (1.4) 
60-69 13.2 (3.4)   10.6 (7.1) 11.9 (5.2) 
70+ 14.0 (5.1) 3.5 (1.9) 9.1 (3.8) 






moderate to severe 
obstruction  
FEV1/FVC ratio<70% 
and FEV1 <80% 
predicted (Locally 
derived ref range) 
18-29 0.5 (0.5) 0.6 (0.7) 0.5 (0.2) 
30-39 - 2.5 (1.8) 1.5(1) 
40-49 3.6 (1.1) 3.1 (1.1) 3.3 (0.4) 
50-59 1.2 (1.4) 4.5 (1.4)        2.6 (1.4) 
60-69 4.6 (1) 8.1 (5.8) 6.4 (3.2) 
70+ 11.1 (2.3) 3.5 (1.9) 7.5 (2) 





Figure 4.5 Estimated Population Prevalence of airway obstruction by age and sex using 
NHANES for the Sudanese population in subjects completing standard ATS spirometry 
(n=1308). The upper graph represents the prevalence of GOLD Stage 1 or higher COPD 
(Post-BD FEV1/FVC <0.7) and the lower graph represents the prevalence of GOLD Stage 2 























































 Spirometry results based on LLN definitions  
Using LLN, COPD prevalence was 4.1% [SE 0.5] in the total population (3.1% [SE 
0.5] in men and 4.8% [SE1.4] in women) using NHANES and was slightly lower 
using the locally derived range at 3.2% [SE 0.4] in total population (3.4 [SE0.6] in 
men and 3.1% [SE1.3] in women). The prevalence of modified stage 2 COPD or 
higher was 3.6% [SE 0.4] (2.75 [SE0.7] in men and 4.4% [SE 1.3] in women). Using 
the locally derived ranges, modified stage 2 COPD or higher was prevalent in 2.1% 
[SE 0.4] of the total population (2% [SE 0.5] in men and 1.9% [SE 1.1] in women). 
Subjects aged 60–69 years and subjects who smoked ≥20 years had the highest 
prevalence of modified stage 1 or higher and modified stage 2 or higher LLN-COPD 
(8.2% [SE2.3] vs. 7.1% [SE4.2]) and (7.6% [SE 2.7] vs. 4.1% [SE 2.5] respectively). 
Males with >20 packs of smoking exposure had the highest prevalence of modified 
stage 1 and 2 COPD using below LLN compared to other smoking groups (7% [SE 
4.2] and 4.2% [SE 2.5]) -  Tables 4.8, 4.9 and Figure 4.6). 
 
 
Table 4.8 Age and gender stratified prevalence estimates for abnormal spirometry, 



















Prevalence of LLN 
Modified Stage 1 or 
higher COPD (Post-
BD FEV1/FVC < 




18-29 1.9 (0.4) 2.3 (1.3)  2.1 (0.6) 
30-39 2.1 (1.8) 8 (3.1) 5.7 ( 1) 
40-49 4.3 (1.7) 6.6 (3.2) 5.5 (1.1) 
50-59 2.1 (1.1) 5.8 (1.4) 3.6 (1.2) 
60-69 10.5 (4) 6 (4) 8.2 (2.3) 
70+ 6.1 (2.6) 3.5 (1.9) 4.8 (0.9) 








Prevalence of LLN 
Modified Stage 1 or 
higher COPD (Post-
BD FEV1/FVC < 
LLN) by age and sex  
(locally derived ref 
range) 
18-29 2.6 (0.8) 1.9 (1.6) 2.3 (0.8) 
30-39 2.1 (1.8 5.3 (1.5) 4 (0.1) 
40-49 4.3 (1.7) 4 (1.8) 4.2 (0.3) 
50-59 2.1 (1.2) 2.9 (2.1) 2.4(1.4) 
60-69 9.5 (4.7) 2.1 (2.1) 5.8 (1.1) 
70+ 6.1 (2.6) 3.5 (1.9) 4.8 (0.9) 
Total 3.4 (0.6) 3.1 (1.3) 3.2 (0.4) 
Prevalence of LLN 
Modified Stage 2 or 
higher COPD (Post-
BD FEV1/FVC < 
LLN and post-BD 
FEV1 < 80% 
predicted) by age and 
sex (NHANES ref 
range) 
18-29 1.4 (0.8) 1.6 (1.3) 1.5 (0.6) 
30-39 2.1 (1.8) 8 (3.1) 5.7 (1.1) 
40-49 3.6 (1.1) 5.7 (3.1) 4.7 (1.5) 
50-59 2.1 (1.1) 5.8 (1.4) 3.6 (1.2) 
60-69 9.1 (3.7) 6 (4) 7.6 (2.7) 
70+ 6.1 (2.6) 3.4 (1.9) 4.8 (0.9) 
Total 2.7 (0.7) 4.4 (1.3) 3.6 (0.4) 
Prevalence of LLN 
Modified Stage 2 or 
higher COPD (Post-
BD FEV1/FVC < 
LLN and post-BD 
FEV1 < 80% 
predicted) by age and 
sex (locally derived 
ref range) 
18-29 1.4 (0.8) 1.4 (1) 1.4 (0.4) 
30-39 1.1 (0.9) 2.5 (1.8) 1.9 (0.7) 
40-49 3.6 (1.1) 2.4 (0.8) 2.9 (0.1) 
50-59 1.2 (1.4)  1.6 (2) 1.6 (1.7) 
60-69 3.6 (1.1) 2.1 (2.2) 2.8 (0.9) 
70+ 6.1 (2.6) 3.5 (1.9) 4.8 (0.9) 











Figure 4.6 Estimated Population Prevalence of airway obstruction by age and sex using 
National Health and Nutrition Examination Survey reference ranges (NHANES) for the 
Sudanese population in subjects completing standard American Thoracic Society spirometry 
(n=1308). The upper graph represents the prevalence of LLN Modified Stage 1 or higher 
COPD (Post-BD FEV1/FVC < LLN) and the lower graph represents the prevalence of LLN 














































































Table 4.9 Estimated Population Prevalence (SE) of abnormal spirometry by pack 
years and sex  
 
   Pack-years   










1 or higher 
COPD 
Male 3.5 (1.5) 2.4 (0.5) 8.1 (4) 15(5.1) 3.9 (0.4) 
Female 2.9 (1.4) * * * 3 (1.5) 






2 or higher 
COPD 
Male 2.8 (0.9) 2 (0.3)  8.1 (4) 12.2(4.1) 3.2 (0.2) 
Female 2.7 (1.2) * * * 2.8 (1.4) 




(SE) of LLN 
Modified 
Stage 1 or 
higher COPD 
Male 3.1 (0.8) 2.3 (0.6) 3.5(3.4) 7(4.2)  3.1 (0.5)  
Female 4.7 (1.3) * * * 4.8 (1.4) 
Total 4.2 (0.6) 2.2 (0.6)  3.5(3.4) 7(4.2) 4 (0.5)  
Prevalence 
(SE) of LLN 
Modified 
Stage 2 or 
higher COPD 
Male 2.6 (1.2) 2.3 (0.6) 3.5(3.4) 4.2(2.5) 2.7 (0.7)  
Female 4.3 (1.2) * * * 4.4 (1.3) 
Total 3.7 (0.5) 2.2 (0.6) 3.5(3.4)  4.2(2.5)  3.6 (0.4) 





 Airway reversibility  
Airway reversibility was reported by 6.4% [SE 0.3] of the total population.  Men 
tended to have more airway reversibility when compared with women (7.2% [SE 0.2] 
vs. 5.7% [0.5]). Airway obstruction defined using LLN persisted after use of a 
bronchodilator in 18.5% [SE 2.6] of subjects with reversibility. Prevalence was lower 
using GOLD definitions (15.1% [SE 2.4]) (Table 4.10). 
 
 
Table 4.10 Age and gender stratified prevalence estimates for airway reversibility 
 
Spirometric definition 
















Airway reversibility FEV1 
increase ≥200ml and ≥12% 
following bronchodilator 
18-29 3.3 (2) 3 (1.8) 3.1 (0.3) 
30-39 9.7 (5.7) 4.6 (2.1)  6.7 (2.1) 
40-49 7.5 (0.6) 7.3 (3.3) 7.3 (1.6) 
50-59 9.9 (4.8) 11.8 (3.3) 10.6 (3.8) 
60-69 12.6 (3.8) 11.2 (3.9) 11.9 (1.0) 
70+ 12.9 (5) 15 (8.9) 13.9 (6.9) 
Total 7.2 (0.2) 5.7 (0.5) 6.4 (0.3) 
 
 
 Low FVC 
A low FVC was more prevalent than obstruction in both sexes and in all age groups. 
Using the NHANES III, overall estimated prevalence was 53.8% [SE 2.7]. Low FVC 
was more common in women when compared with men (56.3% [SE4.3] vs. 50.9% 
[SE1.5]). Similar to the urban findings; respiratory symptoms were more common in 
those with reduced FVC; 53% (Phlegm 53% and shortness of breath 56%) however, 
no significance differences were observed (Table 4.11). Using the local reference 
range, a far lower prevalence estimate of 7.3% [SE1.3] was found (5.3% [SE 0.2] in 






Table 4.11  Presence of respiratory symptoms in those with/without low FVC 
 
Spirometric restriction Abnormal FVC N(%) Normal FVC N(%) P-value 
Cough 119(49.17) 123(50.83) 0.794 
Phlegm 96(53.04) 85(46.96) 0.527 
Wheeze 30(50.00) 30(50.00) 0.707 
Shortness of breathe 107( 56.02) 84(43.98) 0.127 
Functional limitation 51(47.22) 57(52.78) 0.629 
Any respiratory 
symptoms 
244(52.93) 217(47.07) 0.794 
 
 
Table 4.12 Age and gender stratified prevalence estimates for low FVC 
 
Spirometric definition 
















Ratio>0.7 AND FVC<80% 
predicted  
(NHANES ref range) 
18-29 57.2 (1.3) 51.6 (5.3) 54.2 (3.6) 
30-39 49.5 (5.8) 57.7 (6.6) 54.4 (5.7)  
40-49 51.4 (3.8) 66.2 (1.6) 59.3 (3.1) 
50-59 47 (2.8) 62.6 (3.4) 53.6 (0.9)   
60-69 38 (3.4) 59.2 (2.8) 48.7 (3.3) 
70+ 20.5 (5.2) 51.0 (6.9) 35.1 (5.2) 
Total 50.9 (1.5) 56.3 (4.3) 53.8 (2.7) 
Restriction FEV1/FVC 
Ratio>0.7, AND 
FVC<80% predicted  
(Locally derived ref range) 
18-29 5.3 (1.3) 8.9 (3.5)  7.3 (1.4) 
30-39 5.4 (0.4) 6.5 (2.1) 6.1 (1.3) 
40-49 2.5 (2.9) 9.5 (2.2) 6.2 (0.5)   
50-59 9.5 (0.5) 14.7 (6.9) 11.6 (3) 
60-69 1.5 (1.4) 13.4 (5.4) 7.6 (2.9) 
70+ 8.9 (4.2) 7 (3.8) 8 (1.9) 






 Factors associated with respiratory symptoms  
The 60-69 age group were less likely to have a cough (OR 0.53; 95% CI: 0.31-0.92) 
while years of education was significantly associated with having a cough (OR 1.02; 
95% CI: 1.00-1.04). In bivariate analysis, sputum production was associated with 
having hypertension (OR 1.89; 95% CI: 1.34-2.68) though no association was 
identified after adjustment. Having more than 10 people in the household was 
protective against sputum production (OR 0.73; 95% CI: 0.58-0.92) in bivariate 
analysis, but no association was identified after adjustment. Being female resulted in 
the highest odds of having shortness of breath (OR 2.4; 95% CI: 1.6-3.2) in 
multivariate analysis. No association was identified with wheeze or any of the risk 
factors in both bivariate and multivariate analysis (Tables 4.13 and 4.14). 
Having a wheeze was associated with COPD stage 1 and 2 using the GOLD 
definition (OR 3.7; 95% CI: 2.1-6.5 vs. OR 4.3; 95% CI: 1.9-9.5) while sputum 
production was significantly associated with modified stage 1 COPD using the local 
range and LLN definition (OR 1.1; 95% CI: 1.0-1.2).  
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   Table 4.13 Bivariate associations between respiratory symptoms and risk factors  
 
Variable Usual Cough (n= 343/1,829) Usual Sputum (n= 262/1837) Exertional dyspnoea (n= 276/1,481) 
  Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI 
Age Group             
18-29 1 - 1 - 1 - 
30-39 0.78* 0.61-1.0 1.13 0.60-2.11 0.9 0.27-3.06 
40-49 0.64± 0.33-1.23 0.87 0.41-1.87 0.85 0.41-1.74 
50-59 0.74± 0.47-1.17 0.95 0.42-2.12 0.84 0.41-1.74 
60-69 0.65± 0.39-1.07 1.32 0.13-12.97 1.08 0.35-3.33 
70+ 0.67 0.18-2.46 2 0.80-5.01 1.21 0.24-6.16 
Gender             
Male 1 - 1 - 1 - 
Female 1.21± 0.78-1.88 0.9 0.46-1.77 1.57 0.83-2.98 
Year of education 1.02± 0.98-1.05 1.01 0.96-1.06 1.01 0.96-1.06 
Smoking              
Never 1 - 1 - 1 - 
Ever smoked 1.29 0.38-4.37     1.28 0.49-3.33 
Smoking Status             
Current smoker 1.38 0.37-5.18 1.73± 0.53- 5.62 1.4 0.37-5.30 
Ex-smoker 1.18 0.39-3.63 1.29 0.30-5.55 1.13 0.75-1.71 
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Packs per year             
Never 1 - 1 - 1 - 
0-10 packs year 1.15 0.26-5.09 1.08 0.46-2.56 1.11 0.36-3.46 
≥10 packs years  1.66± 0.58-4.73 2.82 0.63-12.65 1.55± 3.07 
BMI (kg/m2)             
Underweight (BMI 
<18.5) 
1.02 0.29-3.56 1.12 0.33-3.74     
Normal (18.5-25) 1 - 1 - 1 - 
Overweight (25-30) 0.92± 0.80-1.06 1.14 0.52-2.49     
Obese (BMI>30) 0.95 0.38-2.35 1 0.34-2.89     
Self-reported TB             
No 1 - 1 - 1 - 
Yes 0.79 0 - 406.68 4.48± 0.28-71.57  - - 
Reported 
Hypertension 
            
No 1 - 1 - 1 - 
Yes 1.39 0.49- 3.92 1.89* 1.34-2.68     
Number of people 
living in house 
0.96± 0.92-1.02  -  - - - 
Any biomass fuel 
exposure 
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No 1 - 1 - 1 - 
Yes 1.38± 0.85-2.25 1.56± 0.93-2.62     
Working in a Farm             
No 1 - 1 - 1 - 
Yes  - - 1.11 0.47-2.59 0.79± 0.48-1.30 
Working as welder             
No 1 - 1 - 1 - 
Yes 1.16± 0.92-1.45 1.22± 0.94-1.59 1.11 0.38 -3.27 
Current Mokken scale  OR P-value  OR P-value  OR P-value 
 1.02 0.564 1.02 0.701 1.06± 0.149 
















Table 4.14  Multivariate associations between respiratory symptoms and risk factors, all variables significant at level <0.2 are included 
 
Variable Usual Cough (n= 343/1,829) Usual Sputum (n= 262 /1837) Exertional dyspnoea (n= 276/1,481) 
  Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI 
Age Group             
18-29 1 - 1 - 1 - 
30-39 0.67 0.39-1.14 0.9  0.39-2.04 0.77 0.24-2.42 
40-49 0.52 0.24-1.14 0.65 0.25-1.64 0.76 0.40-1.45 
50-59 0.67 0.43-1.06 0.75 0 .41-1.35 0.76 0.29-2.00 
60-69 0.53* 0.31-0.92 0.91  0.16-5.11     
70+ 0.66 0.22-2.03 1.38  0.58-3.34 1.04 0.27-4.04 
Gender             
Male 1 - 1 - 1 - 
Female 1.72 0.84-3.52     2.36* 1.67-3.33 
Years of education 1.02* 1.00-1.04  - - - - 
Packs per year             
Never 1 - 1 - 1 - 
0-10 packs year 1.4 0.17-11.88     1.95 0.74-5.16 
≥10 packs years  2.99 0.88-10.12     2.28 0.64-8.12 
BMI (kg/m2)             
 
 123
Underweight (BMI <18.5) 0.98 0.32-3.034      3.93 0 .12-129.57 
Normal (18.5-25)     1 - 1 - 
Overweight (25-30) 0.93 0.80-1.09          
Obese (BMI>30) 0.98 0.50-1.92         
Number of people living 
in house 
0.97 0.88-1.06  - - - - 
Any biomass fuel 
exposure 
            
No 1 - 1 - 1 - 
Yes 1.53 0.92-2.53  - - 1.67 0.80-3.51 
Work as welder             
No 1 - 1 -     
Yes 1.33 0.31-5.68 0.92 0.27-3.14     
Work in a Farm             
No - - - - 1 - 
Yes - - - - 0.94 0.82-1.07 
Current Mokken scale  OR P-value  OR P-value  OR P-value 
 - - - - 1.06 0.231 




 Factors associated with post-bronchodilator airway obstruction defined by 
GOLD 
The 70+ age group had the highest odds of having GOLD stage 1 or higher COPD 
using the NHANES range and GOLD stage 2 or higher COPD using the local 
reference range, as well as GOLD stage 2 or higher COPD ((OR 34.97; 95% CI: 
4.70-257.48), (OR 13.07; 95% CI: 2.38-71.71), (OR 16.61; 95% CI: 3.48-79.28)) 
when compared to the 18-29 age group respectively.  Years of education was also 
associated with GOLD stage 1 COPD and GOLD stage 2 or higher in bivariate 
analysis, while no association was identified after adjustment (Table 4.15 and 4.16). 
Participants who reported exposure to biomass fuels were less likely to have GOLD 
stage 2 or higher COPD using the local reference range (OR 0.7; 95% CI: 0.56-0.88). 
Those who had >5 years of occupational exposure working in agriculture, textile or 
food industry had higher odds of developing GOLD stage 1 or higher COPD (OR 
2.08; 95% CI: 1.19-3.65) in bivariate analysis, while no association identified in 
multivariate analysis. No other association was identified between obstruction and 


















Table 4.15 Bivariate and multivariable associations of risk factors with Stage 1 or 
higher COPD defined using GOLD definitions and NHANESIII reference range  
(Post-BD FEV1/FVC < 0.7; n=95/1320) 
Variable Bivariate association Multivariable association 
  Odds Ratio 95% CI Odds Ratio 95% CI 
Age Group         
18-29 1 - 1 - 
30-39 4.61±  0 .56-38.27 4.07 0.29-58.02 
40-49 8.61*  1.67-44.79 9.41*    2.28-38.87 
50-59 11.82*  4.57-30.54 11.68* 5.88-23.20 
60-69 25.86*  2.62-254.94 30.07* 2.16-417.89 
70+ 29.45*  5.69-152.33 34.97*   4.70-257.48 
Gender         
Male 1 - 1 - 
Female 0.76  0.07-7.72 0.83 0.03-20.24 
Smoking          
Never 1 - - - 
Ever smoked 1.53  0.15-15.17 - - 
Smoking Status         
Never 1 - - - 
Current 0.9 0.04-22.97 - - 
Ex-smoker 2.23 0.17-28.87 - - 
Packs per year         
Never 1 - 1 - 
0-10 packs year 0.77 0.12-4.93 0.83 0.09-7.43 
≥10 packs years  3.76± 0.37-37.63 1.52 0.06-41.14 
Years of education 1* 0 .87-0.98 1.03 0.95-1.10 
Reported 
Hypertension 
        
No 1 - 1 - 
Yes 2.18± 0.86-5.54 1.37  0.17-10.73 
Reported Diabetes          
No 1 - 1 - 
Yes 1.35 0.04-44.88     





0.9 0.25-3.27 - - 
Normal (BMI 18-25) 1 - 1 - 
Overweight (BMI 
25-30) 
0.86 0.19-3.99 - - 
Obese (BMI >30) 1.2 0.10-14.22 - - 
Number of people 
living in house 
1.02 0.84-1.25 - - 
Any biomass fuel 
exposure 
        
No 1 - 1 - 
Yes 1.33  0.68-2.61 - - 
Use of firewood in 
cooking >6 months 
        
No     1 - 
Yes 0.76 0.15-3.80     
Occupation group 1 1.62 0.19-13.22 - - 
>5 years of exposure 
in group1 
2.08* 1.19-3.65 0.75 0.34-1.65 
Occupation group 2 0.68 0 .14-3.39 - - 
>5 years of exposure 
in group1 
1.42 0.61-3.31 - - 
Occupation group 3 0.55 0.12-2.47 - - 
>5 years of exposure 
in group1 
2.03 0.46-9.05 - - 
Working in Farming         
No 1 - 1 - 
Yes 1.57 0.19-12.73 - - 
Current Mokken 
scale 
OR P-value OR P-value 
 0.94 0.514 - - 
*indicates p<0.05; ± indicates p<0.2 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry) 




Table 4.16  Bivariate and multivariable associations of risk factors with moderate-
severe post bronchodilator airway obstruction, defined using GOLD and NHANES III 
reference range (FEV1/FVC ratio <0.7 and FEV1 <80% predicted) n=52/1320 
 
Variable Bivariate association Multivariable 
association 
  Odds 
Ratio 
95% CI Odds 
Ratio 
95% CI 
Age Group         
18-29 1 - 1 - 
30-39 4.62 0.56-38.27 3.13 0.08-126.3 
40-49 7.04± 0.85-58.44 7.39* 1.20-45.40 





70+ 17.75* 8.24-38.24 16.61* 3.48-79.28 
Gender         
Male 1 - 1 - 
Female 0.88 0.08-10.06 1.24 0.06-26.96 
Smoking          
Never 1 - - - 
Ever smoked 1.49 0.21-10.67 - - 
Smoking Status         
Never 1 - - - 
Current 0.83 0 .07-9.78 - - 
Ex-smoker 2.22 0.24-20.62 - - 
Packs per year         
Never 1 - 1 - 
0-10 packs year 0.68 0 .11-4.48 0.96 0.27-3.33 
≥10 packs years  3.78± 0 .51-28.23 2.09 0.10-45.59 
Years of education 1* 0.88-0.98 1 0.94-1.05 
Reported Hypertension         
No 1 - 1 - 
Yes 2.51± 0.82-7.61 1.07 0.13-8.48 
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Reported Diabetes          
No 1 - 1 - 
Yes 1.54 0.06-43.10 - - 
BMI (kg/m2)         
Underweight (BMI<18.5) 1.07 0.33-3.46 - - 
Normal (BMI 18-25) 1 - 1 - 
Overweight (BMI 25-30) 0.94 0.37-2.38 - - 
Obese (BMI >30) 1.29 0.21-7.98 - - 
Number of people living in 
house 
1 0.62-1.60 - - 
Any biomass fuel exposure         
No 1 - 1 - 
Yes 1.32± 0.74-2.36 0.69 0.25-1.87 
Occupation group 1 1.62 0.20-13.22 - - 
>5 years of exposure in 
group 1 
1.63± 0.88- 3.01 - - 
Occupation group 2 0.68 0.14-3.40 - - 
>5 years of exposure in 
group 2 
1.34 0.54-3.34 - - 
Occupation group 3 0.55 0.12-2.47 - - 
>5 years of exposure in 
group 3 
2.30 0.52-10.29 - - 
Working in Farming         
No 1 - 1 - 
Yes     - - 
Current Mokken scale OR P-value OR P-value 
 0.95 0.536 - - 
*indicates p<0.05; ± indicates p<0.2 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry) 
Occupation group 3: Welders, firefighters, cleaners or exposed to chemicals and 






  Factors associated with post-bronchodilator airway obstruction defined 
by LLN 
Those aged 60-69 had the highest odds of having stage 2 COPD or higher using the 
local reference range (OR 2.07, 95% CI 1.13-3.82). Participants with a higher 
educational level were less likely to have stage 1 COPD or higher (OR 0.50, 95% CI 
0.27-0.93), as were those who used firewood for water heating (OR 0.32, 95% CI 
0.13-0.77).  None of the other risk factors were associated with any obstruction 
defined using LLN (Table 4.17 and 4.18). Using the Mokken scale, no association 
was identified between participants’ socioeconomic status and developing COPD 
using LLN and GOLD definitions. Additionally, no association was identified with 
occupational groups and obstruction. 
 
Table 4.17   Bivariate and multivariable associations of risk factors with Modified 
Stage 1 or higher COPD defined using the NHANES III reference range (Post-BD 





  Odds 
Ratio 
95% CI Odds 
Ratio 
95% CI 
Age Group         
18-29 1 - 1 - 
30-39 2.80± 0.57-13.86 2.07 0.59-7.35 
40-49 2.70± 0.34-21.62 2.53 0.32-19.79 
50-59 1.75 0.30-10.21 1.25 0.12-12.83 
60-69 4.16± 0.73-23.84 3.65 0.73-18.24 
70+ 2.35 0.31-18.02 1.7 0.12-24.35 
Gender         
Male 1 - 1 - 
Female 1.58 0.21-11.96 1.52  0.26-8.67 
Level of education         
None  1 - 1 - 
Primary school 0.93 0.21-4.19 1.4 0.03-59.02 
Middle school  0.75 0.30-1.87 1.17 0.02-56.68 
High school or above  0.50* 0.27-0.93 1 0.01-157.5 
Reported Hypertension         
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No 1 - 1 - 
Yes 1.04 0.19-5.58 - - 
Reported Diabetes          
No 1 - 1 - 
Yes 1.13 0.04-30.66 - - 
BMI (kg/m2)         
Underweight (BMI<18.5) 1.81 0.37-8.86     
Normal (BMI 18-25) 1 - 1 - 
Overweight (BMI 25-30) 1.2 0.60-2.38 - - 
Obese (BMI >30) 1.58 0.13-19.78 - - 
Smoking Status         
Never 1 - 1 - 
Ever smoked 0.73 0.15-3.49 - - 
Smoking Status         
Never 1 - 1 - 
Current 0.39 0.01-14.27 - - 
Ex-smoker 1.11 0.14-9.04 - - 
Smoking packs years         
0-10 Years 0.52 0.08-3.55 - - 
≥ 10 Years 1.16 0.23-5.92 - - 
Number of people living in 
house 
1.04 0.94-1.14 - - 
Any biomass fuel exposure         
No 1 - 1 - 
Yes 1.55 0.24-10.19 - - 
Use of firewood in cooking >6 
month 
        
No 1 - 1 - 
Yes 0.53± 0.16-1.80 0.61 0.09-3.96 
Household used wood to heat 
water 
        
No 1 - 1 - 
Yes 0.32* 0.13-0.77 0.47  0.12-1.83 
Occupation group 1 1.16 0.12-10.95 - - 
>5 years of exposure in group1 1.35 0.76-2.40 - - 
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Occupation group 2 0.56 0.13-2.41 - - 
>5 years of exposure in group2 1.02 0.38-2.72 - - 
Occupation group 3 1.06 0.16-7.23 - - 
>5 years of exposure in group3 1.72 0.39-7.62 - - 
Working in Farming         
No 1 - 1 - 
Yes 1.2 0.14-10.68     
Current Mokken scale OR P-value OR P-value 
 0.89 0.220 - - 
*indicates p<0.05; ± indicates p<0.2 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry) 
Occupation group 3: Welders, firefighters, cleaners or exposed to chemicals and 
fumes during work 
 
 
Table 4.18  Bivariate and multivariable associations of risk factors with Modified 
Stage 2 or higher COPD defined using NHANES III reference range (Post-BD 
FEV1/FVC < LLN and post-BD FEV1 < 80% predicted; n=55/1320) 
 
Variable Bivariate association Multivariable association 
  Odds 
Ratio 
95% CI Odds 
Ratio 
95% CI 
Age Group         
18-29 1 - 1 - 
30-39 3.89± 0.53-28.58 2.99 0.57-15.74 
40-49 3.18 0.18- 55.31 3.01 0.17-53.70 
50-59 2.42 0.29-20.59 2.28 0.31-16.73 
60-69 5.26± 0.60-46.36 4.93 0.84-28.81 
70+ 0.7± 0.29-36.58 2.78 0.19-40.16 
Gender         
Male 1 - 1 - 
Female 1.66 0.14-19.10 1.64 0.20-13.28 
Level of education         
None  1 - 1 - 
Primary school 0.85 0.36-2.00 1.21 0.33-4.45 
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Middle school  0.86 0.54-1.36 1.25 0.77-2.01 
High school or above  0.54± 0.18-1.62 1.03 0.48-2.18 
Reported Hypertension         
No 1 - 1 - 
Yes 1.18 0.23-6.00 - - 
Reported Diabetes          
No 1 - 1 - 
Yes 1.28 0.05-36.21 - - 
BMI (kg/m2)     - - 
Underweight (BMI<18.5) 1.73 0.23-12.93 - - 
Normal (BMI 18-25) 1 - 1 - 
Overweight (BMI 25-30) 1.26 0.40-3.96 - - 
Obese (BMI >30) 1.67 0.13-21.67 - - 
Smoking Status         
Never 1 - 1 - 
Ever smoked 0.73 0.15-3.48 - - 
Smoking Status         
Never 1 - 1 - 
Current 0.31 0.02-6.50 - - 
Ex-smoker 1.25 0.14-11.37 - - 
Smoking packs years         
0-10 Years 0.59 0 .10-3.66 - - 
≥ 10 Years 1.02 0.14-7.58 - - 
Number of people living 
in house 
1.03 0.86-1.23 - - 
Any biomass fuel 
exposure 
        
No 1 - 1 - 
Yes 1.5 0.34-6.55 - - 
Use of firewood in 
cooking >6 months 
        
No 1 - 1 - 
Yes 0.56± 0.23-1.33 0.64 0.17-2.38 
Used wood to heat water         
No 1 - 1 - 
Yes         
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Occupation group 1 1.17 0.07-19.16 - - 
>5 years of exposure in 
group1 
1.27 0.69-2.35 - - 
Occupation group 2 0.65 0.16-2.64 - - 
>5 years of exposure in 
group1 
1.16 0.43-3.10 - - 
Occupation group 3 1.2  0.19-7.75 - - 
>5 years of exposure in 
group1 
1.93 0.43-8.61 - - 
Working in Farming     - - 
No 1 - 1 - 
Yes 1.21 0.08-19.02 - - 
Current Mokken scale OR P-value OR P-value 
 0.90 0.202 - - 
*indicates p<0.05; ± indicates p<0.2 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry) 
Occupation group 3: Welders, firefighters, cleaners or exposed to chemicals and 
fumes during work 
 
 
 Factors associated with low FVC 
Being underweight had the highest odds of having low FVC using NHANES III 
reference ranges in both bivariate and multivariate analysis (OR 3.07; 95% CI: 2.24-
4.20). Being aged 60-69 was protective against low FVC using NHANES III (OR 
0.80; 95% CI: 0.66-0.97) in bivariate analysis, though no association was identified 
after adjustment. Moreover, participants who had smoked for more than 20 pack-
years were less likely to have low FVC in both bivariate and multivariate analysis 
(OR 0.33; 95% CI: 0.13-0.82). In bivariate analysis, using biomass fuels for cooking 
for more than 6 months produced higher odds of having a low FVC (OR 1.19; 95% 
CI: 1.01-1.39). No association was identified after adjustment. No association was 
identified between socioeconomic status based on the Mokken scale and spirometric 
restriction (Table 4.19). Using the local reference range, no association was identified 
between low FVC and any of the risk factors. 
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Table 4.19 Bivariate and multivariate associations of risk factors with low FVC, 
defined using NHANES III reference range (FEV1/FVC ratio >0.70 and FVC <80% 
predicted; n=713/1320) 
 
Variable Bivariate association Multivariable association 
  Odds 
Ratio 
95% CI Odds 
Ratio 
95% CI 
Age Group         
18-29 1 - 1 - 
30-39 1.01 0.64-1.60 1.1 0.63-1.92 
40-49 1.23 0.54-2.79 1.44 0.79-2.62 
50-59 0.98 0.61-1.56 1.17 0.59-2.31 
60-69 0.8* 0.66-0.97 0.86 0.42-1.74 
70+ 0.46± 0.09-2.23 0.53 0.12- 2.54 
Gender         
Male 1 - 1 - 
Female 1.24 0.65-2.39 1.14 0.63- 2.05 
Level of education         
None  1 - 1 - 
Primary school 0.88 0.11-6.90 - - 
Middle school  1.22 0.42-3.52 - - 
High school or above  1.01 0.31-3.24 - - 
Reported Hypertension         
No 1 - 1 - 
Yes 1.08 0.73-1.62 - - 
Reported Diabetes          
No 1 - 1 - 
Yes 1.02 0.52-2.03 - - 
BMI (kg/m2)     - - 
Underweight (BMI<18.5) 2.95* 2.30-3.76 3.07* 2.24-4.20 
Normal (BMI 18-25) 1 - 1 - 
Overweight (BMI 25-30) 0.97 0.48-1.96 0.89 0.63-1.23 
Obese (BMI >30) 1.14± 0.96-1.36 1.04 0.75-1.43 
Smoking Status         
Never 1 - 1 - 
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Ever smoked 0.79± 0.37-1.38 - - 
Smoking Status         
Never 1 - 1 - 
Current 0.91 0.34-2.40 - - 
Ex-smoker 0.56± 0.31-1.00 - - 
Smoking packs years         
0-10 Years 0.82 0.29-2.28 0.8 0.30-2.10 
10-20 Years 0.75± 0.18-3.16 0.81 0.21-3.20 
>=20 Years 0.29* 0.11-0.80 0.33* 0 .13-0.82 
Number of people living 
in house 
0.99 0.95-1.03 - - 
Any biomass fuel 
exposure 
        
No 1 - 1 - 
Yes 1.19* 1.01-1.39 1.3 0.91-1.86 
Occupation group 1 0.85±  0.62-1.15 2.77 0.72-10.56 
>5 years of exposure in 
group1 
0.83 0.65-1.07   
Occupation group 2 0.79 0.44-1.40 - - 
>5 years of exposure in 
group1 
0.56± 0.39-0.89   
Occupation group 3 0.8 0.19-3.39 - - 
>5 years of exposure in 
group1 
0.58 0.23-1.41   
 Working in Farming     - - 
No 1 - 1 - 
Yes 1.22±  0.85-1.76 0.34  0.06-1.91 
Current Mokken scale  OR P-value OR P-vlaue 
 1.01 0.667 - - 
*indicates p<0.05; ± indicates p<0.2 
Occupation group 1: Working in agriculture, textile or food industry 
Occupation group 2: Working in Mining and construction industry) 
Occupation group 3: Welders, firefighters, cleaners or exposed to chemicals and 





 Spirometry and age  
Post-bronchodilator obstruction using GOLD (Stage 1 COPD) was prevalent in 7.7% 
[SE 1.8] of those aged ≥40 vs. 1.2% [SE 0.4] of those aged 18-39. While GOLD 
stage 2 or higher COPD was prevalent in 6.6% [SE 1.3] of subjects in the ≥40 group 
vs. 1.1% [SE 0.4] in the 18-39 group, those in the older group had higher odds of 
developing stage 1 and 2 COPD (OR 7.12; 95% CI: 4.38-11.58 vs. OR 6.03; 95% 
CI: 3.09-11.77). 
 
Similarly, using the LLN definition, subjects in the older group had higher estimates 
of modified stage 1 COPD or higher (5.5% [SE 0.8] and 4.1% [0.8]) and stage 2 or 
higher (5% [SE 0.6] and 2.7% [SE 0.5]) using local and NHANES III reference range 
respectively. No association was identified between COPD and age using LLN. 
Airway reversibility scores were higher in those aged ≥40 when compared with those 
aged 18-39 (10% [SE 0.7] vs. 4.3% [SE 0.6] respectively) in both men and women, 
although subjects in the younger group had a higher prevalence of low FVC (54.3% 




















Table 4.20 Age and gender stratified prevalence estimates for abnormal spirometry, 
among participants with full spirometry data (those aged ≥40 vs. those aged 18-39) 
 
Spirometric definition 



















Ratio <70% (NHANES) 
18-39 0.7% (0.6) 1.6% (1.3) 1.2% (0.4) 
≥40 9.4% (1.8) 6% (1.9) 7.7 (1.7) 
Total 3.9% (0.4)  3% (1.5) 3.4% (0.8) 
Post bronchodilator 
moderate to severe 
obstruction FEV1/FVC 
ratio <70% AND FEV1 
<80% predicted 
(NHANES)  
18-39 0.7% (0.6)  1.6% (1.3) 1.2% (0.4) 
≥ 40 7.6% (1.2)  5.7% (1.5) 6.6% (1.3) 
Total 3.2% (0.2) 2.8% (1.4) 3% (0.6) 
Post bronchodilator 
moderate to severe 
obstruction FEV1/FVC 
ratio <70% AND FEV1 
<80% predicted (Locally 
derived) 
18-39 0.4% (0.3)  1.2% (1)  0.9% (0.4) 
≥40 4% (0.9) 4.5% (1.1)  4.3% (1) 
Total 1.7% (0.07) 2.3% (1.1) 2% (0.6) 
Prevalence of LLN 
Modified Stage 1 or higher 
COPD (Post-BD 
FEV1/FVC < LLN) by age 
and sex (NHANES) 
18-39 1.9% (0.8)  4.3% (1.7)  3.2% (0.6)  
≥40 5.1% (0.6)  6% (1.1) 5.5% (0.8) 
Total 3.1% (0.5) 4.8% (1.4) 4% (0.5) 
Prevalence of LLN 
Modified Stage 1 or higher 
COPD (Post-BD 
FEV1/FVC < LLN) by age 
and sex (locally derived) 
 
18-39 2.5% (1)  3.1% (1.6) 2.8% (0.6) 
≥40 4.9% (0.7) 3.3% (1) 4% (0.8) 
Total 3.4% (0.6) 3.1% (1.3) 3.2% (0.4)  
Prevalence of LLN 
Modified Stage 2 or higher 
18-39 1.6% (1.1)  3.8% (1.8) 2.8% (0.5)  




FEV1/FVC < LLN and 
post-BD FEV1 <80% 
predicted) by age and sex 
(NHANES) 
Total 2.7% (0.7)  4.4% (1.3)  3.6% (0.4) 
Prevalence of LLN 
Modified Stage 2 or higher 
COPD (Post-BD 
FEV1/FVC < LLN and 
post-BD FEV1 <80% 
predicted) by age and sex 
(locally derived) 
18-39 1.3% (0.8)  1.7% (1.3) 1.5% (0.4) 
≥40 3.2% (0.4)  2.3% (0.8) 2.7% (0.5)  
Total 2% (0.5) 1.9% (1.1) 2% (0.4) 
Airway reversibility FEV1 
increase ≥200ml AND 
≥12% following 
bronchodilator 
18-39 5.2% (0.3) 3.6% (1) 4.3% (0.6) 
≥40 9.9% (0.8) 10% (0.6)  10% (0.7) 
Total 7.2% (2.2) 5.7% (0.5) 6.4% (0.3) 
Restriction FEV1/FVC 
Ratio>0.7, AND FVC<80% 
predicted (NHANES) 
18-39 55% (2.6)  53.7% (5.7) 54.3% (4.2)   
≥40 43.6% (1.8)  62.1% (0.5) 52.7% (1) 
Total 51% (1.5) 56.3% (4.3) 53.8% (2.7) 
Restriction FEV1/FVC 
Ratio>0.7, AND FVC<80% 
predicted (Locally derived) 
18-39 5.4% (0.8) 8.1% (2.6) 6.9% (1.2) 
≥40 5.2% (0.9) 11.1% (1.8) 8.1% (1.6) 
Total 5.3% (0.2) 9.1% (2.4) 7.3% (1.3)  
 
 
  Spirometry and location 
Wad Medani locality had the highest estimates of airway obstruction using both 
GOLD and LLN definitions (4.8%) followed by Alkamleen locality (2.3% and 4.3% 
respectively), while Sharg-Algezira locality had the lowest estimates (2.3% and 3.4% 
respectively) as well as the lowest estimates of airway reversibility (4.9% [SE 0]).  
Alshnateer village, the only nomadic community included in this study, had the 
highest prevalence estimates using both LLN and GOLD definitions (25.1% [SE 0]). 
Subjects in Wad Medani locality had higher odds of developing stage 1 and 2 COPD 
using the GOLD definition when compared to Sharg-Algezira locality (OR 2.16; 








Figure 4.7 Prevalence of airway obstruction based on both GOLD and LLN by locality. 
The upper panel represents the villages of Alkamleen locality, followed by Sharg Algezira 
and Wad Medani. Prevalence of COPD by village is shown in each panel.  
 
 
  Discussion  
This study aimed to investigate the prevalence of  NCLD in rural Sudan in adults 
aged 18 and older. The main finding was that 3.4% of the overall study population 












































































































































































































percentage was slightly higher when using LLN (4.1%). In subjects aged 40 and 
older, the COPD prevalence estimate based on the GOLD definition was 7.7%, 
though this was lower when using LLN (5.5%). These findings are consistent with 
the urban study results discussed in the previous chapter, as well as literature 
suggesting that using a fixed ratio of FEV1/FVC <0.7 as a cut-off point (as in the 
GOLD definition) might result in an overestimation of COPD prevalence in the 
elderly population (185,186) while using a below-LLN ratio can mitigate the increase 
in COPD diagnoses related to age (6, 7).  
 
Having 55% of the study population below 40 years will likely explain the lower 
prevalence of COPD in the overall population in the rural vs urban study. Previous 
studies in SSA reported similar findings (101).  
 
Like the urban study, findings here suggest a high prevalence of low FVC (53.8%) 
in the overall population. Interestingly, higher estimates of low FVC were identified 
in study participants younger than 40. Overall, women tended to have a higher 
prevalence of low FVC when compared to men. As discussed in chapter 3, there is 
no justification for high prevalence estimates when using NHANES whilst having 
lower estimates using a local reference range derived from the healthy, non-smoking 
Sudanese adult population used in the previous study (188).  
 
The finding that participants aged 40 and older had COPD prevalence of 7.7% when 
using a GOLD definition and 5.5% when using LLN is higher when compared to 
other studies conducted in rural SSA, such as in Rwanda (101). These prevalence 
rates were however far lower when compared with those found in Uganda (97), 
though this study reported high levels of exposure to cigarette smoke and biomass 
fuels. The COPD estimates in our study are higher when compared to a recent study 
from a major city in central Africa which reported the LLN-COPD prevalence at 
2.4%, and the GOLD-COPD prevalence at 0.5% (189). As with the previous study 
discussed in chapter 3, BOLD studies from countries in SSA such as South Africa 
(36) and Nigeria (167) reported higher prevalence estimates than those found in this 
study. However, similar studies from MENA countries such as Saudi Arabia, Abu 
Dhabi, Tunisia (103) and Morocco (165) reported lower prevalence estimates, with 




Age was the main risk factor associated with COPD using LLN and GOLD 
definitions in this study. This is consistent with the previous study (discussed in 
chapter 3) and literature demonstrating that population aging is one of the primary 
COPD risk factors, especially in developing countries with lower levels of smoking 
(18, 19). The finding that years of education was associated with COPD when using 
the GOLD definition and that higher educational level was shown to be protective 
against COPD when using LLN is compatible with previous studies asserting that 
lower educational level is associated with COPD (18, 20, 21). 
 
No association was observed between airway obstruction and increased numbers of 
inhabitants per household, or between airway obstruction and low socioeconomic 
status using the Mokken scale. This contrasts with other studies suggesting that 
crowded housing and low socioeconomic status may be associated with a progression 
of airflow limitation (22, 23). Having large houses and therefore additional space 
within the household may reduce the intensity of exposure to cigarette smoke and 
biomass fuels in this setting. However, the Mokken scale was used to assess the 
socioeconomic status of study participants and an association was found between 
airway obstruction and some socioeconomic status markers including home 
ownership and access to a private source of drinking water. This is consistent with 
previous studies asserting that poor education, low socioeconomic status and being 
underweight are COPD risk factors in developing countries (9, 18, 24, 25). 
 
Reasons behind the high prevalence of low FVC were not explored in this study but 
previous research has reported similar findings (166). Literature suggested that 
unknown environmental factors, genetics, race, low birth weight, early exposure to 
biomass fuels and air pollution and poor diet are common factors associated with low 
FVC in developing countries (8, 10). These factors might also contribute to the high 
estimates of low FVC in this study, as the strongest risk factor for low FVC was 
being under weight. 
 
The negative association found between biomass exposure and moderate to severe 
obstruction using local reference range  as well as a negative association between the 
use of firewood for water heating and any obstruction using LLN is contrasting 
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previous studies. Conversely, this might be a random association as only 0.02% of 
participants with moderate to severe obstruction using local reference range were 
exposed to biomass fuel and only 0.04% of participants with any obstruction used 
firewood for water heating.  
 
On the other hand, no association was identified between the use of biomass fuels 
and low FVC. However, the high prevalence of respiratory symptoms and the high 
occurrence of low FVC found in this study might be explained by the high percentage 
of subjects (48%) who had exposure to biomass fuels for 6 months or more (181), as 
well as exposure to other environmental factors as a result of a living in poor 
communities (nine of 35 villages were “Cambos” – a rural, mixed-composition, 
displaced community – while one was nomadic). In addition, childhood respiratory 
infections might possibly contribute to this high prevalence having pneumonia 
ranked as the second cause of hospitalisation in Sudan (26). The association between 
being female and shortness of breath might be a result of exposure to biomass fuels 
in these poor settings. There were associations between sputum production and low 
socioeconomic status, and between cough and poor educational level, while higher 
socioeconomic status was a factor in preventing lung restriction.  This is consistent 
with previous studies (36,166,188).  
 
Asthma and other respiratory diseases might be prevalent in Gezira state as medically 
diagnosed asthma was reported by 6.4% of the study population, the prevalence of 
airway reversibility was 6.4% and a high prevalence of a cough, shortness of breath 
and functional limitations was reported by younger age groups of (18-39). The 
previous study conducted in Gezira state suggested that asthma prevalence in school 
children aged 13-14 was 9-12% (190) and the ISAAC study reported a prevalence of 
5% in rural and 12% in urban Sudan(191). Other studies in SSA, from rural Tanzania 
and Cameroon, reported a higher prevalence (192), though these studies targeted 
children rather than adults. 
 
In this study, an association was observed between airflow obstruction defined by 
GOLD and occupational exposure for more than 5 years only for those working in 
agriculture, textile and food industry. As found in the urban study from Khartoum, 




Having the highest prevalence estimates of obstruction, low FVC and airway 
reversibility in one locality might be due to the more urban settings of the locality 
when compared to other study localities and because 40.2% of the total current 
smokers studied lived in this locality (94). However, a high prevalence of COPD in 
Alshnateer village might be explained by the factors associated to nomadic life and 
poverty (151). In this village, 75% of participating subjects reported an exposure to 
biomass fuels for 6 months or more. Though no association was identified with either 
obstruction or low FVC, long-term exposure to allergens and various irritants (as a 
consequence of living with animals), having no private source of drinking water and 
no flush toilets or bathrooms might explain the high prevalence of airway obstruction 
(11, 30).  
 
  Comparison with Khartoum study 
Overall, COPD was more prevalent in the urban vs rural study using both LLN and 
GOLD estimates for participants aged ≥40. This contrasts with published literature 
suggesting that people living in more rural settings tend to have more exposure to 
environmental risk factors such as indoor air pollution, biomass fuels and allergen 
irritants. However, this study found that exposure to biomass fuels, especially 
firewood and coal occurred more in urban (82.4%) than rural settings (48%). Having 
higher exposure to biomass fuel in Khartoum is unexpected but could be explained 
by the high levels of migration from rural Sudan to Khartoum State over the last 
decade as a consequence of conflict. As a result, participants might not have lived in 
urban settings their whole lives and therefore continue to use more traditional 
methods for cooking and heating. Furthermore, although Gezira State has been 
officially classified a rural state, it is relatively wealthy as it has the largest agriculture 
project in the country(184). Moreover, the high prevalence of COPD in Khartoum 
might be due to the exposure to air pollutants coming from the large number of 
factories and millions of cars in the State.   
 
In the Gezira study, 92% of participants owned their own houses and 85% had access 
to a private indoor or outdoor water supply, while these percentages were 70% and 
66.2% respectively in the urban study. A higher educational level was also reported 
in Gezira State when compared to Khartoum (44% vs. 32%) as the state was the 
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pioneer in education in Sudan. These factors might contribute to the lower levels of 
post-bronchodilator obstruction observed in Gezira state (18, 20, 21).  
 
The prevalence of reported previous TB was lower in this study than rates reported 
by the National Tuberculosis program in Khartoum and Gezira states. As discussed 
in chapter 3, the stigma around TB in Gezira State (193) and generally in Sudan 
might explain the small number of reported TB cases in both studies, and given the 
high prevalence of low FVC, TB might be more prevalent in this area than reported. 
The lack of the association between TB and COPD or low FVC in either study can 
be justified by the few self-reported TB cases. 
 
The findings regarding airway reversibility in both rural and urban studies highlight 
the need for further investigation of asthma in the area.  
 
Rurally based participants returned a higher low FVC prevalence estimate, especially 
in the group aged <40, while the prevalence of respiratory symptoms in the overall 
population was higher in rural populations compared to urban populations (42% vs. 
23% respectively). The finding of having higher prevalence of respiratory symptoms 
in those with low FVC in both studies is tangible suggestion that the burden of low 
FVC requires more attention and investigation. 
 
Despite a relatively high smoking prevalence, cigarette smoking was only associated 
with post-bronchodilator obstruction in the urban study using the GOLD definition. 
Therefore, the obstruction reported in both studies might not be the result of heavy 
smoking, given that 50% and 94% of the smokers reported a smoking history of 
fewer than 10 pack-years in urban and rural studies respectively.  
 
No association was identified between airway obstruction and body mass index in 
the rural study. However, having a higher BMI was found to be protective against 
airway obstruction in the urban study. A higher BMI generally in the urban 
population might explain this finding as a higher percentage of the rural population 





  Strength, limitations and challenges   
This study is the first of its kind in rural Sudan and including a younger age group of 
18 years and above allowed research to explore different types of condition and lung 
abnormalities. Results were based on spirometry tests conducted to ATS standards 
with careful quality control. The followed sampling technique allowed the estimation 
of a population weighted prevalence and associated risk factor. Moreover, the 
findings suggested a high prevalence of low FVC in younger subjects, which should 
be explored further in future research. Using the BOLD standardised method also 
allowed comparability with other findings from the continent and worldwide. 
  
The study also had limitations. A response rate of 59% occurred because 22% of 
initial sampled participants left the area and it was not possible to locate them. In 
addition, 17% of recruited participants had inadequate spirometry readings mostly 
due to refusal to complete the post-test and taking the inhaler. Yet we included a 
sample size > 600. This reduced the sample size and limited the exploration of 
associations between location and airway obstruction and low FVC having some 
villages with small number of participants.  
 
Moreover, there was of a high refusal rate in different study villages, particularly 
amongst those more rural. There was no record of the number of refusals on those 
villages, though reasons for refusal varied across different villages and ethnic groups. 
Participants declining to take part in spirometric testing was the most common reason 
for incomplete data. This may have been because of local beliefs that blowing into a 
machine and taking an inhaler might transmit asthma. Additionally, working in a 
challenging rural environment and traveling for long distances reduced the amount 
of time that data collectors could spend in villages and recruit participants. 
 
  Conclusions 
Finding COPD prevalence rates of 5.5% and 7.7% (using the GOLD definition and 
LLN respectively) in subjects aged ≥40, an airway reversibility of 6% and a high 
prevalence of low FVC suggest that NCLDs, especially COPD and perhaps asthma, 
are serious public health problems in adults in rural Sudan and emphasise the need 
for more investment in prevention and management of chronic respiratory disease. 
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Similarly, the high prevalence of respiratory symptoms across different age groups, 
especially in younger age groups, needs further investigation and consideration from 
public health authorities and researchers 
 
The gap between medically diagnosed COPD reported in this study and prevalence 
identified by spirometric testing suggests that COPD is under-diagnosed in rural 
areas of Sudan. This might be due to a lack of availability of proper diagnostic tools 
such as spirometry as well as a lack knowledge and consideration of this disease and 
its associated risk factors other than cigarette smoking 
 
Taken together these findings, serious actions and calls for  smoking cessation 
programmes, provision of diagnosis and treatment options for chronic respiratory 
disease with a focus on COPD  and asthma as well as changes to the use of biomass 
fuels in the country is highly needed. 
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 A comparison of smartphone and paper data-collection 
tools in the Burden of Obstructive Lung Disease (BOLD) study in 
Gezira state, Sudan 
 
  Introduction 
Advances in information technology have opened exciting new avenues for how 
research is conducted and data collected, however, traditionally paper-based data 
collection has been the mainstay of data gathering for the Burden of Obstructive 
Lung Disease (BOLD) study. As highlighted in chapter 2, section 5.2.1, BOLD is an 
internationally recognized study that uses standardised methods to measure the 
burden of chronic obstructive lung disease (68). However, automated data collection 
and processing methods are becoming more widespread in healthcare research 
(31,194) and they have many advantages (195–197). There are studies investigating 
the use of automated data collection via smartphones as a research tool in developing 
countries though there are fewer of these studies than in the developed world and 
fewer still exploring smartphone usage in large-scale and complex surveys, such as 
BOLD (197).  Experience with smartphone-based data collection in challenging rural 
environments where internet connection is problematic, as in Sudan, is particularly 
limited. 
 
Paper-based data collection is often convenient for researchers and data collectors. 
Paper questionnaires have several potential advantages over automated methods. 
Paper questionnaires are often easier to produce, modify, manipulate, and implement, 
and data extraction is not restricted to a specific place. Additionally, paper-based data 
collection provides a long-lasting record of all modifications and evaluations of 
completed questionnaires can be completed by different reviewers instantly (32,198). 
 
However, studies from developing countries have found that using a paper-based 
method tends to result in incomplete records more, frequently increases the potential 
for human error and requires more time to organise the data (32,199,200). This is 
because labour-intensive data entry is necessary and this may reduce time available 
for analysis (200). 
  In the last decade, the number of mobile phone users in Africa has dramatically 
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increased, with mobile users representing 83% of total telephone users in the 
continent. South Africa boasts the highest rates of mobile phone ownership with 36.4 
mobile phones per 100 people. They are no longer considered a luxury (196,197). 
 
Smartphones  is deliberated to be the combination of the traditional Personal Digital 
Assistant (PDA) and mobile phone, with an improved focus on the mobile phone 
part. These handheld devices incorporates mobile phone capabilities with the more 
common features of a handheld computer or PDA.  As information communication 
technologies grow, with software supporting ‘Android’ platforms and the 
development of many open-source applications, researchers in the health sector have 
begun using smartphones as a tool in patient data collection, disease surveillance, 
clinical research and national surveys (31,32). However, paper-based questionnaires 
continue to be the main data collection tool in many countries, especially in SSA (32) 
.  
 
Using smartphone technology-based tools for data collection has many potential 
advantages, providing a broad range of options. It facilitates faster reporting, more 
accuracy and greater efficiency, reduce cost, condense survey procedures, and 
improve data quality (199,201,202). Data collection and entry can be combined into 
a single step (31), tools can be developed to ensure that data supplied on forms is 
reliable and complete, and additional features, such as the Global Positioning System 
(GPS), can be deployed. Additionally, time stamps, alarms, automatic completions 
and reminders can help to monitor work-rate and validate data (195,198,203). 
Moreover, Smart phones showed that, it has a great potential when considering 
capacities of messages and alert system  as has been used by the UNICEF in Sudan 
to provide real-time and cost effective abilities for local health personnel to trace 
absentee; and for central disease control authorities to track disease (204).  
Smartphones also allow supervisors to keep better track of the gathered data, which 
in turn enhances performance, enables the identification of potential problems, and 
reveals interesting lines of inquiry while they can still be addressed, as well as 
improves accountability of the various actors (205). 
 
However, data security and connectivity can be a concern, and data collectors need 
to be comfortable using an automated tool (195). Accidental loss of data, battery life, 
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loss or theft of the device, security of the device and network connectivity in rural 
areas are also major concerns (201,205,206). 
 
In Sudan, both the government and civil society frequently use smartphones to gather 
data. There is, however, very little published research regarding this. Therefore, this 
study aims to compare accuracy, completeness and the quality of data collected using 
smartphone-based versus paper-based methodologies for the BOLD study in Gezira 
State, Sudan. The present study in this chapter explored whether BOLD survey data 
collection might be expedited by conducting this work as a one-step process ‘in the 
field’ (smartphone-based data collection), improving the speed with which 
questionnaire data could be processed and improving responsiveness to new data. 
Furthermore, this study aimed to provide evidence that will inform the selection of 
data collection methodologies in future BOLD surveys in rural Sudan and wider SSA 
and MENA region.  
 
  Methods 
 Study design and setting 
The parent BOLD study discussed in chapter 4, is a cross-sectional household survey 
with a multi-stage random sampling plan, conducted in 35 villages in Gezira state, 
Sudan. This exploratory cross-sectional household survey piloted within the same 
setting of the rural BOLD survey following the same study design and targeted the 
same population with identical inclusion criteria: all participants were non-
institutionalised adults, aged 18 and older and lived in Gezira state. 
 
Convenience sampling of 100 accessible participants from 3 randomised villages was 
conducted between August and September 2016. Each of these villages was 
composed of 30 households, which were similar in all study characteristics including 
population density, educational level, geographic area, sex distribution, ethnic groups 
and infrastructure.  
 
The method of data collection was randomized separately from the main BOLD 
survey. A total of eight participants were randomized daily (four to be administered 
by smartphone and four by paper) prior to the start of data collection. The data 
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collector administering the questionnaires for the BOLD team was then also 
randomized. The collection of the BOLD survey core questionnaire data and this 









 Need assessment  
Prior to the start of this study, a needs assessment was conducted with the aim of 
increasing data collection efficiency and of avoiding errors that are common in 
household surveys. This assessment was based on discussions with different experts 
including a software engineer, an epidemiologist and an expert public health 
surveyor. This exercise identified requirements essential to the development and 
implementation of the electronic data collection forms and system. A wide range of 
available software was explored. The Open Data Kit (ODK) was selected based on 
its affordability, its evidence-based use in developing countries and its offline data 
entry facility. Standard operating procedures (SOPs) in line with ethical approval 
were developed prior to the start of data collection (Appendix (7)). 
 
Daily randomisation of 
8 participants within 
BOLD Gezira 
household survey
• 4 interviewed using smartphone 
questionaire










  Open Data Kit (ODK) questionnaire development 
The ODK (207) was used by the study’s principal investigator to develop an 
electronic version of the BOLD core questionnaire for the Samsung S3 smartphone, 
which included seven main sections: demographic information, respiratory 
symptoms and disorders (cough, sputum, wheezing, and shortness of breath), use of 
medication, cigarette smoking, occupational exposure, economic impact and activity 
limitation. The questionnaire was composed of 26 pages with 44 questions (with 
multiple sub-questions and different skip patterns). Each questionnaire consisted of 
204 fields, including 48 keyed-in, open-ended questions and 105 multiple-choice 
questions. A unique six-digit study ID was manually assigned to the participant 
(following the BOLD study protocol) and all questionnaires were labelled with a 
serial number (i.e. 1–100) (See Appendix (3) for BOLD core questionnaire). 
 
Initially the ODK questionnaire was designed using Microsoft excel and then, using 
guidance from the ODK instructions and xlsform.org, an XLSForm was developed. 
To avoid errors, validation check boxes, reliability rules, alerts, skip patterns, and 
fields requiring data were programmed into the ODK. The form included three 
sheets. The first was a ‘survey sheet’, which included all collectable data in Arabic, 
the GPS location, survey start and finish times and notes to guide data collectors, 
including hints and data constraints. The second was a ‘choices sheet’, which 
contained a comprehensive list of all answer options with labels in Arabic and 
English. The third sheet, of ‘settings’, contained the form title in the mobile interface 
and the form ID.  
 
Questions were grouped and answers programed based on whether they were open 
ended or single/multiple choice questions. The excel file was then uploaded into 
http://opendatakit.org/xiframe/ and the fully functioning form was previewed in 
“Enketo” (provided by the ODK). XML forms were then uploaded into ODK 
Aggregate. To use the forms on mobile devices, the ODK Collect application for 
android was used (See appendix (8) for mobile interface snapshots). 
 
After development, the tool was tested and validated in one village independent of 
the two study villages. The study’s principal investigator and another trained data 
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collector from the BOLD team carried out data collection via smartphone-based 
forms. Six data collectors collected paper-based forms. 
 
As Internet connectivity was very limited in the study area, it was essential that 
ODKs could be used offline. Data were entered into smartphones during collection, 
saved, and later uploaded to the server once reliable internet connectivity could be 
secured. 
 
  Data collection and entry 
Data collection involved recording participants’ information simultaneously on both 
paper and electronic forms.  Both smartphone and paper questionnaires were 
administered in local Arabic language. Two data collectors concurrently completed 
the core questionnaire alternately in a random order (i.e. if one data collector asked 
the questions and completed data entry using the paper-based method, the 
smartphone data collector listened and entered data on the smartphone, and vice 
versa) to ensure no additional burden on participants. The order of administration of 
the paper questionnaire and the smartphone questionnaire was randomized each day. 
Study SOPs were agreed between the two data collectors before the start of data 
collection. 
 
The paper-based questionnaire data were double-entered in a predesigned SPSS 
(IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. 
Armonk, NY: IBM Corp) spreadsheet. Data were entered into two different 
spreadsheets, where crosschecking and cleaning were performed before analysis. 
Smartphone forms were submitted to the ODK aggregate server and then retrieved 
using Briefcase, saved as a CVS file, compiled, and then translated into SPSS format. 
All data collectors were graduates and had been extensively trained in BOLD 
questionnaire administration, research methods and ethics by senior researchers, data 
managers and IT specialists. The mobile data collectors were also trained in how to 
use the ODK and how to administer the BOLD core questionnaire using Samsung S3 






  Ethical considerations 
Ethical approval from Liverpool School of Tropical Medicine research Ethics 
Committee was obtained prior to the start of this study (Ref. 11.03RS). Additionally, 
for the main BOLD study, ethical approval was obtained from the ethics committee 
at Imperial College London and the research department at the Ministry of Health in 
Gezira state, Sudan (Appendix (5). During the data collection stage, all data were 
anonymised. All participants received information sheets concerning the details of 
the study and written consent was obtained prior to participation. 
 
 Statistical analysis 
Descriptive statistics for the main variables in the questionnaire were produced 
alongside frequency distributions in order to test for data completeness. A chi 
squared test was used to examine the association between the percentage of forms 
with errors and form type (smartphone-based/paper-based), for collection order (first 
versus second) and possible interaction of form type by order.  
Intraclass correlation coefficient tests were used to test consistency and agreement 
between continuous variables, while percentage agreement and Cohen's Kappa 
statistics were used to test the agreement between categorical variables. P-values of 
less than 0.05 were used to report the significance of the results. Kappa ranges are 
described in Table 5.1 (208). 
 
 
Table 5.1 Kappa range and level of agreement 
 
Kappa range Level of agreement 
0 Less than chance  
0.01–0.20 Slight  
0.21–0.40 Fair  
0.41–0.60 Moderate  
0.61–0.80 Substantial  




  Result 
Data collected via paper forms took approximately 15 days from the initial collection 
to be double entered in SPSS software and cleaned, whereas electronic data were 
rapidly accessible and retrieval took one day. 
 
  Study population demographics 
Of the 100 participants (median age = 41.5 ± 16.4 years), 63% were women. Perfect 
agreement (inter-rater measurement agreement = 0.929) was shown between the two 
methods in the age variable (Table 5.2). 
 
Table 5.2 Characteristics and demographic information of study participants 
Variable Smartphone Frequency 
(%) (N = 100) 
Paper Frequency 
(%) 
(N = 100) 
Age (years)   
18–30 28 (28.0%) 28 (28.0%) 
31–40 21 (21.0%) 21 (21.0%) 
41–50 15 (15.0%) 15 (15.0%) 
51–60 19 (19.0%) 19 (19.0%) 
60–70 15 (15.0%) 13 (13.0%) 
> 70 2 (2.0%) 4 (4.0%) 
Sex   
Male 37 (37.0%) 38 (38.0%) 
Female 63 (63.0%) 62 (62.0%) 
Educational level   
Primary school 26 (26.0%) 26 (26.0%) 
Middle school 11 (11.0%) 11 (11.0%) 
High school 28 (28.0%) 28 (28.0%) 
College (trade/professional/ 
community) 
6 (6.0%) 6 (6.0%) 
Four-year college/university 22 (22.0%) 19 (19.0%) 
None 6 (6.0%) 6 (6.0%) 
Unknown 1 (1.0) 1 (1.0) 
Father’s educational level   
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Primary school 15 (15.0%) 15 (15.0%) 
Middle school 7 (7.0%) 7 (7.0%) 
High school 6 (6.0%) 7 (6.0%) 
College (trade/professional/ 
community) 
4 (4.0%) 1 (1.0%) 
Four-year college/university 9 (9.0%) 9 (9.0%) 
None 28 (28.0%) 33 (33.0%) 
Unknown 31 (31.0%) 28 (28.0%) 
Mother’s educational level   
Primary school 26 (26.0%) 29 (29.0%) 
Middle school 6 (6.0%) 5 (5.0%) 
High school 12 (12.0%) 11 (11.0%) 
College (trade/professional/ 
community) 
2 (2.0%) 2 (2.0%) 
Four-year college/university) 2 (2.0%) 3 (3.0%) 
None 36 (36.0%) 37 (37.0%) 
Unknown 16 (16.0%) 13 (13.0%) 
 
 
Two ethnic groups were dominant in the studied population: Halaween represented 
42% while Jaalia represented 17%, though other ethnic groups were also represented. 
Kappa statistics showed substantial agreement between the two methodologies 
(Kappa = 0.630). Date of birth also represented a strong agreement. Generally, the 
two methodologies agreed on all demographic information on the questionnaire. 
In ‘higher education level achieved’, two records were missing in the paper-based 
data collection and inconsistencies in the values collected using both methods were 
seen. However, the Kappa statistics showed strong to substantial agreement. 
 
  BOLD questionnaire results 
The BOLD questionnaire results are summarised in Table 5.3. The results are from 
both paper and smartphone collected data. Where disagreement occurred both 






Table 5.3 Respiratory symptoms, smoking status, occupational exposure and 
economic impact in BOLD questionnaire (n=100) 
 
Variable Paper-based 
Number (%)  
Smartphone based 
Number (%)  
 Yes No Yes No 
Cough often, without viral illness 24% 75%* 24% 76%* 
Productive cough, without viral 
illness 
15% 85% 15% 85% 
Wheeze in the last 12 months 13%* 5%* 11%* 7%* 
Shortness of breath 18%* 81%* 16%* 84%* 
Took respiratory medicine in last 12 
months 
19% 81% 19% 81% 
Ever smoked Cigarette  20% 78%* 20% 80% 
Current smoker 40% 60% 40% 60% 
Ex-smoker 60% 40% 60% 40% 
Think smoking can cause serious 
illness 
97% * 3%* 99%* 1%* 
Worked in an occupation that has 
dust 
23% * 76%* 20%* 80%* 
Work for income generation 38% * 62%* 40%* 60%* 
Unemployed 60% * 40%* 62%* 38%* 
Unemployed because of respiratory 
problems 
2% 60% 2% 60% 
Unemployed because of other health 
problems 
19%* 41%* 23%* 37%* 
* Indicates a disagreement in reported percentage 
 
 
 Areas of strongest agreement 
Several BOLD questionnaire areas showed almost perfect agreement between the 
two data collection methods. The major questions relating to cough had a 99% 
agreement, with one record missing in the data collected using the paper-based 
methodology, and major questions relating to phlegm demonstrated 100% agreement 
between the two methods. Questions relating to emphysema, asthma, and chronic 
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bronchitis all showed strong to perfect agreement.  
 
Strong to perfect agreement was also seen in the smoking section, as shown in Table 
5.4. No significant differences were found on smoking questions such as smoking 
shisha, cigars, canapés, and special substances. All other smoking related questions 
had a strong level of agreement between results yielded through smartphone and 
paper collection, and substantial agreement was also found in questions regarding 
smoking at work (kappa = 0.77, p < .05).  
 
Significantly low inter-rater agreement was found on questions related to the number 
of cigarettes smoked weekly (Interclass coefficient = 0.552, p < .05) (Table 5.4). The 
mobile variable was calculated automatically for results in the smartphone-based 
collection and calculated manually in the paper-based collection. 
 
 






How old were you when you 
started smoking? 
1.0001 p < .001 No 
How old were you when you quit 
smoking? 
1.0001 p < .001 No 
How many cigarettes do you 
smoke daily?  
0.9761 p < .001 No 
How many cigarettes do you 
smoke weekly? 
0.5522 0.025 No 
1 = High inter-rater agreement, 2 = Low inter-rater agreement. 
 
 
Absolute agreement was demonstrated in most of the questions regarding medication 
use (Table 5.5). The timeframe of taking the medication should have been specified 
in days and weeks in both methods of data collection. In smartphone-based 
questionnaires, there were specifications for this timeframe (days/weeks) but in the 
paper-based questionnaires there were not. Of the ten participants taking medication, 
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only two had the timeframe of medication duration specified. Kappa values cannot 
be calculated for this variable, though there was an 11% agreement between them. 
 
 





If medication had been taken in the 
past 12 months 
0.9352 p < .001 No 
Type of medication 0.6963 p < .001 No 
When the medication was taken 0.8332 p < .001 No 
Period in months 1.0001 p < .001 No 
1 = perfect agreement, 2 = almost perfect agreement, 3 = substantial agreement. 
 
Occupational exposure showed strong agreement (kappa = 0.88) and the inter-rater 
class statistic showed absolute agreement between the two variables for a question 
related to ‘number of years of exposure’. Similarly, questions concerning participant 
comorbidities also had a strong level of agreement between the two versions of the 
data, apart from questions regarding heart disease, which had fair agreement (kappa= 
0.393). 
 
Moderate to substantial agreement was found in questions regarding participant’s 



















p-value Skip required 
Smoking causes stroke 0.4214 < 0.05 No 
Smoking causes heart 
attack 
0.5504 < 0.05 No 
Smoking causes lung cancer 0.4874 < 0.05 No 
Smoking causes chronic 
bronchitis 
0.6633 < 0.05 No 
Smoking causes 
emphysema/COPD 
0.5634 < 0.05 No 
3 = substantial agreement, 4 = moderate agreement. 
 
 
Sections regarding participants’ views of their health, how they feel, and how well 
they can do their usual activities showed almost perfect agreement using Kappa 
statistics with values of 0.927 and 0.818. The only exception was a particular 
question regarding physical health and emotional problems. In this question, 
substantial agreement was shown (kappa = 0.795). 
 
In follow-up questions concerning phlegm, a slight inconsistency was shown in the 
skipping patterns between the two methods. Fair level of agreement (kappa = 0.23, p 
< .05) was seen in skip-pattern questions relating to ‘hearing wheeze’ (Table 5.7). 
 
 Areas of weakest agreement 
The main areas of disagreement were in questions with skip patterns. In the 
‘shortness of breath’ questions demonstrating disagreement, 15 of the paper-based 
questionnaires showed incorrect usage of the skip pattern (e.g. ‘if the answer is no, 
then the next two questions should be skipped’). Kappa statistics showed no 
agreement in results from the two different methods in this area (Table 5.7). Where 












Cough most days 1.0001 < .001 Yes 
Phlegm most days 0.8672 0.001 Yes 
Wheeze in the past 12 month 0.8952 < .001 No 
Wheeze only with cold 0.2395 0.309 Yes 
Wheeze with shortness of breath 1.0001 < .001 Yes 
Cannot walk because of shortness 
of breath 
0.8582 < 0.001 No 
Shortness of breath when going 
uphill 
-0.0137 0.895 Yes 
Walk slower because of shortness of 
breath 
0.040 6 0.674 Yes 
Stop walking to breath better 0.1116 0.439 Yes 
Stop for breath after walking 100 
yards 
0.1496 0.170 Yes 
1 = perfect agreement, 2 = almost perfect agreement, 5 = fair agreement, 6 = slight 
agreement, 7 = less than chance agreement. 
 
 
The skip pattern was also not adhered to in questions related to ex-smokers. Four of 
11 did not appropriately follow the skip pattern in the paper-based collection group, 
while it was appropriately followed during the same questions in the smartphone-
based collection group. Substantial agreement was found in these variables (kappa = 
0.770, p < .05). 
 
Similarly, questions in the economic impact section exhibited variation in the level 
of agreement. The ‘skip pattern’ questions showed moderate to substantial 














Work days lost    
Did you work for income? 0.9852 < 0.05 No 
Did you not work for income mainly due 
to breathing problems?  
0.4924 < 0.05 Yes 
Did you not work for income because you were 
a full-time homemaker or caregiver? 
0.8033 < 0.05 Yes 
Did your health problems stop you from 




< 0.05 Yes 
During the past 12 months, did health problems 
stop you from working for income? 
1.0001 < 0.05 No 
Non-work activities missed    
Did health problems prevent you from 
participating in one or more non-work related 
activities? 
0.7583 < 0.05 No 
How many days did you not participate in non-
work related activities due to your health 
problems? 
1.0001 < 0.05 Yes 























How many days were you unable to 
perform your homemaking/caregiving 
tasks due to your health problems? 
1.0001 < 0.05 Yes 
During the past 12 months, how many days 
were you unable to perform your 
homemaking/caregiving tasks specifically 
due to breathing problems? 
1.0001 <0 .05 Yes 
How often during the past 12 months did 
you work for income? 
0.9972 < 0.05 Yes 
How many days were you unable to work 
for income due to your health problems? 
-0.1155 0.559 Yes 
1 = perfect agreement, 2 = almost perfect agreement, 3 = substantial agreement, 4 = 
moderate agreement, 5= Less than chance agreement 
 
 
 Incomplete records 
Missing records were seen in paper questionnaires across different questions (as 













Table 5.10 Incomplete records in 100 questionnaires 
Questionnaire section Number of missing 
records in paper-based 
forms 
Number of missing 
records in mobile-based 
forms 




Medications 5 0 








Views about own 
health 
1 0 
 Economic 13 0 
 
 
 Forms with errors 
Errors originated from three sources: (1) an erroneous form, (2) erroneous collection 
methodology, and (3) error on the part of the data collector. Errors were defined as 
questions with no answers or wrong use of the ‘skip pattern’. In smartphone-based 
forms, most of the errors found were due to having different answer options (Table 
5.11). A chi Square test demonstrated that paper forms were significantly more likely 
to contain errors (82.5% of the total). In comparison, 10.5% of smartphone-based 
questionnaires contained errors and 7% occurred in both formats (X2 (3, n = 100) = 
64, p < .001). There was no significant association between erroneous forms and the 
order of questionnaire administration with respect to using the smartphone or paper-








Table 5.11 Forms with returned errors 
 










Error type Error in paper 
forms 
47 (82.5%) <0 .05 -0.995 
Error in mobile 
forms 
5 (10.5%) 
Error in both  4 (7.0%) 
Administration 
method 
Mobile-based 27 (47.4%) 0.686 0.061 
Paper-based 30 (52.6) 
Data Collector 1 9 (15.8%) 0.496 -0.038 
 
 
2 16 (28.1%) 
3 2 (3.5%) 
4 8 (14.0%) 
5 8 (14.0%) 
6 14 (24.6%) 
 
There was no statistically significant association between the occurrence of errors in 
forms and the data collector (p = 0.50) and weak negative correlation between these 
variables (Pearson’s R = -0.038). 
 
Furthermore, a multiple linear regression was calculated to predict the errors on 
forms based on who did the data collection and in what order the questionnaire was 
administered; however, no significant association was found (F(2,97) = 0.299, p > 
.05, R2 = 0). 
 
  Discussion 
Data collection is one of the most important steps in conducting health research and 
having consistent, complete, and accurate data is essential to this process. This study 
found that the use of a smartphone-based data collection method in rural Sudan was 
feasible and provided timely and quality data with a lower number of errors and 
inconsistencies when compared with data collected using paper-based methods. 
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These findings are in line with other studies conducted in similar settings 
(194,199,203,208,209). A recent study of routine influenza sentinel surveillance in 
Kenya and southern India both reported similar results, with fewer errors and 
inconsistencies in smartphone-collected data (31,199). 
 
Smartphone data collection allowed data to be gathered more quickly for analysis in 
comparison to the paper-based forms. A collection date, start time and end time of 
each questionnaire could also be electronically logged when using smartphones, 
whereas this information was not routinely available for data obtained using the 
paper-based method. Furthermore, even though both methodologies were 
administered simultaneously, filing electronic forms was quicker compared to paper-
based forms. 
 
Although no cost-specific data were collected or evaluated in this study, electronic 
data collection was relatively cheap as Epi-Lab organisation already possesses some 
of the building blocks for smartphone data collection. Therefore, it was possible to 
use two existing smartphones (Samsung Galaxy S3). Nevertheless, buying 
smartphones is often expensive, previous studies reported that this cost was 
compensate by fewer people needed for data entry, computer devices for database 
entry and printing cost (194,202).  
 
Moreover, using an open source application, such as ODK, also decreased the 
software cost of this study.  
Inadequacies in the data mainly occurred on questions with complicated skip patterns 
on mobile-based forms. However, the use of automated checks and validations on 
electronic forms prevented the occurrence of these errors, which was also found in a 
Kenyan influenza surveillance study (199). Using the wrong skip pattern on such 
surveys can affect the quality of collected data and may lead to misleading results.   
Variables without mandatory data entry requirements on mobile-based forms and 
open-ended questions caused 8 (80%) of the errors from a total of 10 returned errors 
on mobile-based forms. Other studies reported similar findings with the limitation of 
unrestricted questions using mobile data collection(199). The remaining 20% were 




Some of the reported data inadequacies may not have been caused by the data 
collection method used, but because the participant provided unclear answers. 
During data collection, the researcher was required to select the option he/she 
deemed to be most accurate. Therefore, problematic responses to questions (views 
about the paticipants’ own health—how they feel and how well they can do their 
usual activities) may not have been caused by the collection method used. Similarly, 
when assessing the level of education, there were differences in the ‘unknown’ and 
‘none’ classifications as this was dependent on the researcher’s personal assessment. 
 
 Challenges, limitations, and lessons learnt 
One of the main limitations of this study was the use of a convenience sampling plan 
and a sample size of 100 participants. The sample size was selected based on the 
number of previously recruited participants within the main survey each month as 
well as time and budgetary constraints. Additionally, because of the length of the 
BOLD questionnaires the interviews could only be performed once per individual. 
Ideally the questionnaires would be taken using both methodologies simultaneously 
by the same data collector to allow more comparisons with respect to administration 
time and the efficiency of data collectors.   
Although the ODK tool is an open source application, there were some obstacles 
during the development and data extraction stages, as well as during retrieval. Firstly, 
accessibility of the aggregate website in Sudan was difficult. Occasionally, during 
data collection, the ODK application would unpredictably close and the researcher 
would need to restart the application. As internet connectivity and network coverage 
are very limited in the three rural villages, the availability of offline data collection 
facility in ODK makes it a viable tool in rural settings. 
 
Secondly, using Arabic on the ODK software was challenging during questionnaire 
development and data retrieval, particularly with regards to open-ended questions. 
Importing the CVS files from ODK into Excel was also an issue as Excel was not 
able to correctly interpret Arabic content of incoming CVS files. However, other 





One skip pattern in the smoking section had a programming error, which resulted in 
errors in two of the mobile forms and options were incorrectly skipped.  
 
The main challenge with respect to both the paper and electronic forms was the length 
of the BOLD core questionnaire and the frequent skip patterns. Long questionnaire 
completion time affected the programming time, collection, data entry and analysis 
in the electronic version as providing a challenge for the data collectors. These 
collectors were experts in administering the paper-based core questionnaire and were 
sometimes faster than the smartphone-based data collectors when explaining 
questions to participants. In future studies, increased data collector experience may 
accelerate smartphone-based data collection (31).  
 
The electronic format allows, in theory, GPS coordinates to be easily obtained during 
the interview process and therefore accurate mapping of participants’ locations, even 
in rural areas. However, in practice the GPS coordinates were inconsistent, especially 
in the first village, and there was a delay in obtaining data. If fully functional, this 
system does hold an advantage over traditional paper-based data collection (Figure 
5.1–5.2). See Appendix (9) for maps permission letter. 
The overall economic cost of using this mobile data-collection method, including 
software development, mobile/electronic devices, network connection and internet 
accessibility, requires further investigation.  The use of local rather than the current 
cloud servers provided by the ODK platform also needs evaluating. 
 
Lastly, for large questionnaires with many nested questions and multiple skip 
patterns such as the BOLD core questionnaire, having either mobile-friendly 
questionnaires with strict validation checks or minimising the skip patterns on paper-






Figure 5.2 Maps showing geographical locations of study participants in in included villages in Gezira state, Sudan. (A) Rufaa Alhai 4 village. 
(B) Rufaa Alhai 20 village. (C) Altakala Joubara village




This study demonstrates that electronic data collection via smartphones for the 
BOLD study is an effective and efficient method in the challenging environment of 
rural Sudan. It provides timely and accurate data that are comparable with traditional 
method of paper-based formats, with lower levels of user error. When inconsistencies 
between the two formats did occur, this was primarily due to the inappropriate 
completion of the BOLD skip-format questions in paper-based questionnaires. While 
the smartphone-based technique is not without challenges, this study adds to the 
growing body of evidence supporting electronic data collection as a feasible method 

























Chapter 6 : Summary, implications and conclusions 
 
  Summaries and implications   
This thesis describes three related studies that were designed to shed light on the 
burden of chronic non-communicable respiratory disease in SSA and MENA with a 
focus on Sudan and as well as to examine potential methods for improving data 
collection in large health surveys. The overall aim was to improve our understanding 
of the burden, prevalence and factors associated with the development of chronic 
non-communicable lung diseases, as they are a major public health concern which 
receives little investigation in SSA and MENA region. This chapter summarises 
these studies with an emphasis on their rationale, main findings and their 
implications, concluding with suggestions for further research.  
 
Globally, 3.9 millions of NCDs deaths are due to CRDs and COPD in particular (1). 
COPD is now the third most common cause of death globally; 90% of these deaths 
occur in Low and Middle-Income Countries (LMICs) (35–37,210). In 2016, COPD 
affected 251 million people, and its related deaths represented almost 5% of all deaths 
(74). On the other hand, asthma currently affects 235 million people, and causing 
substantial mortality, there were 383,000 deaths due to asthma in 2015 (76). Limited 
literature is published on the epidemiology of COPD and Asthma from SSA and 
MENA. Both diseases are under-diagnosed and underestimated in both SSA and 
MENA. Furthermore, the burden of COPD in SSA is disputed and reports offer 
variable prevalence estimates, ranging from 4.1% to almost 22.2% (92). SSA and 
MENA countries reported similar COPD mortality rates of 18 per 100,000 
population (47). WHO estimates that there are 250,000 deaths per year from asthma. 
Although asthma is a less common cause of death compared to COPD it is a major 
cause of morbidity; for example it is in the top twenty causes of disability in children 
globally. Risk factors for CRDs are genetic and environmental; the latter primarily 
from air pollution exposure including tobacco smoke (129), household air pollution 
(88,124), outdoor air pollution and occupational exposure (136). 
 
Data on COPD prevalence from both SSA and MENA regions are limited and when 
available are often based on varied definitions and lacking standardisation. In Sudan 
particularly, there are no national estimates for COPD while available reports 
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regarding CRDs are of high degree of uncertainty (24). Similar to the broader 
regions, the priority has been always given to communicable disease with a little 
focus on non-communicable disease in the country. The studies that do exist are 
limited to specific populations such as miners and previously treated TB 
patients(27,143). In addition, good quality post-bronchodilator spirometry is lacking 
in Sudan health system and diagnosis generally depends on clinical decision, and 
knowledge about COPD is often limited.  
 
The reported prevalence rates in both SSA and MENA regions propose a similar rate 
of diseases burden in Sudan. This study is the first, to our knowledge, to provide 
prevalence estimates of COPD in Sudanese adults using internationally accepted 
methods and procedures as well as an appropriate sampling technique. Through the 
use of the BOLD study protocol, estimates can be straightforwardly compared with 
other BOLD studies. 
 
The BOLD study described in Chapter 3 set out to estimate the prevalence of chronic 
obstructive pulmonary disease through spirometric testing in urban Khartoum and 
identify the impact of risk factors on the prevalence of the disease. COPD prevalence 
was 10.3% and 14.8%, using the LLN, and GOLD definitions, respectively. The main 
risk factor for COPD was older age, primarily the age group 60-69 years old. 
Smoking  was also identified as a risk factor using the GOLD definition. Using the 
NHANES III reference range, the prevalence of moderate to severe obstruction was 
9.2% and 12.6% using LLN and GOLD definitions respectively. Using local 
reference ranges, the prevalence of COPD was far lower than when using both LLN 
and GOLD definitions. Low forced vital capacity (FVC) prevalence estimates were 
58.1% using NHANES. Airway reversibility was found in 6.1% of the total study 
population while airway obstruction persisted after use of a bronchodilator in 10.5% 
of subjects with reversibility using GOLD and 18.5% using LLN. This study 
suggested that COPD is prevalent and a considerably under-diagnosed public health 
problem in urban Sudan. In addition, with over 50% of the sampled population 
having low FVC and a large variance in prevalence using NHANES and locally 
derived ranges, there is a need for prioritisation of CRDs and investment in 
improving diagnostic tools as well as research to investigate the reasons behind these 
high estimates.  
 
 172 
To explore whether the high burden of non-communicable lung disease that was seen 
in the urban Sudan setting of Khartoum would also be seen in a rural setting, a second 
study was conducted incorporating the same core BOLD Study protocol in the rural 
state of Gezira. We were particularly interested in the extent to which the burden of 
disease would be similar in younger as well as older (aged 40 years and older) adults 
included in the BOLD study. Therefore, the scope of work was expanded to include 
a second age stratum (age 18-39). This study replicated findings from the previous 
urban study and reported a higher prevalence in respiratory symptoms, which were 
reported by 41% participants (19% reported a cough, 14% reported sputum 
production, 19% reported shortness of breath and 5% reported a wheeze). However, 
the prevalence of post-bronchodilator obstruction in the overall population was lower 
compared to the urban study findings (4% using both LLN and GOLD definitions). 
Amongst participants aged 40 years and older the prevalence was 5.5% and 7.7% 
using LLN and GOLD definitions respectively. Similarly, low FVC was seen in 
52.7% of those aged 40 years and older group using NHANES. Factors associated 
with obstruction and low FVC included age, lower level of education, being 
underweight and living in a particular locality called Wad Medani. Airway 
reversibility was 6.4% while airway obstruction persisted after use of a 
bronchodilator in 18.5% of subjects with reversibility using LLN and 15% using 
GOLD. This finding along with findings from the urban study might suggest a high 
prevalence of asthma in both study areas. 
 
Overall, COPD was more prevalent in the urban area than in the rural area using both 
LLN and GOLD estimates in participants aged ≥40 years. This contrasts with the 
published literature suggesting that people who live in more rural settings tend to 
have more exposure to environmental risk factors such as indoor air pollution, 
biomass fuels and allergen irritants. Findings from both studies were consistent with 
published literature suggesting that using a fixed ratio <0.7 with the GOLD definition 
might overestimate the COPD prevalence in elderly populations (185,186) while 
using the below LLN ratio can reduce the increase in COPD diagnoses related to age 
(48,187). However, advocates of GOLD argue that using a fixed ratio can detect 
patients with substantial pulmonary pathology and respiratory morbidity, while 
advocates of LLN claim that the use of  <0.7 as a cut-off point is more likely to return 
false positives (48,172).  
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The prevalence of low FVC was high in both studies. The rural population tended to 
be more symptomatic than the urban population (40% vs. 23% respectively) with a 
higher prevalence of respiratory symptoms occurring in the younger group <40 years. 
The reasons behind this high prevalence are not known and were not investigated in 
these studies. Having higher prevalence of respiratory symptoms in participants with 
low FVC suggests that this phenomena carries a real burden. No association was 
identified between either airway obstruction or low FVC and known risk factors such 
as smoking, biomass fuels and occupational exposure in both present studies in the 
multivariate analysis. A possible reason of high prevalence of respiratory symptoms 
and reduced lung capacity might be previous respiratory infections (59,211) as in 
Sudan, childhood respiratory infections; particularly pneumonia has been reported as 
the second cause of hospitalisation in 2007 (18). This is consistent with previous 
studies in low smoking exposure settings such as Malawi (166), and other studies, 
that suggest that unknown environmental factors such as genetics, race, low birth 
weight, early exposure to biomass fuels and air pollution and poor diet are common 
factors associated with a low FVC in developing countries (36,166,188).  
In both rural and urban studies, no association was identified between occupation 
and airflow obstruction except in rural study for those who had an occupational 
exposure for >5 years working in agriculture, textile and food industry, and farming 
was the primary reported occupation.  
 
Exposure to biomass fuels, especially firewood and coal, was reported in urban 
settings (82.4%) more than in rural settings (48%). This contrasts with findings in 
previous studies that higher exposure to biomass fuels tended to occur in rural 
settings.  
 
However, high levels of migration from rural Sudan to Khartoum state in the last 
decade due to conflict, inflation and lack of work means that participants in the urban 
study might not have been living in urban areas for their whole life. Moreover, 
although Gezira state has been officially classified as rural, the socioeconomic status 
of the state's population is higher than in other areas of Sudan as the state was home 
to the biggest agriculture project in Africa until a decade ago. In the rural study, 92% 
of participants owned their houses and 85% had access to a private supply of drinking 
water, while in the urban study these figures were 70% and 66.2% respectively. 
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Moreover, a higher average educational level was reported in Gezira State more than 
in Khartoum (44% vs. 32%). These factors might contribute to the lower level of 
post-bronchodilator obstruction in Gezira State (66,69,79).  
Though the case finding of tuberculosis was high according to the National 
Tuberculosis program in both Khartoum and Gezira states, the prevalence of reported 
TB history was low in our study. Therefore, we had limited power to explore 
associations between TB and spirometric abnormalities. 
 
In both studies, there were no comorbidities identified with airway obstruction, 
except for having hypertension which was found to be associated with GOLD stage 
2 COPD using the local reference range in the rural study. In both studies, only 
hypertension and diabetes were frequently reported by the participants and  few cases 
reported TB, heart disease and lung cancer. This contrasts with work suggesting that 
COPD is associated with one or more comorbidities (48). However, this might be 
due to the stigma linked with TB which  is known to be a major public health concern 
in Sudan (212), though studies showed that there is a low prevalence of other 
diseases: lung cancer is less common in Sudan (213), and prevalence of 
cardiovascular disease is only 2.5% (214). 
 
Taken together with the findings of the Khartoum study, there is a strong evidence 
that NCLDs are a serious concern in rural Sudan and deserve consideration with 
respect to public health. While estimates reported by WHO are highly uncertain 
because of the unavailability of national estimates, this study confirmed that CRD is 
highly prevalent in both urban and rural Sudan. Our findings suggest that AFO are 
underestimated and under-diagnosed, with only 12 (2.1%) and 31 (1.5%) participants 
reporting medically diagnosed COPD and 39 (6.4%) and 117 (6.4%) reporting 
medically diagnosed asthma in Khartoum and Gezira states respectively.  
Prioritisation of chronic lung diseases and inclusion of proper diagnostic tools such 
as spirometry in Sudan's health system would improve the diagnoses of these 
diseases and therefore provide a clearer representation of the disease burden.   
 
The use of paper-based questionnaires was stipulated by the BOLD Study protocol 
and as such, they were used in both the Khartoum and Gezira state studies. However, 
this approach provided some challenges in the field and in the data entry office, as it 
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was time-consuming. Moreover, poor data accessibility affected data accuracy, 
completeness and information quality. The opportunity was therefore taken to 
explore the possibility of administering the BOLD study questionnaires using a 
digital format alongside the required paper-based questionnaire approach while 
conducting the Gezira state study by selecting 100 participants from three rural 
villages. The ODK was used to programme questionnaires in Arabic into 
smartphones and questionnaire data were collected using both paper-based and 
smartphone-based methods simultaneously. Agreement between the two 
methodologies was tested using the Kohen's Kappa statistics and inter-rater class 
coefficient. The two data collection methods varied from perfect to slight agreement 
across the 204 variables evaluated (Kappa varied between 1.00 and 0.02 and had an 
inter-rater coefficient between 1.00 and -0.12). Errors, incomplete and inconsistent 
records were most commonly seen with paper questionnaires on questions with 
complex skip-patterns, which were a major source of errors. Compared to paper-
based data collection, smartphone technology worked well for data collection in the 
challenging rural setting. This approach provided timely, quality data with fewer 
errors and inconsistencies than paper-based data collection. Based on this research, 
this method is recommended for future BOLD studies and other population-based 
studies in similar settings. 
 
  Pathways to impact  
The  implementation of the two BOLD studies by the Epi-Lab organisation came as 
a continuation of the previous work by the organisation as pathfinder, that led the 
work on Lung Health in Sudan and become a recognised WHO/EMRO lung health 
collaborating centre as well as the union collaborative centre following on its 
achievement on Tobacco cessation, standard Asthma, and Pneumonia case 
management among others (215).   
 
In order to disseminate study findings and find a way to shape and influence health 
policy regarding chronic non-communicable lung diseases in Sudan, we carried out 
a dissemination meeting on April 24th 2018 in Khartoum, Sudan under the title 
"Evidence to promote Lung Health in Sudan". The study findings were presented 
together with other studies concerning lung health. The main objective of the meeting 
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was to shape national policy and practice response to a body of local research 
evidence on CRD (meeting minutes in appendix 10). 
 
The meeting organised by the Epi-Lab and was well attended, with participation from 
Under Secretary for Health, pioneering chest physicians, public health consultants, 
Non-governmental Organisation (NGO) representatives, WHO and United Nation 
Development Program (UNDP) representatives and researchers and academics from 
different fields including the environments, pharmacy sectors and development 
partners.  
 
During the dissemination of the study’s results, it was suggested by the researcher 
that CRD, particularly COPD and asthma are underestimated and underdiagnosed.  
Gaps in Sudan health system and shortage in diagnostic tools, as well as lack of 
national estimates, were highlighted as a priority unmet need in order to estimate 
disease burden and prevalence as well as to provide better disease management and 
treatments. This was prompted by the findings of a high prevalence of spirometric 
abnormality, particularly COPD, airway reversibility and a higher prevalence of low 
FVC and respiratory symptoms in rural population.  
 
The researcher stressed on the importance of including spirometry in the diagnosis 
of chronic lung disease particularly COPD and asthma.  Knowing that spirometry is 
not routinely available in either the private or public sectors, discussion around the 
possibility of introducing spirometry in the Sudan health system and scaling up 
provision took place. This discussion has been picked up by health system 
representative and reinforced that spirometry is crucial for the diagnosis of COPD 
and highlighted the deficiency in diagnostic tools in Sudan. This representative went 
on to state that works is being done to provide spirometric testing in secondary health 
care, however, training of doctors in spirometry is still needed and efficacy 
assessments must be carried out before spirometry can become commonplace across 
other levels of health care, including in primary health care. An area he deemed 
important for future collaboration with the Epi-Lab.  
 
The discussion around study findings and implications highlighted the magnitude of 
the CRDs burden while potential interventions in Sudan health system and policy 
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might be emphasised by these research findings, specifically what can be done by 
community health workers in health education as well as on prevention, management 
and referral for emerging cases. Having a higher prevalence in Khartoum state with 
weak association with smoking that only associated with GOLD definition 
highlighted the need for authorities to address the issue of a high pollutant State in 
order to decrease air pollution. Having proactive health prevention policies will 
possibly manage these conditions sustainably. In addition, anti-smoking campaigns 
should be prioritised by the policymakers to help smokers quit and to initiate smoking 
cessation programs. This should be coupled with non-pharmacological modalities 
such as rehabilitation and nicotine patches (though these are available in the country, 
they are however expensive). There is a need to provide psychological support in 
smoking cessation programs as well as effectively treating existing co-morbidities. 
 
Overall, this meeting highlighted gaps in the Sudanese health system with regard to 
chronic lung health and the deficiency in the diagnosis of COPD and asthma as well 
as investigating the reasons behind these findings. The meeting also highlighted the 
need for research to strengthen existing services and introduce new interventions for 
these diseases. Additionally, the results of this study has provided evidence-based 
estimates using standardised recognised BOLD study protocol and possibly have a 
potential impact in Sudan health system and policy with regard to chronic lung 
diseases having the undersecretary of the Federal Ministry of Health strongly 
emphasized that these were the first data on COPD to be presented, owing to the lack 
of research and surveillance data regarding chronic lung disease in Sudan while 
highlighted the need  for Sudan to prioritise these diseases.   
 
 Conclusions  
In conclusion, the prevalence of COPD in Sudan was relatively high compared to 
other neighbouring countries in SSA and MENA regions, especially in the urban 
survey. The high prevalence of low FVC and high prevalence of reported respiratory 
symptoms in urban and rural settings needs further investigation and research. 
Moreover, the findings regarding airway reversibility in both rural and urban studies 
suggest that asthma may be underdiagnosed and highlight the need for future research 
to assess disease prevalence and burden. The findings of no association with the 
known risk factors to lung abnormality such as smoking and use of biomass fuels 
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suggest that other environmental or racial factors may contribute to the burden of 
lung diseases in Sudan. Sudanese health care institutions need to invest in training, 
diagnosis and service delivery and prioritise non-communicable and chronic lung 
disease. There is a serious need for primary and secondary interventions initiated by 
Sudanese health policymakers and the government to prioritise the development and 
implementation of chronic lung disease policies.  
 
  Recommendations 
1) Prioritisation of airflow obstruction in the Sudanese healthcare system and 
investment in healthcare training and service delivery with regard to COPD, 
asthma and other chronic lung diseases based on this study. 
2) Integration of respiratory health into Primary Health Care (PHC), scale up of the 
existing asthma strategy and development of a management strategy and 
guidelines for clinicians and public health experts for better diagnosis of COPD 
and other CRDs and an improved understanding of the disease burden.  
3) Consideration of the use of spirometry alongside clinical diagnosis, following 
international guidelines for better diagnosis and assessment to help reduce the 
burden of chronic lung disease in Sudan by early detection of disease and prompt 
prevention and management of NCLDs. This can include prioritisation and 
establishment of smoking cessation programs and interventions as a key 
preventive method for airflow obstruction. However, weak association with 
smoking was identified in this study but smoking is known globally as biggest 
risk factor for COPD. 
4) Consider including specific statistics about COPD, asthma and other NCLDs in 
health annual reports of Sudan to help policymakers, practitioner and researchers 
as well as inform decision making regarding disease care, management, 
distribution and required services.  
5) Adopt automated methods such ODK software in data collection for future 
health surveys in Sudan to enhance data quality and accessibility in wider studies 







   Further work 
Several areas were not addressed by this study and some questions remained 
unanswered. This research highlighted the need for further work regarding non-
communicable lung disease in Sudan, including work to:  
1) Investigate the reasons behind the high prevalence of low FVC in urban and rural 
Sudan. 
2) Investigate the reasons behind the high prevalence of respiratory symptoms in 
rural Sudan. 
3) Investigate the association between exposure to air pollution and COPD in urban 
Sudan. 
4) Understand possible contributing risk factors to the prevalence of COPD in 
Sudan. 
5) Assess asthma prevalence and associated risk factors in adults in Sudan. 
6) Understand possible health system and social responses to the burden of CRD 
delineated in this research. 
7) Investigate the use of mobile health and digital technologies in a wide range of 



































Appendix (1): Literature review Search strategy  
A search for all published studies, available in English, and meeting the study scope 
and criteria as below: 
1. The initial stage included a limited search using DISCOVER, that pulls out 
results from PubMed and Medline databases. To carry out this search, 
boolean "AND/OR/NOT" were used to combine keywords and phrases 
included in the study topic. This preliminary search allowed us to identify 
relevant keywords contained in the title, abstract and subject descriptors 
(Table 1).  
2. Terms identified in the previous step and the synonyms used by respective 
databases were used in an extensive search of the literature using Medical 
Subjects Headings (MeSH) approach.  
3. Reference lists and bibliographies of the articles collected from those 
identified in stage two above were then searched. 
Papers indexed in following databases were searched:  PubMed, Science direct, Global 
health, and BOLD website.   Grey literature databases were also used and these 












Table 1. Terms used for online databases search 
Search terms  “NCDs” OR “Non communicable disease ” OR “non-
communicable disease” 
“COPD” OR “Burden” , “Chronic Obstructive Pulmonary 
Disease burden ” OR “global”, “Pulmonary disease chronic 
obstructive” OR prevalence” OR “Africa” , “Global burden 
of COPD” 
“Global initiatives for COPD” OR “GOLD” OR “Lower limit 
of normal”, “Disease definition” OR “COPD definition”, 
“Chronic Obstructive Pulmonary Disease” OR “European 
Respiratory Society” OR “American Thoracic Society” OR 
“British Thoracic Society” 
 “Asthma definition” OR “GINA”, “global initiative for 
asthma” OR “Global Asthma network” OR “asthma 
standardised definition” 
“COPD prevalence*” OR “Sub Saharan Africa*”, OR 
“COPD in Africa” OR “Asthma in Africa” , “ Respiratory 
disease” OR “Africa” OR “SSA” OR “MENA” OR “ Middle 
east and North Africa” OR “Middle East” OR “North Africa” 
OR “Sudan” OR “Khartoum” OR Gezira” OR “Gazeera” OR 
“Algazira” 
“Less developed countr*” OR “developing countr*”OR “low 
to middle income countr*” OR low resource OR  setting” OR 
“underdeveloped countr*” OR “low income countries” OR 
“underserved  
“COPD” OR “Risk factors” OR “associated factor” OR 
“exposure” OR “related factor” OR “older age” OR “aging” 
OR “smoking” OR “smoke” OR “biomass” OR “fuel” OR 
“occupational exposure” OR “work exposure”, “Chronic 
respiratory risk factor” OR “global” OR “Africa” OR 
“developing countr*”  
“COPD burden” OR “rural” OR “urban”, “COPD prevalence 
in country ” , “COPD” or “industrialised” OR “developed”  
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“COPD Comorbidities ”, “ COPD” OR “other disease”, 
“CRD” OR “TB” OR  “hypertension” OR “Diabetes ” OR 
“lung cancer” OR “cardiovascular disease”  
“CRD” OR “adult” OR “ 40 years” OR “18 years” OR 
“forty” OR “eighteen” 
Databases searched PubMed, Science direct, Global health, and BOLD website, 
Google scholar , data banks from WHO and World Bank 
Part of journals 
searched 
European Respiratory Journal, American Thoracic Society 
journal, AIMS, International Journal of Tuberculosis and 
Lung Disease, Chest Journal, Allergy, American Journal of 
Respiratory and Critical Care Medicine, COPD: Journal of 
Chronic Obstructive Pulmonary Disease, Global Health 
Action, International journal of chronic obstructive 
pulmonary disease, Journal of Allergy and Clinical 
Immunology, The Journal of asthma : official journal of the 
Association for the Care of Asthma, The Lancet, Plos 
Medicine, Plos One, Respiratory Medicine, Respirology, 
Thorax 
Years of search There were no time limits. However, most recent publications 
within the period of  5 years were included. 
Language  English 
Inclusion criteria  All published articles/reviews in a peer reviewed journal 
from the globe with the focus on SSA and MENA  regions 












Appendix (2) Participant information sheets and consent 
 
The Epidemiological Laboratory 
A survey on Chronic Obstructive Pulmonary Diseases in Gezira State 
Participant information sheet and consent 
 
Study title: Survey of the burden of lung diseases and disability in Gezira State 
 
Participant’s address…………………………………………. 
Participant’s Phone number…………………………………. 
 
You have been selected to participate in this survey about chronic obstructive 
pulmonary disease. Please read the information below for detailed information on 
the study and ask the researcher about any parts of the study that are unclear to you. 
We would like you to participate after being fully aware of the study and how you 
were selected to participate in it. Your participation is fully voluntary, and you have 
the right of refusal to participate in this study. No ill consequences regarding the 
current or future health service provided will result from refusing to participate in the 
study. You may drop out from the study at any time even after providing initial 
consent. 
 
ü This study has been approved by the Gezira Ministry of Health, Imperial college 
London and Liverpool School of Tropical Medicine and will be conducted 
according to ethical guides of the Declaration of Helsinki and local ethical guides for 
conducting research. 
ü This study is an investigation of chronic lung diseases in Gezira state and will 
involve: 
1. Filling of questionnaires 
2. Conducting a lung function test using a spirometer 
3. Random selection of participants 
4. Participants are requested to give information on the following: 
a) Socioeconomic status 
b) Health status 
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c) Conducting a lung function test using a spirometer before and after giving a safe dose 
of bronchodilator 
d) Waist and hip circumference and pulse which are important for the lung function test 
ü You might also be randomly selected as part of another sub study aims to compare 
two data collection methods. Two researchers will fill part of the questionnaires at 
the same time using both mobile-based forms and paper-based forms for the sake of 
testing the two different methodologies of the data collection. However, only one of 
them will ask you the questions. 
ü Participants will benefit from conducting the lung function test of which they may 
have a copy of the results. No payments will be given in return for participation in 
the study. 
ü There are no risks to participating in this study which has been conducted in many 
other countries around the world where no risks have been reported. 
ü The information obtained from questionnaires is strictly confidential. No names will 
be written on questionnaires or lung function tests. The participant’s address and 
phone number will be written only after consent. 
ü Do you have any questions or enquiries now? If you have questions at any other time 





I ………………………………………………………….agree to participate in the 
survey about chronic obstructive pulmonary disease and declare the following: 
1. I have read and understood the information in the participant information sheet above 
2. I have been given the opportunity to ask questions and all my questions have been 
answered to my satisfaction 
3. I have understood that participation in this study is voluntary and I have not been 
persuaded in any way to be part of it 







I …………………………………………………………..declare the following: 
1. I have informed the participant of the above information  
2. I have encouraged the participant and gave him/her ample time to answer their 
questions 
































Appendix (3): BOLD study Data collection tools  
 
BOLD questionnaires are listed below:  
 
1) Participant tracking questionnaire  
 
 
     1.Age___ ____ ____ years  
 
2 Gender        Male               1  
                          Female             2  
3. Data Collected: 
                                                                         Yes 1    No2  
 Core Questionnaire                                                               
  
 Cigarette Smokers Questionnaire                                          
   
 Biomass Questionnaire                                                          
   
 Spirometry (including Questionnaire)                                   
   
 Minimal Data/Refusal Questionnaire                                    
  
 Occupational Questionnaire                                                  
  











4. Non-Response: [For Participants with no data (all ‘No’) in 
Question 3.] 
Refused/No data collected 4   
Known to have permanently left area 5  
Temporarily out of area 6 
Dead 7  
Age ineligible 8  
Institutionalized  9 
Untraceable (e.g. 
bad address and phone) 10  
Unreachable (e.g. 
never returns mail or answers phone)  11 
5. The following questions 5.1 and 5.2 are optional 
5.1. Record Geographical Information Data (e.g. geographical 
coordinates 
postcode 
zip code)     ________________                                                                           
 
5.2. Record Geographical Information Data                      
________________ 
Compulsory question 
6. For centres that have performed multistage sampling techniques 
kindly enter cluster identifier numbers here 
6.1 locality Number_ __ __ 
6.2. Number given to village __ __ __ 
6.3. Number for house (if applicable) _ __ __ 
If you have performed a simple random sampling 
enter 000 for 6.1 to 6.3 







2) Core questionnaire  
 
             
Demographic data: 
  
1- What is the participant’s gender? 



























4- What is the highest educational level 















5- What is the highest educational level 






Family member phone number 
BOLD core questionnaire 
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 Primary School 
Middle School 









6- 1-What is the highest educational level 
your mother has reached? 

















6-2- does one of these 
things exist at home or 
one of the home residents 
own it? 
Read them all: 
a- Electricity 
b- Siphoning-toilet 
c- Home telephone 
d- Television 
e- Radio 
f- A fridge 
g- A car 
h- Scooter/bike 
i- Washing machine 
j- Do you own the house? 







l- Water tabs inside the 
house 
m- Water tabs outside the 
house 
n- Internet 








Most of the days 
Most of the weeks 
Most of the months 





p- Have you-or one of your family 
members- ever felt hunger, because 
you do not have money? 


















6-3- when you were 5 
years old, was there any 
one in your home who 
owns one of these things? 
Read them all: 
a- Electricity  
b- Siphoning-toilet 
c- Home telephone 
d- Television 
e- Radio 
f- A fridge 
g- A car 
h- Scooter/bike 
i- Washing machine 
j- Do you own the house? 
k- Internal bathroom 




m- Water tabs inside the 
house 
n- Internet 








Most of the days 
Most of the weeks 
Most of the months 




p- Have you ever felt hunger, because 
you don’t have money? 
 …………………… 
6-4-howmany people live with you in 
the same house? (including you) 
 ……………….. 
6-5- how many rooms are there in your 
house? (without the kitchen and the 
bathroom) 
 
  Respiratory symptoms and disorders: 
  
The following questions will be about, if 
possible please answer with Yes or No, if you 
are not sure please answer No. 





7- Do you cough often, when you don’t have 
cold? 
  
If the answer was yes, continue to question 7a, 





7 a- are there some months in which you 
cough most of the days? 
  
If the answer was yes, ask question 7b, 7c if it 
was No move to question 8. 
  
7 b- do you cough most of the days for 3 




More than 5 
years 
7 c- for how many years do you have the 
cough? 





8- Usually, do you expel the phlegm from your 
chest or it stays in the chest and doesn’t get 
out when you don’t have cold? 
  
If the answer was yes, continue to question 8a, 





8 a- are there some months in which you have 
phlegm most of the days? 
  
If the answer was yes, ask question 8b, 8c if it 





8 b- do you expel phlegm from the chest most 




Less than 2 
years 
2-5 years 




8 c- for how many years do you expel 
phlegm? 





9- In the last 12 months, do you hear wheeze in 
your chest? 
  
If the answer was Yes asking question 9a and 





9a- do you hear wheeze in your chest, in the 





9b- in the last 12 months did you have 
wheezing that led to shortness of breath? 





10-  Are you unable to walk for any reasons other 




If the answer for question 10 was Yes, 
describe the reasons in the line below and 
move to question 12. If it was No or you were 
not sure, go ahead to question 11. 







11- Do you get short of breath as you are hurrying 
on level ground, or uphill? 
  
If the answer was Yes, ask the questions 11A-





11a- do you walk slower than your peers on 







11b- do you stop for breathing when walking 







11c-have you stopped for breathing after a 








11d- did you have an attack of breath 
shortness that kept you from going out, or 





12- Have you been told before by a doctor or a 






13- Have you been told before by a doctor that 
you have asthma, chronic bronchitis, or 
allergy? 
If the answer was Yes, move to question 13A, 





13 a- do you still have the asthma, chronic 








14- Have you been told before by a doctor or a 
health worker that you have chronic 
bronchitis? 
If the answer was Yes, move to question 14A, 











15- Have you been told before by a doctor or a 
health worker that you have chronic 
obstructive pulmonary disease? 
 
Section management 
Now I will ask you some questions about your medications that you take to help 
your breath, medication you are taking regularly and those you take when you have 
symptoms, we want to know your medications, their form, and the frequency of 
taking them monthly. 
1- In the last 12 months did you take medications to help your breath (including 
nasal congestion medications)?  Yes 5         No5 









































































































































































































































































you take the 
drug, for how 
many days or 

































































the drug, for 
how many 





2- Please, do you take any other medication or do activities that help your breath? 










3- Have you ever measured your breathing rate by a 
doctor or health worker with the spirometer? 
if the answer was Yes, ask question 18A, if it 











4- Have you had an attack of breath shortness that 
kept you from doing your daily activities or 
going to work? 
  
if the answer was Yes asking question 19A, if it 




19A-How many times have you had this attack in 
the last 12 months? 
  
if the answer for 19A>0 ask question 19B and 




19B-How many times have you had this attack 
and needed to see a doctor or health worker, in 




19C-How many times have you had this attack 
and have been admitted to the hospital for a 
whole night, in the last 12 months? 
  
if the answer for 19C>0 ask question 19C1 if it 




19C1-how many times have you spent the whole 
night admitted to the hospital because of these 





Cigarette smoking  
Whither the participant concerns the 
following questions is currently or 






20-1- have you ever smoked in your 
life? 
  
The answer Yes means more than 
20 boxes in your life, or more than 1 
cigarette every day for a year. 
  
if the answer was Yes asking 
question 20A-20D, if it was No 
move to question 20.2 
 
 years____ ____  
A- How old were you when you started 
smoking regularly? 
 years____ ____  
B- If you have quitted smoking before, 
how old were you when you did that 
for the last time 
  
(if the participant is still smoking, 




C- How many cigarettes do you smoke 





D- During …………. , were you 






20.4- have you ever smoked pipe in 
your life? 
  
if the answer was Yes asking the 
questions 20.4A-20.4D, if it was No 




 years____ ____  
A-How old were you when you 
started smoking pipe regularly? 
 years____ ____  
B-If you have quitted smoking pipe 
before, how old were you at that 
time? 
  
(if the participant is still smoking, 




C-how many pipe tobaccos do you 







20.5-have you ever smoked cigars, 
cheroots, or cigarillos in your life? 
  
if the answer was Yes asking the 
questions A-C, if not move to 
question 20.6 
 
 years____ ____  
A-How old were you when you 
started smoking cigar regularly? 
 years____ ____  
B-how old were you when you 
quitted smoking cigar? 
  
(if the participant is still smoking, 




C-Averagely, in the whole period 
during which you were smoking, 
how many cigars, cheroots, or 






20.6-have you ever smoked water 
pipe (shisha) in your life? 
  
if the answer was Yes asking the 





 years____ ____  
A-How old were you when you 
started smoking shisha regularly? 
 years____ ____  
B-how old were you the last time 
you quitted smoking shisha? 
  
(if the participant is still smoking, 




C-Averagely, in the whole period 
during which you were smoking 
shisha, how many shishas were you 
smoking daily /weekly? 
  
 
Note: you have the choice to be 







20.7-have you ever smoked hashish 
in your life? 
  
if the answer was Yes asking the 
questions A-C, if not move to 
question 20.8 
 
 years____ ____  
A-How old were you when you 
started smoking hashish regularly? 
 years____ ____  
B-how old were you the last time 
you quitted smoking hashish? 
  
(if the participant is still smoking, 




C- Averagely, in the whole period 
during which you were smoking, 








20.8-have you ever smoked or 
sniffed any other substance in your 
life? (e.g. local, recreational smoked 
substances) 
  
20.8.1 Specify the type: 
…………………………………… 
  
20.8.2 What is the unit? 
...................................... 
  
if the answer was Yes asking the 
questions A-C, if not move to 
question 21 
 
 years____ ____  
A-How old were you when you 
started smoking ………. regularly? 
 years____ ____  
B-how old were you the last time 
you quitted smoking or sniffing 
………….? 
  
(if the participant is still smoking or 
sniffing, record the number 999) 
 
……. units / day 
……units/week 
C-Averagely, in the whole period 
during which you were smoking, 
how much was the quantity were 
you consuming daily /weekly? 
  
(if the participant is still smoking 
(question 20B is 999) ask the 
questions 21A and 21B, if not, 
move to question 23 
 times____ ____  
21A- during the past year, how 
many times have you quitted 
smoking for at least 24 hours? 
Yes, during the coming 30 days    
5 




Yes, during the coming 6 months  
5 
No, I am not considering it              
5 
  
If the participant never smoked 
(answered No for all the questions 
20.1-20.5), move to question 24.1, if 
not answer question 23. 





23- have you been recommended 
before, by a doctor or a health 
worker to quit smoking? 
  
If it was yes asking the questions 






23A- have you received a medical 
advice to quit smoking, during the 





23B- have you used any nicotine 
having medication (prescription or 
non-prescription) to help you quit 
smoking? 
  
1, question 23A askingIf it was Yes 
then 24, if it was No move directly 





Nicotine Replacement       
Bupropion  
Tofranil                                                  
Other              
23B-1- What is the type of 
medication you were using to help 





24- have you used or done anything 






If the answer was Yes, ask question 







Acupuncture   
Biofeedback l     
  Other  
24A- what have you done? 
 ……………………… 
24.1 excluding you, how many 







You don’t work 
24.2 do people smoke regularly in 







24.3 how many hours per day are 
you exposed to cigarette smoke 
from others? 
24.3.1 at home 
24.3.2 at work 
24.3.3 in the cinema, bar, café, 
restaurant, or any public place 





24.4 was your father a regular 





24.5 was your mother a regular 
smoker in your childhood? 
 
     Knowledge, opinions, and attitude: 
  
Introduction 






24.6 as to your knowledge belief and faith, 
does smoking cause serious illnesses? 
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If the answer was Yes asking question 24.7, 
if not, move to question 25. 
 
Yes       No   Don’t know 
 
 
24.7 as to your knowledge belief and faith, 
does smoking cause any of the following? 
Read them all: 
a- cerebral thrombosis (a clot in the brain, 
which causes paralysis) 
b- Heart attack 
c- lung cancer 
d- chronic inflammation of lungs 
e- emphysema/ chronic narrowing of airways 
 





25 have you ever worked in an occupation 
that has dust? 
 ………………years 
25A how many years have you worked in 
occupations that expose you to dust? 
  
26 have you been told before, by a doctor or 

































If the answer for 26F was Yes, ask questions 













26F 2 have you ever taken anti tuberculosis 





27 have you have surgery in your chest in 







28 have you been admitted to the hospital 
for a whole night because of breathing 








29 during the last 12 months, did you take 





30 did a doctor or a health worker say that 
your father, mother, sister, or brother has 
lung enlargement (emphysema), chronic 






31 in the last two weeks, is there a cigarette/ 
pipe/ cigar smoker living with you in the 
house? 
12SF: Copyright @ XXX Medical Outcomes Trust. All rights reserved (SF12 Standard US 
Version 2.0)’ 
The following questions are about your health and the health problems that you 
feel, chose the answer that describes your condition the best: 
32- Generally, do you consider your health: 
Excellent               5 
Very good            5 
Good                    5 
Average               5 
Bad                        5 
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33- the following questions are about the activities that you can do in 
a normal day. Does your current health status hinder you from doing 
the following activities? if this is the case, to what extent? 
33A medium effort activities, such as moving a table, pushing a sweeping 
machine, swimming, or cycling. 
Yes, a lot                     5 
Yes, a little bit                     5 
No, not at all              5 
33B walking up several flights of stairs: 
Yes, a lot                     5 
Yes, a little bit                     5 
No, not at all              5 
34- During the last 4 weeks, how many times did you meet any of these 
difficulties, when you are doing your work or your daily activities, because of 
your physical health? 
34A- achieved less than what you want 
Always                      5 
Often                        5 
Sometimes              5 
Seldom                     5 
Never                       5 
34B- your achievement was limited to a specific type of work or other activity 
Always                      5 
Often                        5 
Sometimes              5 
Seldom                     5 
Never                       5 
 
35- During the last 4 weeks, how many times did you meet any of the following 
difficulties, when you are doing your work or any other normal daily activities, 
because of any emotionally related problems (such as feeling depression or 
anxiety)? 
35A- achieved less than what you want 
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Always                      5 
Often                        5 
Sometimes              5 
Seldom                     5 
Never                       5 
35B- achieved your work or other activity with less attention than usual 
Always                      5 
Often                        5 
Sometimes              5 
Seldom                     5 
Never                       5 
36 during the last 4 weeks, to what extent does pain hinder your normal work 
(including your work at home and outside)? 
None                      5 
A little bit                        5 
Averagely              5 
A lot                     5 
So much                       5 
37 the following questions are about your feeling and dealing with things during 
the last 4 weeks, for each question. please give the answer that expresses you’re 
feeling the most. 
During the last 4 weeks, how often have you 
37A- felt calm and peaceful 
Always                      5 
Often                        5 
Sometimes              5 
Seldom                     5 
Never                       5 
37B- been active and energetic 
Always                      5 
Often                        5 
Sometimes              5 
Seldom                     5 
Never                       5 
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37C- felt sadness and depression 
Always                      5 
Often                        5 
Sometimes              5 
Seldom                     5 
Never                       5 
38- During the last 4 weeks, how often did your physical health or emotion 
related problem hinder your social activities (such as visiting friends and 
relatives, etc.….)? 
All the time           5 
Most of the time   5 
For Some time      5 
For little time         5 
Never                       5 
Copyright © XXXX Medical Outcomes Trust. All rights reserved.   (SF-12 Standard U.S.  
Version 2.0) 
  Economic Impact   







The following questions are 
about work and the time lost because 
of health problems 
  
39- any time during last 12 
months, have you worked for 
income generation? 
  
If the answer was No, continue 
with question 39A, if it was Yes, 





39A during last 12 months, you 
were not working in a paid job 





39B during last 12 months, you 
were not able to work because you 
 
 210 
were all day busy at home, or busy 
with your health issues? 
  
If the answer was Yes, 
continue with question 39C, if it was 





39C during last 12 months, is 
there a health problem that keeps 
you from doing your domestic work 
or care about your health? 
  
If the answer was Yes, 
continue with question 39D and E, if 
it was No, move to question 44 
 ………………days 
39D during last 12 months, for 
how many days were you not able to 
do your domestic work or care about 
your health because of a health 
problem? 
 ………………days 
39E during last 12 months, for 
how many days were you not able to 
do your domestic work or care about 





40-before how many months, 
during the last 12 months, were you 




41- in the months during which 
you were working, how many paid 
days per week did you work? 
 ……………hours 
42-how many paid hours a day 





43- During last 12 months, 
were there health problems that 




If the answer was Yes, 
continue with question 43A and 
43B, if it was No, move to 
question44. 
 ………days 
43A- during the last 12 months, 
what is the sum of the paid days you 
were not able to work because of 
health problems? 
 ………days 
43B- during the last 12 months, 
what is the sum of the paid days you 
were not able to work because of 
respiratory problems? 
  Lost activities other than work 
  
The following questions are 
about the time in which you can’t do 
your normal activities (shopping, 
visiting friends and family, going to 





44- During last 12 months, 
were there health problems that keep 
you from doing any activity other 
than work? 
  
If the answer was Yes 
continuing with question 44A and 
44B, if it was No, move to done by 




44A- During last 12 months, for how many 
days you were not taking part in public activities 




44B- During last 12 months, what is the 
sum of the days in which you were not taking 
part in non-job-related activities particularly 




3) Spirometry questionnaire 
 
 
Security questions           




No   
5  
2- In the last 3 months, have you had a cardiovascular event? Yes  
5 
No   
5  
3- have you had ………or did a surgery in your eye? Yes  
5 
No   
5  
 
4- Have you been admitted to the hospital for any other problem during 
the last month? 
Yes  
5 
No   
5  
 
5- Are you in the last trimester of pregnancy? Yes  
5 










6- Does the participants heart rate exceed 120 bpm at rest? Yes  
5 
No   
5  
 
7- Are you currently on anti-tuberculosis medications? Yes  
5 
No   
5  
 




No   
5  
 
If the answer for any of the questions from 1-8 is yes, the test should 
not be performed, move to the test results, and answer the questions 
11A and 11B with “No”, and chose the second option “the participant 
was medically excluded” for question 11c. 
Yes  
5 
No   
5  
 
9- In the last 3 weeks, have you had a respiratory infection (cold)? Yes  
5 
No   
5  
 
10- 1-Did you take any respiratory medication in the last 24 hours? Yes  
5 
No   
5  
 







if the answer for 10-1 was yes and the medicine used is in this table, 
answer the question 10-2, if not, answer question 10-5. 
 Examples TYPE OF MEDICATION 




















that have a LABA) 
12 hours prior to 
clinic visit 
Albuterol Oral beta-2 agonist 
12-24 hours prior 
to clinic visit, 
depending upon 
preparation 
Theodur Oral theophylline 









10-2- did the participant take short acting beta agonist or anticholinergic 
inhaler    alone or combined with something else in the last 6 hours? 
Yes  
5 
No   
5  
10-3- did the participant take long acting Beta agonist and selective 




No   
5  
10-4- did the participant take an oral theophyllin or long acting 








10-5- when was your last cigarette?   …….. day(s) ago 
…….. hour(s) ago 
Write 999 if non-smoker or ex-smoker (doesn’t smoke last month). 
 
10-6- optional 
Record carbon monoxide ……. 
                   (before performing spirometry) 
 
(before performing spirometry) 
10-7- heart rate 
10-8- height  
10-9-weight 
10-10-A primary measure for the hip circumference. 
10-10-B secondary measure for the hip circumference. 
10-11-A primary measure for the waist circumference. 











Spirometry Outcome                                                                                 
11A. Acceptable pre-bronchodilator test completed?   
  Yes                                                                                                     No
   
 
11B. Acceptable post-bronchodilator test completed?  
  Ye  
 No                                                                                                  
 
11C. Unable to obtain satisfactory spirometry (check one) 
The participant did not understand instructions              
The participant was medically excluded                              
The participant was unable to physically cooperate         








12-has the test performer seen any side effects due to spirometry? 
 




13- does the participant have any conditions that can affect spirometry 






























4) Cigarette smoking questionnaire  
 
 
Please, ask this question to all the participants who are still smoking: 
     Nicotine addiction questionnaire 
 
 
Cigarette economy: In the following, we are going to ask you about the last time 






Cigarette smokers’ questionnaire 











2- Do you find it difficult to stop smoking in 





3- Which kind of smoking is the most difficult 
to stop? 
The first cigarette 
in the morning 




4- how many cigarettes do you smoke daily? 10 or less 
11-20 
21-30 





5- Do you usually smoke immediately after 














7- Have you ever bought cigarettes for yourself? 
If the answer is yes, ask the questions 
from6-1 to 6-6, if the answer is NO, move 









6-1- the last time you bought cigarettes for 
yourself, you bought? 
(for………, enter the group and the 
number, chose one answer a, b, c, or d): 
a- A Cigarette 
 
b- I- Box 
ii-How many cigarettes were in the box? 
 
c- I-Box 
ii-How many cigarettes were in the box? 
 
d- I-Something else: specify………. 














6-2- how much did you spend for buying 
cigarettes? 
(for the ………… if s/he doesn’t know, 
enter 0) 





6-3-what was the trademark of the cigarette 
you bought? 
(consult the list of country specific answers 
by entering the code). The code…………… 
…………………… 
 
6-4- the last cigarette you bought for yourself, 
where did you get it from? 


































6-6- are the cigarettes you smoke light, 
medium or heavy? 




Nothing of the above 

























9- Is smoking allowed in the workplace? Yes 
No 







In the following question is about your exposure to media in the last 30 days. 

















yes no I don’t 
know 
1- Cigarette free sample 
   
 
 
2- Cigarette discounts    
3- cigarette    
4- Gifts or special deals for any other products to 
buy cigarettes 
   
5- Clothes, cars, or any other things with the 
trade mark on it or the shape of a cigarette. 
   
6- Cigarette deals in the mail. 
   
 
7- A cigarette trade mark supporting any sport 
event. 
Done by:……………. 
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5) Occupational questionnaire 
 
 
1-have you worked in one or more of the 
following occupations for 3 months or 
more? 
 Chose Yes or No for each case 
Work years: (if less than one year write 
00) 
Yes  5 
No   5  
 
            
a- In solid rock mines Yes  5 
No   5  
 
 ___ ___years 
b-in coal mines Yes  5 
No   5  
 
 ___ ___years 
c- Cleaning or enamelling stones or 
glass using the sandblasting machine 
Yes  5 
No   5  
 
 ___ ___years 
d- in asbestos (rock silk) Yes  5 
No   5  
 
___ ___years 
e-in plastics and petrochemical industry Yes  5 
No   5  
 
___ ___years 
f-in a mill Yes  5 










g- In cotton and fibre industry Yes  5 
No   5  
 
___ ___years 
h-In iron and steel melting Yes  5 
No   5  
 
___ ___years 
I- In welding. Yes  5 
No   5  
 
___ ___years 
j- In fire control Yes  5 
No   5  
 
___ ___years 
k- In agriculture Yes  5 




Questions from L-O concern some occupations that are known for being a risk 
factor for COPD 
If you need to use these questions please contact: boldcentreuk@imperial.ac.uk  
 
Chose Yes or No for each case 
 
Number of working years (unless it 
is less than one year, write 00) 
l- building Yes  5 





m-cleaning: domestic and industry 
detergents, working with detergents 
and antiseptics or other chemicals 
Yes  5 




n- textile Yes  5 






o-cement industry Yes  5 
























4- do you use any protective (such as mask) in 











4-1- currently you are: (chose one answer only) 
- Working (including military work) 
- Working, free work. 
- Unemployed, looking for work. 
- Not working, for health reasons. 





















5-what is the job you have occupied for the 
longest time? (name the job) 
....................................................................... if the 
participant has never worked (e.g. all the time at 




    
 




 5B- What is the industry you are working in 
now? 
 










c- Worker and not administrative or supervisor? 
 
d-  free worker 
 
 
Yes  5 
No   5  
Yes  5 
No   5  
Yes  5 
No   5  
 
Yes  5 
No   5  
 
5E- enter ISCO code 
--------   
6- Have you ever decided to leave your job 
because it causes respiratory problems to you? 
Yes  5 




If the answer is yes, ask the questions from6 A to 
6E, if the answer is NO, move to the next 
question. 
  
6A-what is this job? (name it) 
6B-what do you do exactly in this job? (describe) 
....................................................................... 
6c- how many years do you have in this job? 













c- Worker and not administrative or supervisor? 
 
d- free worker? 
 
Yes  5 
No   5  
 
Yes  5 
No   5  
 
Yes  5 
No   5  
 
Yes  5 


















the resident’s questionnaire about her daily use of fuel  
1- have you ever used charcoal as a major 
cooking fuel in your house for more than 6 
months? 
If the answer to question 1 is yes, ask the 
questions from A1 to D1, if the answer is NO, 








 A1-how many years have you been using charcoal 
for cooking in your house? 
............  
years 
B1- in average, how many hours daily do you 










D1- does the smoke go outside through a 






2- have you ever used wood, straw, crop residues or 
animal wastes as a major cooking fuel in your house for 
more than 6 months? 
If the answer to question 1 is yes, ask the questions 







 A2-how many years have you been using 
wood, straw, crop residues or animal wastes for 





B2- in average, how many hours daily do you 
personally spend cooking with wood, straw, 




C2-Do you still use wood, straw, crop 
residues or animal wastes for cooking 





D2- does the smoke goes outside 







3- have you ever used charcoal as a major way for 
warming/heating in your house for more than 6 months? 
If the answer to question 3 is yes, ask the questions 







 A3-how many years have you been using charcoal as a 
major way for warming/heating your house? 
............  
years 
B3-Do you still use charcoal as a major way 






4- Have you ever used wood, straw, crop residues or 
animal wastes as a major way for warming/heating in 
your house for more than 6 months? 
If the answer to question 4 is yes, ask the questions 









 A4-how many years have you been using wood, straw, 
crop residues or animal wastes as a major way for 





B4-Do you still use wood, straw, crop residues 
or animal wastes as a major way for warming 






4-1 have you ever used wood, straw, crop residues or 
animal wastes as a major way for heating water in your 
house for more than 6 months? 
If the answer to question 4-1 is yes, ask the questions 










 A4-1 how many years have you been using wood, 
straw, crop residues or animal wastes as a major way for 
heating water in your house? 
............  
years 
B4-1 Do you still use wood, straw, crop 
residues or animal wastes as a major way for 






4-2 have you ever used Kerosene as a major cooking 
fuel in your house for more than 6 months? 
If the answer to question 4-2 is yes, ask the questions 








 A4-2 how many years have you been using Kerosene 
for cooking in your house? 
............  
years 
B1- in average, how many hours daily do you 












D1- does the smoke go outside through a 







5- what is the fuel that is used the most in your house for cooking: 
(you can choose more than one answer) 
a- Electricity   
b-  Gas   (liquefied petroleum gas LPG) 
c- Kerosene      
d- Charcoal   
e-  Wood   
f- Hay   
g-  Crop residue   
h- Other   ……… specify: 
6- how many hours do you spend cooking every day?  
…………..hours 
6-1- Do your eyes get teary or itch when you are cooking? 
5No, never 
5 yes, sometimes 
5yes, always 
7- in your house, where most of the cooking is done? 
(chose one answer only) 
a- Outside, in the plain air. 
b- Outside, in an isolate room. 
c- Inside, in the kitchen. 
d- Inside, in the living room. 
If the answer is yes to question 7b,7c, or 7d continue to question 8 otherwise 
move to question 12. 
 
































































If the answer is yes continuing to question 13 if No move to the next 
question. 
 
13- How many months in the year do you heat 
your house most of the time? 
……….. months 






If the answer is yes answer question 14-A, if it is No answer question 14-B. 
14-A- in case the answer was yes: does the 






14-B-- in case the answer was no: are there open 






15- what is the fuel that is used the most for warming the house? 
(you can choose more than one answer) 
a- Electricity   
B- gas   (liquefied petroleum gas LPG) 
a) Kerosene      
b) Charcoal   
c)  Wood   
d) Hay   
e)  Crop residue   




















2-Date of birth?   ____ ____ /____ ____ /____ ____ ____ ____   
Respiratory symptoms and disorders:   
3-Have you ever been told by a doctor that you have: 
emphysema, asthma , asthmatic bronchitis, chronic 





Co morbidities:   
4-Have you ever been told by a doctor that you have: 
Cardiovascular disease, hypertension, diabetes, lung 







The following questions are about smoking 
 
 






(yes, about more than 20 boxes of cigarette, water 
pipe or tumbac in my life, or more than one cigarette, 
water pipe or tumbac sniff every day for an year) 
 
 
If the answer was Yes, ask question 5-A and 5-B   



































What is the rate in which you are smoking cigarette or 






Done by:……………………  
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Appendix (4) Khartoum and Gezira sampling plans 
 









































































b) BOLD-Plus Gezira sample plan 
 
Centre name: Gezira State, Sudan 
Contact for queries about sampling: name: Rana Atta and Rashid Osman 
email: rana.atta85@gmail.com 
 rashildo@hotmail.com  
 phone: +249912927665 
POPULATION 
What is your population of interest? (note, this should be defined by meaningful 
administrative boundaries) 
 






Give a brief, general background on the population (if possible, include 
information that might be relevant for studies of COPD, e.g. air quality 
measurements, key industries) 
The Gezira state population is urban, rural, and nomadic. This study contrasts with 
the recently completed Khartoum BOLD study by a predominance of rural and 
nomadic populations. Farming is the most common occupation and with farming-
related exposures expected to dominate. There are no previous studies of the 
prevalence of chronic airways disease and its risk factors in the State.  
What is the total population of all ages? (if not known precisely, give an 
approximate figure) 
The total population of Gezira state is 3575280 
If figures are available e.g. from census data, tabulate the total population aged 
40 or over, by sex, age-group, or other relevant grouping 
See below table  
 
Gezira State  Gender 
Total Males females 
Age group 3,575,280 1,724,330 1,850,950 
15  -  19 394,011 187,435 206,576 
20  -  24 323,837 143,704 180,133 
25  -  29 273,472 117,082 156,390 
30  -  34 213,878 93,780 120,098 
35  -  39 214,234 94,639 119,595 
40  -  44 162,516 75,335 87,181 
45  -  49 133,179 65,181 67,998 
50  -  54 112,953 54,807 58,146 
55  -  59 69,173 36,174 32,999 
60  -  64 72,602 37,085 35,517 
65  -  69 45,076 24,787 20,289 
70  -  74 48,854 25,326 23,528 
75 + 62,574 34,463 28,111 













For multi-stage designs: 
List the sampling stages (there is space on the form for describing up to three 
stages – if you are planning more than three you should discuss the practicality of 
this with the Coordinating Centre): 
Stage 1: Localities 
Stage 2: Villages  
Stage 3: Households 
 
Stage 1 
How will sampling units be selected, and how many sampling units will be 
chosen? Describe any stratification. 
Gezira state is divided into seven localities. We have selected three of these 
 localities to include in this study using a simple random sampling approach 
 using Excel: 
1. Sharg Algezira 
2. Wad Medani 
3. Alkamleen 
 
How will sampling units be identified or coded in the database? 
Locality  Code 
Sharg Algezira 1 
Wad Medani  2 
Alkamleen  3 
 
How will you determine and record the total number of sampling units available to 
be sampled? If numbers of sampling units are already known, tabulate them here. 
 
We have selected the three localities as above. The total population of the three 





How will sampling units be selected, and how many sampling units will be chosen? 
Describe any stratification. 
Each of the three localities is divided into several administrative units each of which 
is divided into villages/areas as summarised below. A simple random sample of 5% 
of the villages (n=35) villages will be selected. 
 
 
Admin Unit  Total HHS Villages/ar
ea 
Algazeera East 463,154 78,831  
Wad_rawah Town and Rural 85,516 15,272 61 
Tambool Town and Rural 141,078 24,109 115 
Alhilallia Town and Rural 91,221 14,940 39 
Rufaa Town 28,374 4,701 25 
Rufaa Rural 116,965 19,809 79 
Alkamleen 401,930 66,814  
Alsinaat 105,788 18,318 53 
Almaseed Rural 108,199 17,003 37 
Alkamleen Town and Rural 88,995 14,559 54 
Almiailiq Town and Rural 98,948 16,934 67 
Wad Madani Alkoobra 423,863 69,326  
Alshabarga 32,330 5,066 25 
Hantoob 79,574 13,286 33 
Madani North-West 80,577 12,937 28 
Madani Central 75,864 12,976 37  
Alwaha (Madani-East) 67,074 11,031 17 
Alsouq Almarkazi 88,444 14,030 19 
 
How will sampling units be identified or coded in the database? (If sampling units 
are individuals they will be identified using a unique 6-digit BOLD ID number.) 
Each village will be given a unique identifying number.  
 
How will you determine and record the total number of sampling units available to 
be sampled? If numbers of sampling units are already known, tabulate them here. 
 





How will sampling units be selected, and how many sampling units will be chosen? 
Describe any stratification. 
 
Each household in Gezira State has on average 3 adults.  
 
We plan to sample approximately 2000 adults in total with the aim of having 
complete datasets on approximately 1200 participants.  
By including 1000 households we anticipate being able to sample 2000-3000 adults.  
We will seek to include all eligible individuals in the households to increase the 
efficiency of recruitment whilst recognising the impact of household-level clustering. 
Since we will include 35 villages we will sample 1000/35 = 30 (rounded up to nearest 
10) households per village. 
A mapping exercise will then be conducted in each village/area to count and locate 
all households including nomadic households present at the time of the mapping and 
campo (migrants from other states) residents.  
Sampling of households at village level will be a simple random sample of all 
households in the village.  
How will sampling units be identified or coded in the database? (If sampling units 
are individuals they will be identified using a unique 6-digit BOLD ID number.) 
Sampling units will be individuals identified using a unique 6-digit BOLD ID 
number 
How will you determine and record the total number of sampling units available to 
be sampled? If numbers of sampling units are already known, tabulate them here. 
 











Appendix (5) Ethics approvals  
Below are ethics approval from the Ethical Review Committee of the Liverpool 
School of Tropical Medicine (LSTM) ,he BOLD operation centre at the Imperial 
collage London and the Gezira Ministry of health Wad Medani, Khartoum Ministry 
of Health Sudan. 
 















c) LSTM ethics approval for comparison between smartphone and paper-























Appendix (6) Data management strategic plan for  BOLD Gezira 
 
Project Title: BOLD Plus -Gezira State -Sudan 
Data Owners: Epi-Lab BOLD Team/LHL LSTM Consultants/Imperial College 
Data Managers: Rana Ahmed 
Other Contributors and Roles: Rashid Kamal, Co-investigator 
 





This plan is designed to define the procedures that are performed in flow monitoring 
and/or other aspects of the BOLD-Plus project as part of Epi-Lab database to ensure 
the accuracy and usability of the data after the raw data has been collected.  
The Principal investigator who is responsible for the management of data for the 
study should: 
o Develop instructions in the case where data management is performed directly 
within the Epi-Lab. 
o Manage authorizations for access to data 
o Ensure the protection and security of data 
o Ensure confidentiality of the identity of subjects 
 
1.    Field data management: 
 
Filed data management means the first step in the collection of data as follow: 
 
1-    Design the data collection tools (when needed) which are the responsibility of 
project researchers 
2-    Data collection tools to be revised by Data management unit of the Epi-Lab and 
approved by the project consultants (LSTM and LHL).  
3-    Piloting and Testing of data collection tool at the field by the data collectors. 
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4-    Collection of data: The collection of the data will be daily during the project life 
cycle except for weekends and national holidays.  
 
3 Project Data Types and Structure 
 
• BOLD plus project has seven types of questionnaires, they contain quantitative 
data and each of them covered a special area of the study. 
•  Data will be interred directly from collected paper's questionnaires using 
imperial college online data entry system.   
• One questionnaire will be designed by Epi-Lab researchers and entered in BOLD 
Plus data entry designed form in Epi-info data format. 
• In addition readings from spirometer will be stored. 
 
4 Data Acquisition, Integrity and Quality 
 
• Trained data collectors/researchers will collect data.  
• The training of the team will cover Overview on the project, data collection 
tools and techniques, practical work on filling questionnaires and data ethics.  
• The team will be divided into small teams and they will have a field supervisor.  
•  Field supervisor is responsible for ensuring data accuracy, integrity, and 
completeness.  
• The field supervisor will carry out daily onsite field verifications and any 
incorrect questionnaire will be terminated.  
• Data will then be stored in a separate and locked cabinet.  
• Daily and a weekly Backup plan will be followed.  
• Two data entry personnel will be assigned to use the online entry system. They 
will ensure that entry is up to date will the collection.  
 
5 Procedure for Compiling and Managing Field notes/checklist 
 
• Site Data  and field notes  
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At least every 7 days, the field supervisor shall provide notes about data collection 
and field experience, all data should be looked at thoroughly and any noticeable 
problems with the data or site will be recorded in the field notes.  
 
• Upon returning to the office after site visits, the field notes entries should be 
placed in the project desktop computers and saved to the server/backup PC.  
 
5.    Data management: 
•  The coordinator of the project with statistician must supervise the 
submission/verification of the collected data from the data collectors. 
•  The Collected data to be handled by the coordinator of the project to the Data 
entry personnel and entered daily on the BOLD study platform. 
• The cleaning of data it's the responsibility of the project statistician and to be on 
monthly basis. 
 
6.    Procedures for data backup: 
     
• Data backup is the responsibility of the field supervisor and project statistician 
in addition to close supervision from the project coordinator. 
• Frequent backup to ensure the safety of data will be carried out. 
 
• Following Epi-Lab SOP: Data backup should be also conducted at least once 
every month in the backup server. 
7.    Confidentiality and Ethical Procedures: 
 
• All data should be anonymous, no names or other personal identification of study 
participants  should be kept nor collected.   
•  Complete datasets should be placed in the backup pc and no editing /changes is 
allowed after the backup. 
• A restricted data use form should be provided by a person (other than data 
owners) authorized to access the data and signed by the management and data 
management unit responsible person. 
 
 253 
• No complete data set should be provided to anyone(other than data owners), only 
aggregated data. 
• Accessibility to the final dataset of the project from The BOLD operation centre 
to Epi-Lab researchers shall be provided as in the agreement. 
• No personal information or data of a secret nature regarding project interviewee 
will be stored or shared.  
• Data will then be stored in a separate and locked cabinet only accessible by 
project researchers and data entry personnel. 
 
8.    Security: 
• No USB disk should be used on the entry PC, only the backup external hard disk  
• Only the entry personnel, project coordinator and project statistician should 
know the restricted complex password of the entry pc. 
• Antivirus software should be installed and updated frequently  
 
9.    Publications: Following the Epi-Lab SOP 
• All data obtained in the project within the Epi-Lab is the property of the Epi-Lab  
• All researchers who wish to use the Epi-Lab data for publication purpose are 
required to follow the Epi-Lab publications SOP and sign the data use agreement 
form. 
• Epi-Lab (Director / PIs of any project/Section/research) will be included as an 
author in all publications that used the organization data.  
• Epi-Lab researchers who are working in the BOLD project should agree on 
authorship orders before starting the paper/article drafting. 
• All published papers/Articles that used the Epi-Lab data must be given back to 










Appendix (7) Standard operating procedures for data collection 
using both paper-based and mobile based methodology 
 
The two collection methods will run in parallel during the data collection. 
Randomization on which methodology will be used to administer the questionnaire 
will be conducted prior to start the data collection. Below are SOPs to be followed in 
conducting this part of the study. 
•   Pre-field preparation 
o    Make sure mobile phones are fully charged. 
o    Take your spare batteries. 
o    Make sure you took the field diary to record all events during data collection. 
• On-field procedures 
o    Selection of the participant should follow the overall BOLD study. This 
should be done daily before data collection starts to follow BOLD-Plus survey 
samples selection. 
o    the participant should be consented before starting the data collection and be 
aware by using the mobile technology in parallel with the paper-based 
questionnaire. 
o    Randomization of using which method to administer the questionnaire should 
be done before starting data collection. 
o    Survey completion can take place offline, and no network coverage is 
necessary. 
o    If there is no mobile network coverage, completed surveys will be stored 
securely until a signal is found at which time completed surveys are uploaded. 
o    the data collector can incorporate multiple choice, free text, numeric, date, 
time, and other question types. In addition, data collector should follow the flow 
of the designed questionnaire with all skips pattern and don't edit or interfere 
with the skips pattern. 
o    in case of questions administered by the paper-based data collectors, mobile 
data collector should follow the paper-based data collector in answering the 
questions. In case of asking the different/wrong question, the mobile data 
collector should fill out the questions he/she thinks correct and vice versa.  
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o    in the opposite situation, paper-based data collector should follow the mobile-
based data collector in filling out the questionnaire with no interference of 
questions asking during the collection time. However, in case of asking different 
or wrong question the above methodology should be followed. 
o    in both situations of administering the questionnaire, no interference should 
be allowed to correct or modify the other researcher work in filling out the 
questionnaire. However, data collector may ask the question skipped or wrongly 
administered at the end of the interview.  
o    Investigators may not collect any data from individuals who decline to 
Participate. In case of withdrawal, the investigator should record that on the field 
diary.  
o    in case of running out of power during the data collection, other researched 
should carry on and this should be recorded in the field diary. 
• Investigators must not collect any data that is not explicitly approved by the 
research participant in the consent document.  
 
Security consideration: 
o    During the field visits,  mobile phones shouldn’t be left unwatched on a desk, 
chair, or bed in the houses you visit.  
o   Mobile phones should be kept in researcher pocket or handbag, before and 
after the completion of data collection. 
o  Researcher should make sure he/she  saves all collected forms after finishing 
the interview. 
o    No forms should be submitted after the completion of the data collection. 
Researcher should just save it.  
o   in case you accidentally closed ODK application, researcher is advised to 
restart the application, most of the time it will open again where left.  
o    If the application crashes during the data collection, researcher should restart 
the phone then restart the application and check if the data you were entering 
have been saved. You should find it back in the "Edit Saved Form" menu. 
o  in case of each of the above situations, researcher should continue the data 
collection if the form is still saved. Otherwise, the other data collector should 




To save your mobile device power, below consideration should be taken. 
o    Put the phone on the flight mode  
o    Turn off the WIFI  
o    the screen's brightness must be low  
o    Recharge the battery and make sure it full before you go to the field 
o    Make sure the date is correctly set in the mobile device; you need to set up 





















Appendix (8) Smartphone snapshots from ODK collect 
 





































Appendix (10) Evidence to promote lung health in Sudan, 
dissemination meeting 
 
a) Meeting minutes  
The meeting was opened by the Epi-Lab director by highlighting the global  burden 
of NCDs and stating the meeting objectives. This was followed by a talk from the  
federal Ministry of Health Under-secretary.  As a policy maker, he highlighted the 
need for such research in Sudan and the importance of focussing more on NCDs and 
CRDs in general. He also appreciated how this research will help to see how many  
people at states seeking for treatment as well as how these health problems affect the 
wellbeing of the Sudanese population and the economy. He stated that this was an 
important piece of research and will complement the efforts of the Ministry of Health 
in Sudan and others in addressing the burden of chronic lung diseases such as COPD 
and asthma. He also asserted that Sudan needs to prioritise these diseases and 
highlighted COPD as an under-estimated disease within the country. He claimed that 
results provided by the present study should be included in the planning for Ministry 
of Health programs as they are trying to improve health services for sufferers of lung 
disease and integrate other stand-alone services into the NCDs program. He closed 
by concluding that having evidence of the burden of lung diseases in Sudan is crucial 
and that the integration of these findings into Ministry of Health polices and plans is 
paramount.  
 
The burden of non-communicable lung diseases in adults in Sudan from both urban 
and rural studies were presented and the rationale, methodologies, findings, and 
study recommendations were discussed with the audience.  Various concerns were 
raised and addressed during these discussions: 
• The smaller sample size led to exaggerated prevalence figures in Khartoum? 
It was said that, to make sure the sample selected researchers represent all population 
followed a similar multistage sampling plan in both Khartoum and Gezira with a 
random selection at each sampling stage in both studies. Additionally, the study used 
weighted analysis in reported COPD prevalence and all other estimates. 
Consequently, choice bias was reduced, and the subjects were representative of the 
general populations in both Khartoum and Gezira studies.   
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•  The study choice criteria and the justification of excluding the non-institutionalised 
population (e.g. prisoners). Researchers clarified that a standardised BOLD study 
was mimicked to assure comparability with other studies in the region and around 
the world. This included following the project selection and exclusion criteria. 
Additionally, ethical issues may have arisen from the inclusion of individuals such 
as prisoners. Inmates, for example, are unable to freely give consent in a manner 
consistent with non-institutionalised persons. They may be subjected to coercion and 
undue inducement. Moreover, institutionalised persons may be exposed to other risk 
factors with different durations and intensities when compared to those in the 
community. 
• The investigation of known risk factors for COPD with a focus on biomass fuels, 
environmental factors and air pollution was raised. Discussion around the high 
reported burden of COPD in Khartoum state highlighting the need to explore whether 
air pollution is a factor in COPD prevalence in Khartoum state. These studies used 
standardised BOLD questionnaires and there were no specific questions about air 
pollution. However, there were other questions about occupational exposure to gas 
and smoke, as well as exposure to biomass fuels and no association found between 
these factors and developing COPD. Future exploration of these risk factors will 
strengthen these findings and clarify weather air pollution and other environmental 
factors contribute to the burden of COPD in Sudan. 
 
Following the presentation, a panel discussion session conducted and chaired by Epi-
Lab and LSTM.  Panellists included Dr Hamad Elturabi, Associate Professor of 
Medicine/Consultant Physician and Pulmonologist, Soba University Hospital, 
University of Khartoum, Sudan and Academic Secretary, Sudan Medical 
Specialization Board; Dr Momen Mokhtar, Secretary General Sudanese Chest 
Physician Society; Dr Manal El Emam, Director of NCD Program; and Professor 
Sudan Suliman, Research Director at Sudan Medical Heritage Foundation. 
 
The Panel discussion concerned primarily questions listed and addressed below: 
1. What is your reaction to the burden of chronic lung disease that has now been 





b) Abnormal spirometry? 
Firstly, the panel responded that these were the first data on COPD to be presented, 
owing to the lack of research and surveillance data about this disease in Sudan. In 
this study, a higher prevalence of both respiratory symptoms and lung restriction 
were found in in Gezira while a higher prevalence of stage 1 and stage 2 COPD was 
found in Khartoum. Given that the prevalence of moderate to severe obstruction was 
12% in Khartoum compared to 6.6% in Gezira, and that higher prevalence of 
moderate to severe obstruction should correspond with higher prevalence of 
respiratory symptoms, panellists were surprised that COPD prevalence was lower in 
Gezira state. 
The response to this concern was that a younger age stratum (age 18-39) had been 
included in data for Gezira state. This group had a high prevalence of respiratory 
symptoms (cough and shortness of breath) and a higher prevalence of lung restriction 
while the older group (age 40+) had a higher prevalence of COPD. The high 
prevalence of respiratory symptoms in Gezira state might not be the result of COPD 
but other restrictive lung diseases, given the high prevalence of low FVC in this 
group. 
Another panellist questioned whether COPD was more prevalent than asthma, even 
though asthma tends to be more prevalent than COPD generally.  
The response was that a BOLD study was conducted which focussed on COPD rather 
than asthma. However, airway reversibility was assessed in both studies and 
estimates of airway obstruction that persisted after the use of a bronchodilator were 
18.5% using LLN in both states while 15% in Gezira and 10.5% in Khartoum using 
GOLD. These findings show that asthma prevalence is high, even higher than COPD 
estimates in both states.  
Further questions were asked about how biomass fuels exposure was assessed. The 
response to this concern was, study participants were asked if they used charcoal, 
kerosene, firewood for cooking for 6 months or more in their life in addition if they 
used this different biomass fuels for heating. 
2. We have seen that spirometry is not routinely available in either the private or 
public sectors. Do you think spirometry is needed in the diagnostic algorithms 
for chronic lung diseases and, if so, how would you go about introducing and 
scaling up provision? 
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Panellists responded by asserting that spirometry is crucial for the diagnosis of COPD 
and highlighted the deficiency in diagnostic tools in Sudan. Additionally, a 
representative of the ministry of health said that a patient pathway should be created, 
so as simplify the process of diagnosis. This representative went on to state that work 
is being done to provide spirometric testing in secondary health care. Training of 
doctors in spirometry is still needed and efficacy assessments must then be carried 
out before spirometry can become commonplace across other levels of healthcare, 
including in primary health care. 
Other researchers emphasised the importance of spirometry in the diagnosis of 
chronic lung disease. However, spirometers are expensive and need special training 
to carry out testing and correctly interpret results. As a solution, it was explained that 
the Epidemiological laboratory used peak flow meters in asthma clinics at district 
hospitals. Where the standard asthma case management program is provided, peak 
flow meters in primary healthcare would help give better diagnoses. Though results 
obtained are not as correct as those from spirometric testing, peak flow meters could 
help to ease diagnoses in most of cases where spirometric testing can be called on 
upon referral (at the secondary and tertiary level).  
A researcher on the present study suggested that the Ministry of Health may be able 
to utilise the existing school health program and screen school children for asthma, 
whilst understanding that asthma is prevalent in adults as well as in children from 
this, and the earlier ISAAC study conducted in Sudan. The panellist and session chair 
agreed that existing programs should be made use of rather than investing new ones.  
3. What do you see as the major treatment modalities to offer patients with COPD 
in Sudan in terms of: 
a) Non-pharmacological interventions e.g. (pulmonary rehabilitation / smoking 
cessation)? 
b) Medicines? 
One panellist responded that, as an environmentalist, preventative strategies stand 
for the most sustainable way forward. Teaching individuals how to prevent and 
manage attacks for example can be far more effective than giving treatment 
modalities. In Sudan, many factories (e.g. sugar processing plants) run close to 
domestic areas and represent a greater risk for asthma patients. The panellist said that 
public authorities must address this issue to decrease air pollution. In addition, this 
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panellist highlighted that there is a need to encourage proactive health-protecting 
behaviours to manage these conditions sustainably. 
Another panellist echoed the sentiment that prevention is better than cure. However, 
this panellist argued that, in Sudan, anti-smoking campaigns should be prioritised to 
help smokers quit and to start smoking cessation programs. This should be coupled 
with non-pharmacological modalities such as rehabilitation and nicotine patches 
(though these are available, they are however expensive). There is a need to give 
psychological support in smoking cessation programs as well as effectively treating 
existing co-morbidities. 
The panel chair pointed out that every urban city in the world has above acceptable 
levels of air pollution. Additionally, community health workers should work more in 
health education as well as on prevention, management, and referral for emerging 
cases. 
Other discussions took place around the costs associated with asthma care as well as 
societal feelings about disability and the over-use of emergency room treatment for 
asthma, and how the health system policies should be changed in response. One 
panellist said that asthma is an under-diagnosed and under-treated disease, where 
stigma, encompassing the feeling of patients and people in community, plays a 
leading role in the lack and delay of diagnoses. This places a high demand on the 
health system and results in great cost to patients, The panellist added that the study 
revealed gaps in the Sudanese health system, that the structure of Asthma units in 
hospitals needs to be reformed, and that nurses must be trained to identify Asthma as 
a first line of defence. Additionally, the perceived cost of diagnosis and treatments 
(such as inhalers) may explain why patients preferentially come to emergency rooms, 
despite this being more expensive.  
Professor Asma Elsony commented that in the standard asthma case management 
program, implemented by the Epidemiological Laboratory (Epi-Lab) in selected 
hospitals in Khartoum and Gezira States, the UNION model of standard case 
management is used. Most hospitals at the first referral level (district hospitals), with 
a catchment area of 100,000 were selected.  Each hospital had an emergency room 
and asthma clinic with a medical officer for the clinical evaluation of asthma, a nurse 
or sister to give health education, and one clerk statistician or medical assistant for 
recording and reporting. Those clinics managed to effectively reduce the number of 
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hospitalizations and emergency visits, thus being a model attractive to policy makers 
for widespread adoption. 
 
Overall, the policy makers, consultants, chest physicians, practitioners and 
researchers that took part in this meeting highlighted gaps in the Sudanese health 
system with regard to lung health (specifically focussed on COPD and asthma) and 
the need for research to strengthen existing programs and introduce new 
interventions. Additionally, the results provided by this study about the prevalence 
of COPD in urban and rural Sudan has shed light on this disease and its burden. 
Policy makers represented by the Undersecretary at the Ministry of Health 
emphasised that there will be a continuation of detailed work based on this study’s 
results and recommendations. Additionally, there will be a focus on COPD and 
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Appendix (11) Academic outputs arising from this thesis 
 
Posters and Presentations  
 
The burden of chronic lung diseases in adults in rural and urban Sudan, Study 
overview, methodology and preliminary results [Poster] at LSTM postgraduate 
research degree student conference; May 2017, May 2016. 
 
The prevalence and main determinant of COPD in urban Sudan [Oral presentation] 
at LSTM postgraduate research degree student conference; May 2017. 
 
Rana Ahmed, Ryan Robinson, Kevin Mortimer. A comparison of smartphone and 
paper data-collection tools in the Burden of Obstructive Lung Disease (BOLD) study 
in Gezira state, Sudan[abstract].  In abstract book of the 48th World conference on 
Lung Health of the International Union Against Tuberculosis and Lung Disease (The 
union); 11-14 October 2017, Guadalajara Mexico; IJTULD; Volume 21, number 11 
November 2017; Pages S1-S481; ISSN 10273719. Abstract no OA-104-12 
 
The burden of non-communicable lung diseases in adults in rural and urban Sudan [ 
Video presentation] LSTM postgraduate research degree student conference; May 
2018. 
 
The burden of non-communicable lung diseases in adults in rural and urban Sudan 
[Oral presentation] at Evidence to promote Lung Health in Sudan dissemination 
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